Adverse drug reactions as cause of admission to hospital patients

BMJ: British Medical Journal

329, 15-19

DOI: 10.1136/bmj.329.7456.15

Citation Report

#	Article	IF	CITATIONS
1	Adverse drug reactions as cause of admission to hospital: Admissions to ear, nose, and throat departments were not mentioned. BMJ: British Medical Journal, 2004, 329, 460.1.	2.4	0
2	The road to health care. BMJ: British Medical Journal, 2004, 329, 1-2.	2.4	56
3	NICE and its value judgments: Option of safe "understudy―treatments should be available. BMJ: British Medical Journal, 2004, 329, 740.1.	2.4	0
5	Diureticâ€Related Side Effects: Development and Treatment. Journal of Clinical Hypertension, 2004, 6, 532-540.	1.0	90
6	Pharmacogenetics and cardiovascular disease management. British Journal of Hospital Medicine, 2004, 65, 594-598.	0.3	1
7	Epidemiology of hypersensitivity drug reactions. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 309-316.	1.1	346
8	Recording adverse drug reactions in a forensic psychiatry unit: how can we improve standards?. British Journal of Forensic Practice, 2005, 7, 7-11.	0.6	2
9	Best practices for safe handling of products containing concentrated potassium. BMJ: British Medical Journal, 2005, 331, 274-277.	2.4	21
11	Adverse Drug Reaction Reporting: Attitudes of Australian Hospital Pharmacists and Doctors. Journal of Pharmacy Practice and Research, 2005, 35, 9-14.	0.5	6
12	Workshop Introduction: Personalized medicine: desirable, affordable, attainable?. Personalized Medicine, 2005, 2, 143-144.	0.8	O
13	Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70. BMJ: British Medical Journal, 2005, 330, 1306.	2.4	45
14	Reviewing the reality: why we need to change. Country Review Ukraine, 2005, 7, E15-E20.	0.8	35
16	Selecting Nonprescription Analgesics. American Journal of Therapeutics, 2005, 12, 67-79.	0.5	41
17	Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 2005, 106, 135-140.	0.6	335
18	Accuracy of a Pharmacovigilance Algorithm in Diagnosing Drug Hypersensitivity Reactions. Archives of Internal Medicine, 2005, 165, 1500.	4.3	48
19	Write on. British Journal of Clinical Pharmacology, 2005, 59, 141-142.	1.1	O
20	Drug-drug interactions and adverse drug reactions: the bollards and flashing lights syndrome. Journal of Clinical Pharmacy and Therapeutics, 2005, 30, 97-99.	0.7	13
21	Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics, 2005, 22, 285-289.	1.9	57

#	Article	IF	CITATIONS
22	Measuring the value of pharmacogenomics. Nature Reviews Drug Discovery, 2005, 4, 500-509.	21.5	88
23	Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. Pharmacogenomics Journal, 2005, 5, 221-225.	0.9	119
24	Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics Journal, 2005, 5, 262-270.	0.9	434
25	Keynote review: Is declining innovation in the pharmaceutical industry a myth?. Drug Discovery Today, 2005, 10, 1031-1039.	3.2	103
26	Investigation of toxic metabolites during drug development. Toxicology and Applied Pharmacology, 2005, 207, 425-434.	1.3	94
27	The role of hospital and community pharmacists in pharmacovigilance. Research in Social and Administrative Pharmacy, 2005, 1, 126-133.	1.5	72
28	New drug targets for depression and anxiety: Is the peptides era arriving?. Drug Development Research, 2005, 65, 93-96.	1.4	2
29	Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study. European Journal of Clinical Pharmacology, 2005, 61, 231-236.	0.8	44
30	Patterns of drug prescription in a geriatric evaluation and management unit as compared with the general medical wards: a randomised study. European Journal of Clinical Pharmacology, 2005, 61, 921-928.	0.8	64
31	Continuity of long-term medication use after surgical hospital stay. European Journal of Clinical Pharmacology, 2005, 61, 433-438.	0.8	10
33	Medication for older people—. Zeitschrift Fur Gerontologie Und Geriatrie, 2005, 38, 190-195.	0.8	13
35	Polypharmacy and older people—. Zeitschrift Fur Gerontologie Und Geriatrie, 2005, 38, i14-i17.	0.8	12
36	Ten lessons to be learned from the withdrawal of Vioxx� (rofecoxib). European Journal of Epidemiology, 2005, 20, 127-129.	2.5	8
37	Adverse drug events in emergency department population: a prospective Italian study. Pharmacoepidemiology and Drug Safety, 2005, 14, 333-340.	0.9	57
38	Which drug reactions should be reported?. Practice Nursing, 2005, 16, 584-589.	0.1	0
39	Drug safety and regulation. BMJ: British Medical Journal, 2005, 331, 4-5.	2.4	15
40	Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules. Expert Opinion on Drug Safety, 2005, 4, 103-128.	1.0	36
41	Long-Term Therapy to Prevent Stroke. Journal of the American Board of Family Medicine, 2005, 18, 528-540.	0.8	12

#	Article	IF	CITATIONS
42	Pharmacogenomics steps toward personalized medicine. Personalized Medicine, 2005, 2, 325-337.	0.8	72
43	Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report. Journal of Medical Ethics, 2005, 31, 144-148.	1.0	30
44	Opening Pandora's Pillbox: Using Modern Information Tools To Improve Drug Safety. Health Affairs, 2005, 24, 938-948.	2.5	17
45	Patient safety features of clinical computer systems: questionnaire survey of GP views. Quality and Safety in Health Care, 2005, 14, 164-168.	2.5	27
46	Identification of Inappropriate Drug Prescribing by Computerized, Retrospective DUR Screening in Korea. Annals of Pharmacotherapy, 2005, 39, 1918-1923.	0.9	9
47	Drug-Related Visits to the Emergency Department. Journal of Pharmacy Practice, 2005, 18, 329-335.	0.5	32
48	The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. Journal of Medical Screening, 2005, 12, 60-68.	1.1	49
51	It's Your Health: Use Your Medications Safely. Journal of Women's Health, 2005, 14, 16-18.	1.5	2
52	Improving the Use and Safety of Medications in Women Through Sex/Gender and Race/Ethnicity Analysis: Introduction. Journal of Women's Health, 2005, 14, 12-15.	1.5	6
53	Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ: British Medical Journal, 2005, 330, 293.	2.4	263
54	What Happened to the Coxibs on the Way to the Cardiologist?. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 555-556.	1.1	5
56	Who needs health care—the well or the sick?. BMJ: British Medical Journal, 2005, 330, 954-956.	2.4	32
57	Pharmacogenomics has promising applications in a number of areas of the drug discovery pipeline. Drugs and Therapy Perspectives, 2005, 21, 24-26.	0.3	0
58	Pharmacogenomics and the Drug Discovery Pipeline. Molecular Diagnosis and Therapy, 2005, 5, 53-62.	3.3	30
59	Genomic medicine: genetic variation and its impact on the future of health care. Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1543-1550.	1.8	58
60	Response to Sykiotis and Papavassiliou: Professional education in molecular medicine – pharmacogenetics first. Trends in Molecular Medicine, 2005, 11, 485-486.	3.5	1
61	Une synthÃ"se surÂl'épidémiologie desÂhypersensibilités médicamenteuses. Revue Francaise D'allergolo Et D'immunologie Clinique, 2005, 45, 626-632.	gie 0.1	4
63	Hepatic Findings in Long-Term Clinical Trials of Ximelagatran. Drug Safety, 2005, 28, 351-370.	1.4	168

#	Article	IF	Citations
64	Physicians??? Attitudes and Adverse Drug Reaction Reporting. Drug Safety, 2005, 28, 825-833.	1.4	129
65	Adverse Drug Reactions in an Elderly Hospitalised Population. Drugs and Aging, 2005, 22, 767-777.	1.3	272
66	Clinical Drug Interactions with Medicinal Herbs. Evidence - Based Integrative Medicine, 2005, 2, 207-228.	0.2	16
67	The Human Cytochrome P450 Allele Nomenclature Committee Web Site: <i>Submission Criteria, Procedures, and Objectives </i> ., 2006, 320, 183-192.		57
68	Drug-Related Deaths: Analysis of an Italian Spontaneous Reporting Database. Drug Safety, 2006, 29, 911-1010.	1.4	0
70	Antibiotic Selection in the Penicillin-Allergic Patient. Medical Clinics of North America, 2006, 90, 1257-1264.	1.1	25
71	The risks of warfarin use in the elderly. Expert Opinion on Drug Safety, 2006, 5, 417-431.	1.0	14
72	Screening for Dihydropyrimidine Dehydrogenase Deficiency: To Do or Not To Do, That's The Question. Cancer Investigation, 2006, 24, 215-217.	0.6	27
73	Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer. Journal of the National Cancer Institute, 2006, 98, 1108-1117.	3.0	299
74	Personalized medicine: new perspectives – new ethics?. Personalized Medicine, 2006, 3, 187-194.	0.8	10
75	Chapter 5 Idiosyncratic Drug Reactions: Clinical Evidence for Mechanistic Hypotheses. Advances in Molecular Toxicology, 2006, 1, 139-183.	0.4	0
77	Clinical pharmacology—too young to die?. Lancet, The, 2006, 367, 799-800.	6.3	72
78	Adverse Cutaneous Drug Eruptions and HIV: a Clinician's Global Perspective. Dermatologic Clinics, 2006, 24, 459-472.	1.0	35
79	Conséquences des déficits en protéines de la coagulation. Praticien En Anesthesie Reanimation, 2006, 10, 28-32.	0.0	0
80	Contrat de bon usage des médicaments: proposition d'une méthodologie pour réaliser l'état de du circuit du médicament dans un Centre Hospitalier Général. Pharmacien Hospitalier, 2006, 41, 85-98.	es lieux 0.1	1
81	Pharmacologic Issues in Geriatric Emergency Medicine. Emergency Medicine Clinics of North America, 2006, 24, 449-465.	0.5	14
83	The Erice Declaration. Drug Safety, 2006, 29, 91-93.	1.4	27
84	Adverse Drug Reaction-Related Hospitalisations. Drug Safety, 2006, 29, 161-168.	1.4	160

#	Article	IF	CITATIONS
85	Influence of Pharmacists??? Attitudes on Adverse Drug Reaction Reporting. Drug Safety, 2006, 29, 331-340.	1.4	96
86	Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance. Drug Safety, 2006, 29, 735-768.	1.4	89
87	Oral Anticoagulants in Development. Drugs, 2006, 66, 1411-1429.	4.9	73
89	Role of bioactivation in drug-induced hypersensitivity reactions. AAPS Journal, 2006, 8, E55-E64.	2.2	60
90	Antibiotic Allergy. New England Journal of Medicine, 2006, 354, 601-609.	13.9	183
91	Applying Semantic Web Technologies to Drug Safety Determination. IEEE Intelligent Systems, 2006, 21, 82-86.	4.0	21
92	Pharmacocinétique des médicaments cardiovasculaires chez la personne âgée Bulletin De L'Academie Nationale De Medecine, 2006, 190, 843-853.	0.0	1
93	Medical management and the legal framework. Nursing and Residential Care, 2006, 8, 182-185.	0.1	O
94	Adverse drug reactions and non-compliance with prescribed medication. NursePrescribing, 2006, 4, 69-72.	0.1	0
95	Adverse drug reactions in old age. Adverse Drug Reaction Bulletin, 2006, &NA, 907-910.	0.6	1
96	Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics, 2006, 7, 61-65.	0.6	49
97	Challenges and opportunities of pharmacogenetics in drug development. Personalized Medicine, 2006, 3, 195-206.	0.8	6
98	Sex Selection Bias in Schizophrenia Antipsychotic Trials. Journal of Clinical Psychopharmacology, 2006, 26, 489-494.	0.7	27
99	Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiology and Drug Safety, 2006, 15, 179-184.	0.9	44
100	Multiple consultations and polypharmacy of patients attending geriatric outpatient units of university hospitals. Geriatrics and Gerontology International, 2006, 6, 244-247.	0.7	31
101	Is there an Interaction between the Cardiovascular Protective Effects of Low-Dose Aspirin and Ibuprofen?. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 275-280.	1.2	29
102	The Established and Emerging Uses of Aspirin. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 283-286.	1.2	6
103	Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan. British Journal of Dermatology, 2006, 155, 491-493.	1.4	11

#	Article	IF	CITATIONS
104	Diclofenac induces basophil degranulation without increasing CD63 expression in sensitive patients. Clinical and Experimental Immunology, 2006, 147, 061127015327004-???.	1.1	30
105	Adverse drug reactions in hospital in-patients: a pilot study. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 335-341.	0.7	61
106	Risk perception in drug therapy. British Journal of Clinical Pharmacology, 2006, 62, 135-137.	1.1	27
107	Warfarin: almost 60 years old and still causing problems. British Journal of Clinical Pharmacology, 2006, 62, 509-511.	1.1	283
108	Balanced prescribing. British Journal of Clinical Pharmacology, 2006, 62, 629-632.	1.1	39
109	A change in the market—investing in diagnostics. Nature Biotechnology, 2006, 24, 922-926.	9.4	19
110	A call for the creation of personalized medicine databases. Nature Reviews Drug Discovery, 2006, 5, 23-26.	21.5	47
111	The future of pharmacology. British Journal of Pharmacology, 2006, 147, S304-S307.	2.7	36
113	Use of a patient information leaflet to influence patient decisions regarding mode of administration of NSAID medications in case of acute low back pain. European Spine Journal, 2006, 15, 1737-1741.	1.0	13
114	Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. European Journal of Clinical Pharmacology, 2006, 62, 65-73.	0.8	25
115	Adverse drug reactions: a cohort study in internal medicine units at a university hospital. European Journal of Clinical Pharmacology, 2006, 62, 143-149.	0.8	60
116	Primary care physicians' behaviors towards risk of iatrogenesis in elderly patients. European Journal of Clinical Pharmacology, 2006, 62, 563-570.	0.8	5
117	Drug-related problems and pharmacotherapeutic advisory intervention at a medicine clinic. European Journal of Clinical Pharmacology, 2006, 62, 1075-1081.	0.8	39
119	Drug-Related Hospitalizations in a Tertiary Care Internal Medicine Service of a Canadian Hospital: A Prospective Study. Pharmacotherapy, 2006, 26, 1578-1586.	1.2	71
120	Adverse Drug Reactions in United States Hospitals. Pharmacotherapy, 2006, 26, 601-608.	1.2	104
122	A prescription for better prescribing. BMJ: British Medical Journal, 2006, 333, 459-460.	2.4	102
123	Teaching and practicing pharmacogenomics: a complex matter. Pharmacogenomics, 2006, 7, 243-246.	0.6	8
124	Medication errors in mental healthcare: a systematic review. Quality and Safety in Health Care, 2006, 15, 409-413.	2.5	71

#	Article	IF	CITATIONS
125	A case of minimal-change nephrotic syndrome in pediatric lupus erythematosus: just a coincidence?. Lupus, 2006, 15, 244-247.	0.8	19
126	Preventing drug related morbidity: a process for facilitating changes in practice. Quality and Safety in Health Care, 2006, 15, 116-121.	2.5	6
127	GI Risk Factors and Use of GI Protective Agents Among Patients Receiving Nonsteroidal Antiinflammatory Drugs. Annals of Pharmacotherapy, 2006, 40, 1924-1931.	0.9	9
128	A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 101-111.	1.7	31
129	Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics, 2006, 7, 783-792.	0.6	124
130	Personalized medicine: decades away?. Pharmacogenomics, 2006, 7, 237-241.	0.6	31
131	Are Medical Students Adequately Trained to Prescribe at the Point of Graduation? Views of First Year Foundation Doctors. Scottish Medical Journal, 2006, 51, 27-32.	0.7	64
132	Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ: British Medical Journal, 2006, 332, 1177-1181.	2.4	209
133	Hazards Associated with the Use of Herbal and Other Natural Products. , 2006, , 312-344.		1
134	Massive haemorrhage after a low-energy pubic ramus fracture in a 71-year-old woman. Postgraduate Medical Journal, 2006, 82, e25-e25.	0.9	32
135	Implementation of an electronic system for medication reconciliation. American Journal of Health-System Pharmacy, 2007, 64, 404-422.	0.5	83
136	Adverse drug events in the elderly. British Medical Bulletin, 2007, 83, 259-274.	2.7	<b>7</b> 5
137	Clinical work-up of adverse drug reactions. Expert Review of Dermatology, 2007, 2, 217-231.	0.3	6
138	Drugs in the elderly – more good than harm?. Expert Opinion on Drug Safety, 2007, 6, 229-231.	1.0	4
139	Evaluation of the quality of drug therapy among elderly patients in nursing homes. Scandinavian Journal of Primary Health Care, 2007, 25, 9-14.	0.6	90
140	Hidden danger, obvious opportunity: error and risk in the management of cancer. British Journal of Radiology, 2007, 80, 955-966.	1.0	22
141	Developing the role of the drug and therapeutics committees: perceptions of chairs. International Journal of Health Care Quality Assurance, 2007, 20, 161-178.	0.2	10
142	Pain management: setting up a nurse-led femoral nerve block service. British Journal of Nursing, 2007, 16, 702-705.	0.3	11

#	Article	IF	Citations
143	Personalized Medicine., 2007,, 279-295.		0
144	Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine, 2007, 4, 33-43.	0.8	4
145	Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases. Current Drug Safety, 2007, 2, 47-63.	0.3	23
146	Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics, 2007, 8, 851-861.	0.6	58
147	Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics, 2007, 8, 311-314.	0.6	13
148	Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics, 2007, 8, 519-519.	0.6	9
149	Injectable medication therapy: a patient safety challenge. Nursing Standard (Royal College of Nursing) Tj ETQq0	0 0 rgBT /	Overlock 10 1
150	Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care. Annals of Pharmacotherapy, 2007, 41, 1411-1426.	0.9	325
151	†Drug reactions, enzymes, and biochemical genetics': 50 years later. Pharmacogenomics, 2007, 8, 1479-1484.	0.6	31
152	Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes. Age and Ageing, 2007, 36, 414-418.	0.7	18
153	Aspirin Dose for the Prevention of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2007, 297, 2018.	3.8	394
154	Herbal Medicine: Potential for Intoxication and Interactions With Conventional Drugs. , 2007, , 183-207.		4
157	Aspirin for primary prevention of cardiovascular disease in older persons: where is the evidence?. Aging Health, 2007, 3, 159-164.	0.3	0
158	The Hospital Discharge. Journal of Patient Safety, 2007, 3, 97-106.	0.7	128
159	Investigation of Trigger Tools for Detecting Adverse Drug Reactions. Journal of Pharmacy Practice and Research, 2007, 37, 225-227.	0.5	3
160	Adverse Drug Reactions in Hospitals: A Narrative Review. Current Drug Safety, 2007, 2, 79-87.	0.3	82
161	Pharmacogenomics and its implications for autoimmune disease. Journal of Autoimmunity, 2007, 28, 122-128.	3.0	27
162	Individualizing warfarin therapy. Personalized Medicine, 2007, 4, 11-31.	0.8	51

#	ARTICLE	IF	CITATIONS
163	Admissions to a medical intensive care unit related to adverse drug reactions. American Journal of Health-System Pharmacy, 2007, 64, 1840-1843.	0.5	46
164	Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6. Drug Metabolism Reviews, 2007, 39, 45-60.	1.5	39
165	Epidemiology and Causes of Drug Hypersensitivity., 2007,, 2-17.		32
166	Idiosyncratic Drug Reactions: Current Understanding. Annual Review of Pharmacology and Toxicology, 2007, 47, 513-539.	4.2	276
167	Home-Based Medication Review in Older People. Pharmacoeconomics, 2007, 25, 171-180.	1.7	53
168	Warfarin Pharmacogenetics. Pharmacoeconomics, 2007, 25, 899-902.	1.7	17
170	Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. Molecular Pharmaceutics, 2007, 4, 895-910.	2.3	22
171	Hémorragies sous antivitamines K : les freins à la prescription du PPSB, mythes et réalités. JEUR/Journal Européen Des Urgences, 2007, 20, 1S1-1S9.	0.0	1
172	Emergency Department Management of the Salicylate-Poisoned Patient. Emergency Medicine Clinics of North America, 2007, 25, 333-346.	0.5	94
173	Factors that Influence Under-Reporting of Suspected Adverse Drug Reactions among Community Pharmacists in a Spanish Region. Drug Safety, 2007, 30, 1073-1082.	1.4	100
174	Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics, 2007, 8, 713-719.	0.6	19
175	Postmarketing Surveillance., 2007,, 755-777.		1
176	Interactions Between Antihypertensive Drugs and Other Medications., 2007,, 1075-1086.		0
177	The importance of earnest record keeping. NursePrescribing, 2007, 5, 363-366.	0.1	3
178	Exploiting the potential of informatics in health care. NursePrescribing, 2007, 5, 391-394.	0.1	2
179	Pharmacogenomics: clinical applications. , 0, , 516-528.		0
180	Drug induced liver injury., 0,, 247-270.		0
181	Pharmaceutical Strategy and Innovation: An Academics Perspective. ChemMedChem, 2007, 2, 768-788.	1.6	45

#	Article	IF	CITATIONS
182	Understanding rehospitalization risk: Can hospital discharge be modified to reduce recurrent hospitalization?. Journal of Hospital Medicine, 2007, 2, 297-304.	0.7	70
183	Colorectal Cancer Therapeutics and the Challenges of Applied Pharmacogenomics. Current Problems in Cancer, 2007, 31, 315-366.	1.0	5
184	Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clinical Pharmacology, 2007, 7, 8.	2.5	95
185	Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clinical Pharmacology, 2007, 7, 9.	2.5	150
186	Pharmacists' attitudes towards the reporting of suspected adverse drug reactions in Norway. Pharmacoepidemiology and Drug Safety, 2007, 16, 429-434.	0.9	82
187	Nurses are increasingly involved in pharmacovigilance in Sweden. Pharmacoepidemiology and Drug Safety, 2007, 16, 532-537.	0.9	53
188	Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiology and Drug Safety, 2007, 16, 641-651.	0.9	233
189	Results of forty years Yellow Card reporting for commonly used perioperative analgesic drugs. Pharmacoepidemiology and Drug Safety, 2007, 16, 687-694.	0.9	7
190	Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling. Clinical Pharmacology and Therapeutics, 2007, 81, 298-304.	2.3	327
191	Novel Statistical Tools for Monitoring the Safety of Marketed Drugs. Clinical Pharmacology and Therapeutics, 2007, 82, 157-166.	2.3	201
192	What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice?. Journal of Internal Medicine, 2008, 263, 16-27.	2.7	49
193	Drug allergy claims in children: from selfâ€reporting to confirmed diagnosis. Clinical and Experimental Allergy, 2008, 38, 191-198.	1.4	138
194	Inappropriate prescribing in the elderly. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 113-121.	0.7	349
195	Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 169-175.	0.7	120
196	Which drugs cause preventable admissions to hospital? A systematic review. British Journal of Clinical Pharmacology, 2007, 63, 136-147.	1.1	499
197	Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. British Journal of Clinical Pharmacology, 2007, 63, 148-156.	1.1	245
198	Risk factors for medication misadventure among residents in sheltered housing complexes. British Journal of Clinical Pharmacology, 2007, 63, 171-176.	1.1	22
199	Comparative assessment of four drug interaction compendia. British Journal of Clinical Pharmacology, 2007, 63, 709-714.	1.1	133

#	Article	IF	CITATIONS
200	Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980?2003. British Journal of Clinical Pharmacology, 2007, 63, 163-170.	1.1	83
201	Adverse drug reactions? no farewell to harms. British Journal of Clinical Pharmacology, 2007, 63, 131-135.	1.1	19
202	Foundation year 1 doctors and clinical pharmacology and therapeutics teaching. A retrospective view in light of experience. British Journal of Clinical Pharmacology, 2007, 64, 363-372.	1.1	100
203	Communicating information about drug interactions. British Journal of Clinical Pharmacology, 2007, 63, 637-639.	1.1	22
204	Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms. Alimentary Pharmacology and Therapeutics, 2007, 26, 211-219.	1.9	94
205	Daily vitamin K supplementation improves anticoagulant stability. Journal of Thrombosis and Haemostasis, 2007, 5, 2043-2048.	1.9	74
206	Preventing adverse drug reactions. International Journal of Clinical Practice, 2007, 61, 13-14.	0.8	1
207	Clinical Pharmacy Services, Pharmacy Staffing, and Hospital Mortality Rates. Pharmacotherapy, 2007, 27, 481-493.	1.2	304
208	Communicating the risks and benefits of medicines. Drug Discovery Today, 2007, 12, 355-364.	3.2	16
209	Safer use of anticoagulants: the NPSA patient safety alert. The Prescriber, 2007, 18, 17-24.	0.1	1
210	Genotypic Approaches to Therapy in Children: A National Active Surveillance Network (GATC) to Study the Pharmacogenomics of Severe Adverse Drug Reactions in Children. Annals of the New York Academy of Sciences, 2007, 1110, 177-192.	1.8	28
211	Recognition and management of potential drug–drug interactions in patients on internal medicine wards. European Journal of Clinical Pharmacology, 2007, 63, 1075-1083.	0.8	30
212	Detection and prevention of prescriptions with excessive doses in electronic prescribing systems. European Journal of Clinical Pharmacology, 2007, 63, 1185-1192.	0.8	16
214	Current strategies for ischemic stroke prevention: role of multimodal combination therapies. Journal of Neurology, 2007, 254, 1414-1426.	1.8	22
215	Evaluation of frequently used drug interaction screening programs. International Journal of Clinical Pharmacy, 2008, 30, 367-374.	1.4	105
216	Adverse-drug-reaction related admissions to a hospital in Scotland. International Journal of Clinical Pharmacy, 2008, 30, 854-862.	1.4	37
217	Pharmacist intervention reduces gastropathy risk in patients using NSAIDs. International Journal of Clinical Pharmacy, 2008, 30, 947-954.	1.4	12
218	The clinical implications of ageing for rational drug therapy. European Journal of Clinical Pharmacology, 2008, 64, 183-199.	0.8	200

#	Article	IF	CITATIONS
219	The future of pharmacovigilance: a personal view. European Journal of Clinical Pharmacology, 2008, 64, 173-181.	0.8	13
220	A nurse-led intervention for identification of drug-related problems. European Journal of Clinical Pharmacology, 2008, 64, 451-456.	0.8	12
221	Factors predicting hospital readmissions related to adverse drug reactions. European Journal of Clinical Pharmacology, 2008, 64, 715-722.	0.8	62
222	Documentation of drug allergy on drug chart in patients presenting for surgery. Irish Journal of Medical Science, 2008, 177, 243-245.	0.8	11
223	The use of questionnaires for measuring patientâ€reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiology and Drug Safety, 2008, 17, 278-296.	0.9	36
224	Adverse drug reactionâ€related hospitalisations: a populationâ€based cohort study. Pharmacoepidemiology and Drug Safety, 2008, 17, 365-371.	0.9	128
225	Criteria for high-risk medication use in Thai older patients. Archives of Gerontology and Geriatrics, 2008, 47, 35-51.	1.4	67
227	The Art of Prescribing Pharmacological Management of Psychosis in Alzheimer's Disease: Clinical Challenges Associated With Second-Generation Antipsychotic Medications. Perspectives in Psychiatric Care, 2008, 44, 120-123.	0.9	1
228	Zebrafish: an emerging technology for <i>in vivo</i> pharmacological assessment to identify potential safety liabilities in early drug discovery. British Journal of Pharmacology, 2008, 154, 1400-1413.	2.7	236
229	Pain and Osteoarthritis in Primary Care: Factors Associated with Pain Perception in a Sample of 1,021 Patients. Pain Medicine, 2008, 9, 903-910.	0.9	52
230	Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. British Journal of Clinical Pharmacology, 2008, 65, 396-406.	1,1	98
231	Response to †Communicating Information about Drug Interactions'. British Journal of Clinical Pharmacology, 2008, 65, 617-618.	1.1	1
232	Incidence of fatal adverse drug reactions: a population based study. British Journal of Clinical Pharmacology, 2008, 65, 573-579.	1.1	265
233	Minimising Harm: Human Variation and Adverse Drug Reactions (ADRs). British Journal of Clinical Pharmacology, 2008, 65, 451-452.	1.1	9
234	Neutropenia, thrombocytopenia and hepatic injury associated with dexketoprofen trometamol therapy in a previously healthy 35-year-old woman. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 79-81.	0.7	16
236	Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Services Research, 2008, 8, 108.	0.9	165
237	Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthritis and Cartilage, 2008, 16, 1277-1288.	0.6	76
238	Utilization of a community pharmacy-operated national drug information call center in Finland. Research in Social and Administrative Pharmacy, 2008, 4, 144-152.	1.5	27

#	Article	IF	CITATIONS
239	Drug metabolism. Medicine, 2008, 36, 355-359.	0.2	5
240	Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1415-1427.	1.5	71
241	The Genetics of Adverse Drug Reactions. Methods in Pharmacology and Toxicology, 2008, , 121-147.	0.1	3
242	Prevalence, Clinical Features and Avoidability of Adverse Drug Reactions as Cause of Admission to??a??Geriatric Unit. Drug Safety, 2008, 31, 545-556.	1.4	181
243	Ethnic Differences in the Risks of Adverse Reactions to Drugs Used in the Treatment of Psychoses and Depression. Drug Safety, 2008, 31, 597-607.	1.4	35
244	Drug-Related Deaths. Drug Safety, 2008, 31, 703-713.	1.4	38
245	Risk Factors Associated with Adverse Drug Reactions Following Hospital Admission. Drug Safety, 2008, 31, 789-798.	1.4	85
247	Hypersensitivity Pneumonitis Due to Venlafaxine. Archivos De Bronconeumologia, 2008, 44, 571-573.	0.4	7
248	Clinical manifestations and mechanisms of skin reactions after systemic drug administration. Drug Discovery Today Disease Mechanisms, 2008, 5, e237-e247.	0.8	5
249	ADME-tox issues for the elderly. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1321-1331.	1.5	40
250	Inappropriate Medication Use and Prescribing Indicators in Elderly Australians. Drugs and Aging, 2008, 25, 777-793.	1.3	101
251	Increasing Exposure to Drug-Drug Interactions Between 1992 and 2005 in People Aged ≥55 Years. Drugs and Aging, 2008, 25, 145-152.	1.3	42
252	New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process. Journal of Clinical Pharmacology, 2008, 48, 662-670.	1.0	333
253	Adverse drug reactions as a cause of hospital admissions: A 6-month experience in a single center in Greece. European Journal of Internal Medicine, 2008, 19, 505-510.	1.0	83
254	Prevalence of drug–drug interactions at hospital entry and during hospital stay of patients in internal medicine. European Journal of Internal Medicine, 2008, 19, 413-420.	1.0	88
255	Chiropractic manipulation: Reasons for concern?. Clinical Neurology and Neurosurgery, 2008, 110, 422-423.	0.6	0
256	Analysis of the association between polypharmacy and socioeconomic position among elderly aged ≥77 years in Sweden. Clinical Therapeutics, 2008, 30, 419-427.	1.1	89
257	Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study. Current Therapeutic Research, 2008, 69, 118-129.	0.5	28

#	Article	IF	CITATIONS
259	Prise en charge des accidents des anticoagulants. Reanimation: Journal De La Societe De Reanimation De Langue Française, 2008, 17, 363-369.	0.1	0
260	Pharmacogenomics of 4-Hydroxycoumarin Anticoagulants. Drug Metabolism Reviews, 2008, 40, 355-375.	1.5	91
261	A Practical "ABCDE―Approach to the Metabolic Syndrome. Mayo Clinic Proceedings, 2008, 83, 932-943.	1.4	42
262	Clinical perspectives in drug safety and adverse drug reactions. Expert Review of Clinical Pharmacology, 2008, 1, 695-705.	1.3	30
263	Do nonâ€steroidal antiâ€inflammatory drugs influence chronic inflammation? The effects of piroxicam on chronic antigenâ€induced arthritis in rats. Scandinavian Journal of Rheumatology, 2008, 37, 469-476.	0.6	7
264	A 30-year survey of drug use in the 1914 birth cohort in Glostrup County, Denmark: 1964–1994. Aging Clinical and Experimental Research, 2008, 20, 145-152.	1.4	8
265	The Potential for Interaction between Warfarin and Coprescribed Medication. American Journal of Cardiovascular Drugs, 2008, 8, 207-212.	1.0	29
266	Biomarkers of drug-induced adverse events. Expert Review of Clinical Pharmacology, 2008, 1, 81-91.	1.3	6
267	Managing Pain in the Older Person. Journal of Pain and Palliative Care Pharmacotherapy, 2008, 22, 167-170.	0.5	1
268	Perifollicular Xanthomatosis as the Hallmark of Axillary Fox-Fordyce Disease. Archives of Dermatology, 2008, 144, 1020-4.	1.7	423
269	Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Multiple Sclerosis Journal, 2008, 14, 94-105.	1.4	21
270	Nationwide Survey of Subjectively Reported Adverse Drug Reactions in Sweden. Annals of Pharmacotherapy, 2008, 42, 347-353.	0.9	17
271	A substantial cause of preventable illness. BMJ: British Medical Journal, 2008, 336, 956.1-957.	2.4	30
272	Predicting Future Human and Environmental Health Challenges: The Health and Environmental Sciences Institute's Scientific Mapping Exercise. Critical Reviews in Toxicology, 2008, 38, 817-845.	1.9	4
273	Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Family Practice, 2008, 25, 27-32.	0.8	25
274	The contribution of a pharmacy admissions service to patient care. Clinical Medicine, 2008, 8, 53-57.	0.8	10
275	Adverse drug reactions and pharmacogenomics: recent advances. Personalized Medicine, 2008, 5, 11-23.	0.8	21
276	Aspirin for all over 50 revisited. Heart, 2008, 94, 1364-1365.	1.2	0

#	Article	IF	Citations
277	Improved arthritic knee health in a pilot RCT of phytotherapy. Perspectives in Public Health, 2008, 128, 255-262.	0.5	11
279	Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. Cmaj, 2008, 178, 1563-1569.	0.9	248
280	Temporal pattern discovery for trends and transient effects. , 2008, , .		35
282	Characterization of Total Plasma Glycosaminoglycan Levels in Healthy Volunteers Following Oral Administration of a Novel Antithrombotic Odiparcil With Aspirin or Enoxaparin. Journal of Clinical Pharmacology, 2008, 48, 1158-1170.	1.0	16
283	Which drug reactions should be reported?. Practice Nursing, 2008, 19, 182-184.	0.1	1
284	Retropharyngeal haematoma – an unusual bleeding site in an anticoagulated patient: a case report. Cases Journal, 2008, 1, 294.	0.4	11
285	A Practical "ABCDE―Approach to the Metabolic Syndrome. Mayo Clinic Proceedings, 2008, 83, 932-943.	1.4	73
286	Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: aÂtranslational pharmacogenomics platform – from R&D to the clinic. Pharmacogenomics, 2008, 9, 1391-1396.	0.6	2
287	Statin Induced Myopathy and Myalgia: Time Trend Analysis and Comparison of Risk Associated with Statin Class from 1991–2006. PLoS ONE, 2008, 3, e2522.	1.1	72
288	A Steep Increase in Domestic Fatal Medication Errors With Use of Alcohol and/or Street Drugs. Archives of Internal Medicine, 2008, 168, 1561.	4.3	34
289	The art of prescribing. British Journal of Hospital Medicine (London, England: 2005), 2008, 69, M72-M73.	0.2	0
290	Low drug doses may improve outcomes in chronic disease. Medical Journal of Australia, 2009, 191, 511-513.	0.8	19
291	Toxicology and Genetics of Adverse Drug Events. , 2009, , 339-344.		1
292	Contribuição do uso de medicamentos para a admissão hospitalar. Brazilian Journal of Pharmaceutical Sciences, 2009, 45, 163-170.	1.2	11
293	Improving reporting of adverse drug reactions: Systematic review. Clinical Epidemiology, 2009, 1, 75.	1.5	66
294	Reporting medication errors and near misses. , 2009, , 155-172.		5
295	Chairman of the Joint Formulary Committee, British National Formulary. Clinical Medicine, 2009, 9, 349-352.	0.8	5
296	Pitfalls in the Diagnosis and Therapy of Infections in Elderly Patients – A Mini-Review. Gerontology, 2009, 55, 241-249.	1.4	44

#	Article	IF	CITATIONS
297	High-Mobility Group Box-1 Protein and Keratin-18, Circulating Serum Proteins Informative of Acetaminophen-Induced Necrosis and Apoptosis In Vivo. Toxicological Sciences, 2009, 112, 521-531.	1.4	199
298	Inflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models. Pharmacological Reviews, 2009, 61, 262-282.	7.1	118
299	Medication errors: the impact of prescribing and transcribing errors on preventable harm in hospitalised patients. Quality and Safety in Health Care, 2009, 18, 22-27.	2.5	71
300	Point: Use of Pharmacogenetics in Guiding Treatment with Warfarin. Clinical Chemistry, 2009, 55, 709-711.	1.5	18
301	The swine flu, advice giving and the reporting of adverse drug reactions. British Journal of Community Nursing, 2009, 14, 405-409.	0.2	2
302	Small molecules as friends and foes of the immune system. Future Medicinal Chemistry, 2009, 1, 1583-1591.	1.1	8
303	Clinical pharmacology, biomarkers and personalized medicine: education please. Biomarkers in Medicine, 2009, 3, 685-700.	0.6	9
304	DrugNerAR., 2009,,.		3
305	Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics, 2009, 10, 157-159.	0.6	21
306	Adverse drug reactions in elderly: challenges in identification and improving preventative strategies. Age and Ageing, 2009, 38, 358-359.	0.7	51
307	Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics Journal, 2009, 9, 23-33.	0.9	98
308	Potential contribution of aspirin to cancer control programmes. Ecancermedicalscience, 2009, 3, 100.	0.6	0
309	Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007. American Journal of Health-System Pharmacy, 2009, 66, 481-487.	0.5	25
310	Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies. PLoS ONE, 2009, 4, e7960.	1.1	89
311	Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics, 2009, 10, 961-969.	0.6	78
312	Simulated patient visits with immediate feedback to improve the supply of over-the-counter medicines: a feasibility study. Family Practice, 2009, 26, 532-542.	0.8	49
313	Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ: British Medical Journal, 2009, 338, a2752-a2752.	2.4	154
314	Algorithms for assessing the probability of an Adverse Drug Reaction. Respiratory Medicine CME, 2009, 2, 63-67.	0.1	48

#	Article	IF	CITATIONS
315	Quality of medication use in primary care - mapping the problem, working to a solution: a systematic review of the literature. BMC Medicine, 2009, 7, 50.	2.3	64
316	The future of drug safety testing: expanding the view and narrowing the focus. Drug Discovery Today, 2009, 14, 162-167.	3.2	256
317	What factors affect the use of electronic patient records by Irish GPs?. International Journal of Medical Informatics, 2009, 78, 551-558.	1.6	55
319	Dogma driven science, the need to establish a common base line. Chemico-Biological Interactions, 2009, 179, 68-70.	1.7	3
321	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. American Journal of Hematology, 2009, 84, 584-588.	2.0	56
323	Patient self-reporting of potential adverse drug reactions to non-steroidal anti-inflammatory drugs in Thailand. International Journal of Clinical Pharmacy, 2009, 31, 559-564.	1.4	29
326	Adverse drug reactions and deliberate self-poisoning as cause of admission to the intensive care unit: a 1-year prospective observational cohort study. Intensive Care Medicine, 2009, 35, 266-274.	3.9	59
327	Teaching improves adherence to clinical guidelines in the treatment of oral anticoagulation-related severe bleeding in the emergency department. Intensive Care Medicine, 2009, 35, 1444-1448.	3.9	15
328	Nurse-led medication reviews and the quality of drug treatment of elderly hospitalized patients. European Journal of Clinical Pharmacology, 2009, 65, 1089-1096.	0.8	20
329	Adverse drug reactions in patients in an Iranian department of internal medicine. Pharmacoepidemiology and Drug Safety, 2009, 18, 104-110.	0.9	27
330	Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?. Pharmacoepidemiology and Drug Safety, 2009, 18, 1176-1184.	0.9	162
331	Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clinical Pharmacology, 2009, 9, 14.	2.5	134
332	The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clinical Pharmacology, 2009, 9, 8.	2.5	82
333	Interns' knowledge of clinical pharmacology and therapeutics after undergraduate and on-going internship training in Nigeria: a pilot study. BMC Medical Education, 2009, 9, 50.	1.0	42
334	Modelâ€based costâ€effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). Journal of Evaluation in Clinical Practice, 2009, 15, 299-306.	0.9	108
335	Prospective observational study of adverse drug reactions to diclofenac in children. British Journal of Clinical Pharmacology, 2009, 68, 243-251.	1.1	19
336	Heart Failure and Adverse Drug Reactions Among Hospitalized Older Adults. Clinical Pharmacology and Therapeutics, 2009, 86, 307-310.	2.3	33
337	An agenda for personalized medicine. Nature, 2009, 461, 724-726.	13.7	293

#	ARTICLE	IF	CITATIONS
338	Perception of risk of adverse drug reactions: a 3-year follow-up of a cohort of medical students. Fundamental and Clinical Pharmacology, 2009, 24, 423-427.	1.0	8
339	Medical malpractice as reflected by the forensic evaluation of 4450 autopsies. Forensic Science International, 2009, 190, 58-66.	1.3	55
340	Medical negligence in drug associated deaths. Forensic Science International, 2009, 190, 67-73.	1.3	23
341	Pharmacogenetics in Neurological Diseases. , 2009, , 65-75.		1
342	A new model of pharmacovigilance? A pilot study. Biomedicine and Pharmacotherapy, 2009, 63, 451-455.	2.5	7
346	Are herbals as safe as their advocates believe?. Journal of Hepatology, 2009, 50, 13-16.	1.8	20
347	Immune-Mediated Adverse Drug Reactions. Chemical Research in Toxicology, 2009, 22, 24-34.	1.7	92
348	Negative results related to drugs required in hospitalisation. Farmacia Hospitalaria (English Edition), 2009, 33, 12-25.	0.0	2
349	Spontaneous ADR Reports as a Trigger for Pharmacogenetic Research. Drug Safety, 2009, 32, 255-264.	1.4	15
350	Laboratory Tests in the Clinical Risk Management of Potential Drug-Drug Interactions. Drug Safety, 2009, 32, 1189-1197.	1.4	20
351	A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling. Clinical Pharmacokinetics, 2009, 48, 653-666.	1.6	38
352	Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Medicine, 2009, 1, 10.	3.6	33
353	Genomic and proteomic approaches for predicting toxicity and adverse drug reactions. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 29-37.	1.5	19
354	Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica, 2009, 39, 565-577.	0.5	47
355	Adverse Drug Reactions and Impaired Renal Function in Elderly Patients Admitted to the Emergency Department. Drugs and Aging, 2009, 26, 595-606.	1.3	76
356	Hospitalizations because of Adverse Drug Reactions in Elderly Patients Admitted through the Emergency Department. Drugs and Aging, 2009, 26, 475-482.	1.3	112
357	Pharmacist-Based Medication Review Reduces Potential Drug-Related Problems in the Elderly. Drugs and Aging, 2009, 26, 123-133.	1.3	110
358	Teaching of medical pharmacology: The need to nurture the early development of desired attitudes for safe and rational drug prescribing. Medical Teacher, 2009, 31, 847-854.	1.0	28

#	Article	IF	CITATIONS
359	Organic cation transporters and their roles in antiretroviral drug disposition. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 773-787.	1.5	9
360	Cytochrome P450 2D6 Genotyping. CNS Drugs, 2009, 23, 181-191.	2.7	33
361	Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs. Current Medical Research and Opinion, 2009, 25, 2785-2793.	0.9	30
362	Neurochirurgie d'urgence et AVK: retarder la chirurgie n'est pas nécessaire. Neurochirurgie, 2009, 55, H23-H28.	0.6	0
363	Compliance to Recommended Liver Function Monitoring in Patients on Statin Therapy. Cardiovascular Therapeutics, 2009, 27, 96-100.	1.1	11
364	Prise en charge des h $ ilde{A}$ ©morragies sous antivitamine K en 2008 : Enfin des recommandations !. JEUR/Journal Europ $ ilde{A}$ ©en Des Urgences, 2009, 22, S5-S10.	0.0	0
365	Épidémiologie des accidents hémorragiques survenant chez les patients sous antivitamine K. JEUR/Journal Européen Des Urgences, 2009, 22, S1-S4.	0.0	3
366	Gastrointestinal Bleeding in the Setting of Anticoagulation and Antiplatelet Therapy. Journal of Clinical Gastroenterology, 2009, 43, 5-12.	1.1	41
367	Gross Lower Gastrointestinal Bleeding in Patients on Anticoagulant and/or Antiplatelet Therapy. Journal of Clinical Gastroenterology, 2009, 43, 36-42.	1.1	24
368	A Drug Interactions Elective Course. American Journal of Pharmaceutical Education, 2009, 73, 72.	0.7	13
369	Undesirable Events With Radiopharmaceuticals. Tohoku Journal of Experimental Medicine, 2009, 217, 251-257.	0.5	14
371	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. Annals of Internal Medicine, 2009, 150, 379.	2.0	152
372	Awareness and Reporting of Adverse Drug Reactions Among Health Care Professionals in Sudan. Joint Commission Journal on Quality and Patient Safety, 2009, 35, 324-AP2.	0.4	15
374	Pharmacogenetics and Psychoactive Drug Therapy: Ready for the Patient?. Therapeutic Drug Monitoring, 2010, 32, 381-386.	1.0	16
375	Involving patients and providers to develop an Irish patient education tool on medication safety. Journal of Management and Marketing in Healthcare, 2010, 3, 73-86.	0.3	1
376	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. Yearbook of Cardiology, 2010, 2010, 287-289.	0.0	O
377	Patch testing in drug allergy. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 291-296.	1.1	66
378	Evaluating the Safety and Effectiveness of New Drugs. Obstetrics and Gynecology, 2010, 116, 1405-1409.	1.2	5

#	Article	IF	CITATIONS
379	Azole antimycotics and drug interactions in the perioperative period. Current Opinion in Anaesthesiology, 2010, 23, 441-448.	0.9	8
381	Effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. British Journal of General Practice, 2010, 60, e10-e19.	0.7	46
383	An innovative software solution for personalized pharmacotherapy. Therapeutic Delivery, 2010, 1, 643-650.	1.2	0
384	Is hospital admission a sufficiently sensitive outcome measure for evaluating medication review services? A descriptive analysis of admissions within a randomised controlled trial. International Journal of Pharmacy Practice, 2010, 15, 85-91.	0.3	11
386	Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. European Journal of Clinical Pharmacology, 2010, 66, 137-144.	0.8	43
387	Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. European Journal of Clinical Pharmacology, 2010, 66, 755-774.	0.8	60
388	An expert panel assessment of comprehensive medication reviews for clients of community mental health teams. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 1071-1079.	1.6	46
391	Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wiener Klinische Wochenschrift, 2010, 122, 81-88.	1.0	40
392	Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. Wiener Klinische Wochenschrift, 2010, 122, 62-64.	1.0	20
393	Contribution of drug related problems to hospital admission in the elderly. Journal of Nutrition, Health and Aging, 2010, 14, 477-482.	1.5	48
394	Determining the frequency of prescription errors in an Irish hospital. Irish Journal of Medical Science, 2010, 179, 183-186.	0.8	18
395	Potential drug–drug interactions and radiodiagnostic procedures: an in-hospital survey. International Journal of Clinical Pharmacy, 2010, 32, 200-205.	1.4	3
396	Detection of adverse drug reactions through the minimum basic data set. International Journal of Clinical Pharmacy, 2010, 32, 322-328.	1.4	12
397	Relationship between drug-related problems and health outcomes: a cross-sectional study among cardiovascular patients. International Journal of Clinical Pharmacy, 2010, 32, 512-519.	1.4	40
398	Training Australian pharmacists for participation in a collaborative, home-based post-discharge warfarin management service. International Journal of Clinical Pharmacy, 2010, 32, 637-642.	1.4	8
399	Temporal pattern discovery in longitudinal electronic patient records. Data Mining and Knowledge Discovery, 2010, 20, 361-387.	2.4	148
400	Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information. , 2010, 125, 230-248.		87
401	Receiving a pharmaceutical care service compared to receiving standard pharmacy service in Sweden–How do patients differ with regard to perceptions of medicine use and the pharmacy encounter?. Research in Social and Administrative Pharmacy, 2010, 6, 185-195.	1.5	20

#	Article	IF	CITATIONS
402	Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Research, 2010, 5, 4-22.	0.3	66
403	A pill for every ill': Explaining the expansion in medicine use. Social Science and Medicine, 2010, 70, 934-941.	1.8	120
404	Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicology and Applied Pharmacology, 2010, 243, 154-166.	1.3	202
405	Resolving anaphoras for the extraction of drug-drug interactions in pharmacological documents. BMC Bioinformatics, 2010, 11, S1.	1.2	31
406	Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006). BMC Health Services Research, 2010, 10, 287.	0.9	68
407	Drug profiling: knowing where it hits. Drug Discovery Today, 2010, 15, 749-756.	3.2	60
408	Differential effect of covalent protein modification and glutathione depletion on the transcriptional response of Nrf2 and NF-κB. Biochemical Pharmacology, 2010, 80, 410-421.	2.0	32
410	Personal digital assistant with a barcode readerâ€"A medical decision support system for nurses in home care. International Journal of Medical Informatics, 2010, 79, 232-242.	1.6	33
411	Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: From risk factor identification to risk factor intervention. Joint Bone Spine, 2010, 77, 6-12.	0.8	32
413	Prévention des complications digestives des anti-inflammatoires non stéroÃ <sup>-</sup> diensÂ: de la connaissance des facteurs de risque à leur prise en compte. Revue Du Rhumatisme (Edition Francaise), 2010, 77, 7-13.	0.0	0
414	Pharmacogenetics in medico-legal context. Forensic Science International, 2010, 203, 44-52.	1.3	38
415	The anti-vaccination movement and resistance to allergen-immunotherapy: a guide for clinical allergists. Allergy, Asthma and Clinical Immunology, 2010, 6, 26.	0.9	8
416	Patient safety in Dutch primary care: a study protocol. Implementation Science, 2010, 5, 50.	2.5	26
417	Analgesic and antiinflammatory activity of <i>Morinda citrifolia</i> L. (Noni) fruit. Phytotherapy Research, 2010, 24, 38-42.	2.8	64
418	Effectiveness and safety of topical capsaicin cream in the treatment of chronic soft tissue pain. Phytotherapy Research, 2010, 24, 1877-1885.	2.8	46
419	Hospital pharmacists' knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiology and Drug Safety, 2010, 19, 217-222.	0.9	66
420	Adverse drug events in the outpatient setting: an 11â€year national analysis. Pharmacoepidemiology and Drug Safety, 2010, 19, 901-910.	0.9	260
421	Is suboptimal prescribing a risk factor for poor health outcomes in communityâ€dwelling elders? The ICARe Dicomano study. Pharmacoepidemiology and Drug Safety, 2010, 19, 954-960.	0.9	28

#	Article	IF	Citations
422	Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. Journal of Thrombosis and Haemostasis, 2010, 8, 678-683.	1.9	79
423	A Pharmacogeneticsâ€based Approach to Reduce Cardiovascular Mortality with the Prophylactic Use of Statins. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 357-361.	1.2	35
424	Clinical Pharmacology in Research, Teaching and Health Care. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 531-559.	1.2	91
425	Nationwide drugâ€dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6â€dependent drug interactions. British Journal of Clinical Pharmacology, 2010, 69, 411-417.	1.1	23
426	Potentially inappropriate prescribing and cost outcomes for older people: a national population study. British Journal of Clinical Pharmacology, 2010, 69, 543-552.	1.1	326
427	Teaching of clinical pharmacology and therapeutics in UK medical schools: current status in 2009. British Journal of Clinical Pharmacology, 2010, 70, 143-148.	1.1	54
428	Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents. British Journal of Clinical Pharmacology, 2010, 70, 102-108.	1.1	6
429	Prevalence of potentially hazardous drug interactions amongst Australian veterans. British Journal of Clinical Pharmacology, 2010, 70, 252-257.	1.1	48
430	Emergency reâ€admissions to hospital due to adverse drug reactions within 1 year of the index admission. British Journal of Clinical Pharmacology, 2010, 70, 749-755.	1.1	99
431	Community pharmacy dispensing of prescription medicine sample packs: changing the business of medicine initiation?. Journal of Evaluation in Clinical Practice, 2010, 16, 1357-1360.	0.9	0
432	Antiplatelet drug interactions. Journal of Internal Medicine, 2010, 268, 516-529.	2.7	39
433	Does gastric acid suppression increase the risk of drug allergies?. Clinical and Experimental Allergy, 2010, 40, 362-364.	1.4	2
434	An analysis and comparison of commonly available United Kingdom prescribing resources. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 453-64.	0.7	3
435	A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients. Clinical Pharmacology and Therapeutics, 2010, 87, 74-86.	2.3	67
436	Registered nurses' medication management of the elderly in aged care facilities. International Nursing Review, 2010, 57, 98-106.	1.5	23
437	Quality of drug prescribing in older patients: is there a problem and can we improve it?. Internal Medicine Journal, 2010, 40, 7-18.	0.5	59
438	Successful implementation of a national HLAâ€B*5701 genetic testing service in Canada. Tissue Antigens, 2010, 75, 12-18.	1.0	26
439	Making medicines safe: a focus on good prescribing. NursePrescribing, 2010, 8, 130-132.	0.1	O

#	ARTICLE	IF	CITATIONS
440	Patients' attention to and understanding of adverse drug reaction warnings. Patient Intelligence, 2010, , 59.	0.2	5
441	Opportunities for Medication-Related Support after Discharge from Hospital. Canadian Pharmacists Journal, 2010, 143, 170-175.	0.4	5
442	Possible pharmacological interactions in hypertensive and/or diabetic elderly in family health units at Blumenau (SC). Brazilian Journal of Pharmaceutical Sciences, 2010, 46, 795-804.	1.2	13
443	Quality Improvement Opportunities in Prescriber Alert Programs. Journal of Managed Care Pharmacy, 2010, 16, 292-296.	2.2	4
444	Pharmacist and Physician Satisfaction and Rates of Switching to Preferred Medications Associated with an Instant Prior Authorization Program for Proton Pump Inhibitors in the North Carolina Medicaid Program. Journal of Managed Care Pharmacy, 2010, 16, 250-263.	2.2	7
445	The UK National Health Service approach to the economic crisis. Journal of the Royal Society of Medicine, 2010, 103, 123-124.	1.1	4
446	Adverse Drug Events in Adult Patients Leading to Emergency Department Visits. Annals of Pharmacotherapy, 2010, 44, 641-649.	0.9	47
447	Idiosyncratic Drug-Induced Liver Injury and the Role of Inflammatory Stress with an Emphasis on an Animal Model of Trovafloxacin Hepatotoxicity. Toxicological Sciences, 2010, 118, 7-18.	1.4	112
448	Prescribing Safely. InnovAiT, 2010, 3, 180-181.	0.0	0
449	Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. Journal of Clinical Pathology, 2010, 63, 288-295.	1.0	109
450	Factors Influencing Uptake of Pharmacogenetic Testing in a Diverse Patient Population. Public Health Genomics, 2010, 13, 48-54.	0.6	33
451	Definitions and mechanisms of drug hypersensitivity. Expert Review of Clinical Pharmacology, 2010, 3, 539-551.	1.3	13
452	Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. Journal of the Royal Society of Medicine, 2010, 103, 239-250.	1.1	137
453	The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology. Thyroid, 2010, 20, 681-687.	2.4	67
454	The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1083-1094.	1.5	15
455	Adverse drug reactions in older people. Reviews in Clinical Gerontology, 2010, 20, 246-259.	0.5	15
456	Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics, 2010, 11, 573-585.	0.6	99
457	Septic arthritis in the elderly. Aging Health, 2010, 6, 495-500.	0.3	3

#	Article	IF	Citations
458	Community-Dwelling Elders' Knowledge of Drug-to-Drug Interactions. Journal of Community Health Nursing, 2010, 27, 61-69.	0.1	2
459	Bioethics and the Reinforcement of Socio-technical Expectations. Social Studies of Science, 2010, 40, 163-186.	1.5	61
460	Development and Validation of a Score to Assess Risk of Adverse Drug Reactions Among In-Hospital Patients 65 Years or Older. Archives of Internal Medicine, 2010, 170, 1142-8.	4.3	249
461	Pharmacogenomics and active surveillance for serious adverse drug reactions in children. Pharmacogenomics, 2010, 11, 1269-1285.	0.6	19
462	Improving pharmacovigilance in Europe. BMJ: British Medical Journal, 2010, 340, c1694-c1694.	2.4	22
463	Pharmacogenetics education: 10 years of experience at Tel Aviv University. Pharmacogenomics, 2010, 11, 647-649.	0.6	16
465	Antidepressants: Clinically Relevant Drug Interactions to Be Considered. Pharmacology, 2010, 86, 203-215.	0.9	63
466	Potentially inappropriate drug prescription in older subjects across health care settings. European Geriatric Medicine, 2010, 1, 9-14.	1.2	60
467	Stimulation of human T cells with sulfonamides and sulfonamide metabolites. Journal of Allergy and Clinical Immunology, 2010, 125, 411-418.e4.	1.5	109
468	Investigation of drug–drug interactions and pain—From volunteer studies to randomized controlled trials in patients with chronic pain. Scandinavian Journal of Pain, 2010, 1, 5.	0.5	0
471	The Relationship Between Study Characteristics and the Prevalence of Medication-Related Hospitalizations. Drug Safety, 2010, 33, 233-244.	1.4	82
472	Improving Adverse Drug Reaction Reporting in Hospitals. Drug Safety, 2010, 33, 409-416.	1.4	32
473	Identifying Adverse Drug Reactions Associated with Drug-Drug Interactions. Drug Safety, 2010, 33, 667-675.	1.4	77
474	Preventability of Drug-Related Harms – Part I. Drug Safety, 2010, 33, 985-994.	1.4	61
475	Pharmaceutical intervention with parenteral nutrition. Farmacia Hospitalaria (English Edition), 2010, 34, 9-15.	0.0	5
476	Psychiatric side effects of non-psychiatric drugs. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784	314.rgBT / 	Overlock 10
477	Drug treatment in an ageing population: Practical implications. Maturitas, 2010, 66, 246-250.	1.0	26
478	Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in Romania. European Journal of Internal Medicine, 2010, 21, 453-457.	1.0	28

#	Article	IF	Citations
480	Systematic Review of the Symptom Burden, Quality of Life Impairment and Costs Associated with Peptic Ulcer Disease. American Journal of Medicine, 2010, 123, 358-366.e2.	0.6	103
481	Personalized medicine: the impact on chemistry. Therapeutic Delivery, 2010, 1, 651-665.	1.2	8
482	Metabolic and Chemical Origins of Cross-Reactive Immunological Reactions to Arylamine Benzenesulfonamides: T-Cell Responses to Hydroxylamine and Nitroso Derivatives. Chemical Research in Toxicology, 2010, 23, 184-192.	1.7	25
483	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thrombosis and Haemostasis, 2010, 103, 572-585.	1.8	119
485	A Pharmaceutical Intelligent Information System to detect allergies and Adverse Drugs Reactions based on internet of things. , 2010, , .		41
486	Medication Errors in Psychiatry. CNS Drugs, 2010, 24, 595-609.	2.7	42
487	Treatment of osteoarthritis in hypertensive patients. Expert Opinion on Pharmacotherapy, 2010, 11, 393-403.	0.9	20
488	An Investigation of Disagreement in Causality Assessment of Adverse Drug Reactions. Pharmaceutical Medicine, 2011, 25, 17-24.	1.0	10
489	In Vitro Testing for Hypersensitivity-Mediated Adverse Drug Reactions: Challenges and Future Directions. Clinical Pharmacology and Therapeutics, 2011, 90, 455-460.	2.3	13
490	Enzyme-Based Amperometric Platform to Determine the Polymorphic Response in Drug Metabolism by Cytochromes P450. Analytical Chemistry, 2011, 83, 2179-2186.	3.2	46
491	Attitudes and Approaches to Decision Making About Antihypertensive Treatment in Elderly Patients. Journal of the American Medical Directors Association, 2011, 12, 121-128.	1,2	10
493	Drug-drug Interactions in Hospitalized Cardiac Patients. Journal of Young Pharmacists, 2011, 3, 329-333.	0.1	31
494	Prevalence of hospital admission due to adverse drug reaction in Salvador, Bahia. Revista Da Associação MÃ@dica Brasileira (English Edition), 2011, 57, 42-45.	0.1	3
495	Nutrigenetics and Nutrigenomics: Viewpoints on the Current Status and Applications in Nutrition Research and Practice. Journal of Nutrigenetics and Nutrigenomics, 2011, 4, 69-89.	1.8	240
497	Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study. Value in Health, 2011, 14, 34-40.	0.1	87
499	Reporting Patterns Indicative of Adverse Drug Interactions. Drug Safety, 2011, 34, 253-266.	1.4	24
500	Adherence to Biochemical Monitoring Recommendations in Patients Starting with Renin Angiotensin System Inhibitors. Drug Safety, 2011, 34, 605-614.	1.4	18
501	Patient Experiences of Serious Adverse Drug Reactions and Their Attitudes to Medicines. Drug Safety, 2011, 34, 319-328.	1.4	52

#	Article	IF	Citations
502	Patient Follow-Up and Monitoring Medicines. Drug Safety, 2011, 34, 1121-1123.	1.4	2
503	Market trends of injectable drug delivery systems. Journal of Medical Marketing, 2011, 11, 237-243.	0.2	2
504	Adverse drug reactions to osteoporosis treatments. Expert Review of Clinical Pharmacology, 2011, 4, 593-604.	1.3	37
505	Cytochrome P450 polymorphisms and drug-induced interstitial lung disease. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1547-1560.	1.5	5
506	Drug eruptions in the elderly. Clinics in Dermatology, 2011, 29, 43-48.	0.8	20
507	Profiling of a Prescription Drug Library for Potential Renal Drugâ€"Drug Interactions Mediated by the Organic Cation Transporter 2. Journal of Medicinal Chemistry, 2011, 54, 4548-4558.	2.9	141
508	The prevalence of herbal medicine home use and concomitant use with pharmaceutical medicines in Jamaica. Journal of Ethnopharmacology, 2011, 137, 305-311.	2.0	86
509	Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends in Pharmacological Sciences, 2011, 32, 72-81.	4.0	91
511	A Novel Method for the Immunoquantification of UDP-Glucuronosyltransferases in Human Tissue. Drug Metabolism and Disposition, 2011, 39, 2258-2263.	1.7	21
512	A qualitative study exploring barriers and facilitators for reporting of adverse drug reactions (ADRs) among community pharmacists in Malaysia. Journal of Pharmaceutical Health Services Research, 2011, 2, 71-78.	0.3	26
513	Aspirin in the prevention of cancer. Lancet, The, 2011, 377, 1650-1651.	6.3	5
514	A deserving role for the National Center for Advancing Translational Sciences. Lancet, The, 2011, 377, 1745-1746.	6.3	1
515	Safety of medicines and the use of animals in research. Lancet, The, 2011, 378, 127-128.	6.3	8
516	Potential drug interactions in patients admitted to cardiology wards of a south Indian teaching hospital. Australasian Medical Journal, 2011, 4, 9-14.	0.1	37
517	Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal. Revista De Saude Publica, 2011, 45, 129-135.	0.7	38
518	Accountability for medication management. NursePrescribing, 2011, 9, 94-97.	0.1	1
519	Pharmacogenetics Role in Forensic Sciences. , 2011, , .		0
520	Incidence and cost estimate of treating pediatric adverse drug reactions in Lagos, Nigeria. Sao Paulo Medical Journal, 2011, 129, 153-164.	0.4	30

#	Article	IF	CITATIONS
521	How dangerous is prescribing?. NursePrescribing, 2011, 9, 426-426.	0.1	0
522	Pharmacology and the safe prescribing of drugs. , 0, , 1-14.		0
523	Pharmacovigilance amongst doctors in private hospitals in Lagos West Senatorial District, Nigeria. International Journal of Risk and Safety in Medicine, 2011, 23, 217-226.	0.3	13
524	Evaluation of Marine Brown Algae and Sponges from Brazil as Anticoagulant and Antiplatelet Products. Marine Drugs, 2011, 9, 1346-1358.	2.2	17
525	Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool. PLoS ONE, 2011, 6, e28096.	1.1	157
526	Authors' reply to Zermansky and Khatib. BMJ: British Medical Journal, 2011, 343, d7718-d7718.	2.4	0
527	High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ: British Medical Journal, 2011, 342, d3514-d3514.	2.4	179
528	Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs. Pharmacogenetics and Genomics, 2011, 21, 357-364.	0.7	17
529	Prevalence of Potentially Inappropriate Medication Use in Elderly Hospitalised Patients. Journal of Pharmacy Practice and Research, 2011, 41, 122-125.	0.5	8
530	Involvement of the Immune System in Idiosyncratic Drug Reactions. Drug Metabolism and Pharmacokinetics, 2011, 26, 47-59.	1.1	41
531	Overview: Adverse Drug Reactions., 0,, 27-37.		0
532	A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. Therapeutic Delivery, 2011, 2, 1437-1453.	1.2	28
533	Development of prescribing-safety indicators for GPs using the RAND Appropriateness Method. British Journal of General Practice, 2011, 61, e526-e536.	0.7	66
534	Diabetes medication patient safety incident reports to the National Reporting and Learning Service: the care home setting. Diabetic Medicine, 2011, 28, 1537-1540.	1.2	17
535	Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 283-298.	0.7	5
536	Adverse drug reactions causing admission to a paediatric hospital: a pilot study. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 194-199.	0.7	27
537	Delayed drug hypersensitivity: models of Tâ€cell stimulation. British Journal of Clinical Pharmacology, 2011, 71, 701-707.	1.1	127
538	Sexâ€related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. British Journal of Clinical Pharmacology, 2011, 71, 95-104.	1.1	71

#	Article	IF	CITATIONS
539	Using primary care prescribing databases for pharmacovigilance. British Journal of Clinical Pharmacology, 2011, 71, 244-249.	1.1	14
540	Medication details documented on hospital discharge: crossâ€sectional observational study of factors associated with medication nonâ€reconciliation. British Journal of Clinical Pharmacology, 2011, 71, 449-457.	1.1	67
541	Current progress in pharmacogenetics. British Journal of Clinical Pharmacology, 2011, 71, 824-831.	1.1	17
542	Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration. British Journal of Clinical Pharmacology, 2011, 72, 143-152.	1.1	62
543	Adverse drug reactions: treatment burdens and nurse-led medication monitoring. Journal of Nursing Management, 2011, 19, 377-392.	1.4	32
544	Collaboratively planning for medicines administration competency: a survey evaluation. Journal of Nursing Management, 2011, 19, 366-376.	1.4	17
545	Adverse events: expecting too much of nurses and too little of nursing research. Journal of Nursing Management, 2011, 19, 287-292.	1.4	6
546	A New Multimodal Geriatric Discharge-Planning Intervention to Prevent Emergency Visits and Rehospitalizations of Older Adults: The Optimization of Medication in AGEd Multicenter Randomized Controlled Trial. Journal of the American Geriatrics Society, 2011, 59, 2017-2028.	1.3	105
547	The Phenotype Standardization Project: Improving Pharmacogenetic Studies of Serious Adverse Drug Reactions. Clinical Pharmacology and Therapeutics, 2011, 89, 784-785.	2.3	61
548	Gastrointestinal malignancies and cardiovascular diseasesâ€"Non-negligible comorbidity in an era of multi-antithrombotic drug use. Journal of Cardiology, 2011, 58, 199-207.	0.8	3
549	Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond., 2011, 129, 267-289.		52
550	Outcomes of Emergency Department Patients Presenting With Adverse Drug Events. Annals of Emergency Medicine, 2011, 58, 270-279.e4.	0.3	81
551	Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chemico-Biological Interactions, 2011, 192, 30-36.	1.7	82
552	Drug–drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?. Current Medical Research and Opinion, 2011, 27, 1551-1562.	0.9	55
553	Treatment of adverse drug reactions in a dermatology department. Open Medicine (Poland), 2011, 6, 37-44.	0.6	0
554	Drug-related problems identified in post-discharge medication reviews for patients taking warfarin. International Journal of Clinical Pharmacy, 2011, 33, 621-626.	1.0	19
555	Adverse drug reaction reporting in the Czech Republic 2005–2009. International Journal of Clinical Pharmacy, 2011, 33, 683-689.	1.0	9
556	The process of identifying, solving and preventing drug related problems in the LIMM-study. International Journal of Clinical Pharmacy, 2011, 33, 1010-1018.	1.0	36

#	Article	IF	CITATIONS
557	Strategies for improving documentation and reducing medication errors related to drug allergy. International Journal of Clinical Pharmacy, 2011, 33, 879-880.	1.0	5
559	Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. Calcified Tissue International, 2011, 89, 91-104.	1.5	170
560	Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. European Journal of Clinical Pharmacology, 2011, 67, 371-381.	0.8	20
561	Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database. European Journal of Clinical Pharmacology, 2011, 67, 633-641.	0.8	36
562	Impact of the Lund Integrated Medicines Management (LIMM) model on medication appropriateness and drug-related hospital revisits. European Journal of Clinical Pharmacology, 2011, 67, 741-752.	0.8	130
563	Performance of different data sources in identifying adverse drug events in hospitalized patients. European Journal of Clinical Pharmacology, 2011, 67, 909-918.	0.8	4
564	Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case–control study in a large population-based German database. European Journal of Clinical Pharmacology, 2011, 67, 941-951.	0.8	29
565	Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification. European Journal of Clinical Pharmacology, 2011, 67, 1273-1282.	0.8	10
566	Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources. European Journal of Clinical Pharmacology, 2011, 67, 1301-1308.	0.8	21
567	Isolation and Characterization of the CYP2D6 Gene in Felidae with Comparison to Other Mammals. Journal of Molecular Evolution, 2011, 72, 222-231.	0.8	2
568	"User-testing―as a method for testing the fitness-for-purpose of written medicine information. Patient Education and Counseling, 2011, 83, 404-410.	1.0	55
569	Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Science, Medicine, and Pathology, 2011, 7, 162-184.	0.6	62
570	Role of transporters in drug interactions. Archives of Pharmacal Research, 2011, 34, 1865-1877.	2.7	158
572	Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data. BMC Health Services Research, 2011, 11, 134.	0.9	77
573	Selfâ€reported prevalence of hypersensitivity reactions against drugs among medical students: does awareness cause any difference?. Pharmacoepidemiology and Drug Safety, 2011, 20, 154-161.	0.9	12
574	Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiology and Drug Safety, 2011, 20, 626-634.	0.9	102
575	Medicine safety: experiences and perceptions of the general public in Liverpool. Pharmacoepidemiology and Drug Safety, 2011, 20, 1098-1103.	0.9	25
576	The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals. Pharmacoepidemiology and Drug Safety, 2011, 20, 1295-1302.	0.9	52

#	Article	IF	Citations
577	Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction) Tj ETQq0 0 (	O rg <b>B</b>	erlovek 10 Tf 5
578	Mixed methods evaluation: Pharmacists' experiences and beliefs toward an interactive communication approach to patient interactions. Patient Education and Counseling, 2011, 83, 432-442.	1.0	21
579	Drug poisoning deaths in Sweden show a predominance of ethanol in mono-intoxications, adverse drug–alcohol interactions and poly-drug use. Forensic Science International, 2011, 206, 43-51.	1.3	84
580	Student experiences of medicines management training and education. British Journal of Nursing, 2011, 20, 291-298.	0.3	8
581	The new BMJ series on therapeutics. BMJ: British Medical Journal, 2011, 342, d37-d37.	2.4	2
582	Using Routinely Collected Prescribing Data to Determine Drug Persistence for the Purpose of Pharmacovigilance. Journal of Clinical Pharmacology, 2011, 51, 279-284.	1.0	8
583	Combating inappropriate use of medicines. Expert Review of Clinical Pharmacology, 2011, 4, 335-348.	1.3	56
584	Co-prescription of co-trimoxazole and spironolactone in elderly patients. BMJ: British Medical Journal, 2011, 343, d5656-d5656.	2.4	4
585	Opportunities and challenges in creating an international centralised knowledge base for clinical decision support systems in ePrescribing. BMJ Quality and Safety, 2011, 20, 625-630.	1.8	17
586	Can an electronic prescribing system detect doctors who are more likely to make a serious prescribing error?. Journal of the Royal Society of Medicine, 2011, 104, 208-218.	1.1	19
587	Diagnosis and management of chronic liver disease in older people. Reviews in Clinical Gerontology, 2011, 21, 1-15.	0.5	10
588	Prescribing in care homes: the role of the geriatrician. Therapeutic Advances in Chronic Disease, 2011, 2, 353-358.	1.1	7
590	Pharmacy Students' Knowledge and Perceptions About Pharmacovigilance in Malaysian Public Universities. American Journal of Pharmaceutical Education, 2011, 75, 96.	0.7	54
591	Drug Induced Hypersensitivity and the HLA Complex. Pharmaceuticals, 2011, 4, 69-90.	1.7	31
592	Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study. Croatian Medical Journal, 2011, 52, 604-614.	0.2	34
593	The incidence and nature of drug-related hospital admission: A 6-month observational study in a tertiary health care hospital. Journal of Pharmacology and Pharmacotherapeutics, 2011, 2, 17-20.	0.2	31
594	Clinical pharmacogenomics and concept of personalized medicine / KliniÄka farmakogenomika i koncept personalizovane medicine. Journal of Medical Biochemistry, 2012, 31, 281-286.	0.7	14
595	Application of Complementary and Alternative Medicine on Neurodegenerative Disorders: Current Status and Future Prospects. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-2.	0.5	15

#	Article	IF	CITATIONS
596	Signal and noise: applying a laboratory trigger tool to identify adverse drug events among primary care patients. BMJ Quality and Safety, 2012, 21, 670-675.	1.8	35
597	From Omics to Drug Metabolism and High Content Screen of Natural Product in Zebrafish: A New Model for Discovery of Neuroactive Compound. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-20.	0.5	42
598	Routinely recorded patient safety events in primary care: a literature review. Family Practice, 2012, 29, 8-15.	0.8	31
599	Cutaneous adverse drug reaction profile in a tertiary care out patient setting in Eastern India. Indian Journal of Pharmacology, 2012, 44, 792.	0.4	45
600	Braving a faceless new world? Conceptualizing trust in the pharmaceutical industry and its products. Health (United Kingdom), 2012, 16, 57-75.	0.9	18
601	Are predictive biomarkers of toxicity worth having? An economic model. Xenobiotica, 2012, 42, 4-10.	0.5	2
602	Prediction of warfarin dose: why, when and how?. Pharmacogenomics, 2012, 13, 429-440.	0.6	66
603	Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients. Swiss Medical Weekly, 2012, 142, w13615.	0.8	14
604	Current advances in pharmacovigilance in the USA and Europe. Current Opinion in HIV and AIDS, 2012, 7, 292-298.	1.5	9
605	Indicator development for the assessment of pain management: a practical approach. European Journal of Hospital Pharmacy, 2012, 19, 330-335.	0.5	1
606	Genetics and the Potential for Predictive Tests in Adverse Drug Reactions. Chemical Immunology and Allergy, 2012, 97, 18-31.	1.7	42
607	Effect of Aspirin on Vascular and Nonvascular Outcomes. Archives of Internal Medicine, 2012, 172, 209.	4.3	252
608	Pharmacy Students' Attitudes Toward Reporting Serious Adverse Drug Events. American Journal of Pharmaceutical Education, 2012, 76, 194.	0.7	27
610	Predicting and detecting adverse drug reactions in old age: challenges and opportunities. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 527-530.	1.5	31
611	HOME Q-Score: Assessing the quality of healthcare provisioning. , 2012, , .		1
612	Is There an Improvement on the Web Sites of the National and International Pharmaceutical Companies in Turkey? A Follow-Up Study. Telemedicine Journal and E-Health, 2012, 18, 238-243.	1.6	0
613	Implementing a Competence Framework for Administering Medication: Reporting the Experiences of Mental Health Nurses and Students in the UK. Issues in Mental Health Nursing, 2012, 33, 657-664.	0.6	6
615	Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers. Indian Journal of Human Genetics, 2012, 18, 326.	0.7	9

#	ARTICLE	IF	CITATIONS
616	Clinical Pharmacology in Old Persons. Scientifica, 2012, 2012, 1-17.	0.6	41
617	Survey of Safety Architectural Patterns. , 2012, , 137-158.		2
618	Adverse drug reaction-related admissions in paediatrics, a prospective single-centre study. BMJ Open, 2012, 2, e000934.	0.8	23
619	Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness method. BMJ Open, 2012, 2, e001431.	0.8	61
620	Protocol for the Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS) study: a cluster randomised controlled trial using ePrescribing data. BMJ Open, 2012, 2, e002359.	0.8	8
621	Effect of Carbamazepine on Fluindione's Anticoagulant Activity: a Case Report. Therapie, 2012, 67, 488-489.	0.6	2
622	Capture and Documentation of Coded Data on Adverse Drug Reactions: An Overview. Health Information Management Journal, 2012, 41, 27-36.	0.9	9
623	Drug Disposition in Pathophysiological Conditions. Current Drug Metabolism, 2012, 13, 1327-1344.	0.7	70
624	Adverse Drug Reactions: Trends in a Tertiary Care Hospital. Current Drug Safety, 2012, 7, 384-388.	0.3	9
626	Adverse Drug Reactions during Hospital Stay: Evaluation of a Model for Informing Patients. Journal of Pharmacy Practice and Research, 2012, 42, 95-99.	0.5	5
627	A Fatal Outcome After Unintentional Overdosing of Rivastigmine Patches. Current Drug Safety, 2012, 7, 30-32.	0.3	21
629	Drug safety: reporting systems for the general public. BMJ, The, 2012, 345, e4916-e4916.	3.0	8
630	Evaluation of a Web-Based Tool in Screening for Medication-Related Problems in Community-Dwelling Older Adults. The Consultant Pharmacist, 2012, 27, 106-113.	0.4	6
631	Assessing prescribing competence. British Journal of Clinical Pharmacology, 2012, 74, 632-639.	1.1	34
632	eâ€Learning initiatives to support prescribing. British Journal of Clinical Pharmacology, 2012, 74, 621-631.	1.1	33
633	Monitoring medicines use: the role of the clinical pharmacologist. British Journal of Clinical Pharmacology, 2012, 74, 685-690.	1.1	12
634	Medication reviews. British Journal of Clinical Pharmacology, 2012, 74, 573-580.	1.1	163
635	Safe prescribing: a titanic challenge. British Journal of Clinical Pharmacology, 2012, 74, 676-684.	1.1	13

#	Article	IF	CITATIONS
636	Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clinical Genetics, 2012, 82, 388-394.	1.0	219
638	Workshop- and Telephone-Based Interventions to Improve Adverse Drug Reaction Reporting. Drug Safety, 2012, 35, 655-665.	1.4	43
639	Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments. Drug Safety, 2012, 35, 769-781.	1.4	116
640	Safety Monitoring of Herb-Drug Interactions. Drug Safety, 2012, 35, 785-791.	1.4	37
642	Prevalence, seriousness and effect of previous adverse drug reactions on prescribing during acute medical admission. International Journal of Clinical Pharmacy, 2012, 34, 871-875.	1.0	1
643	Implementing a clinical pharmacy survey of adverse drug events in a French emergency department. International Journal of Clinical Pharmacy, 2012, 34, 902-910.	1.0	16
644	The Medicine with Respect Project: A stakeholder focus group evaluation. Nurse Education in Practice, 2012, 12, 310-315.	1.0	9
645	PIH30 Potentially Inappropriate Prescribing and Adverse Health Outcomes in Community Dwelling Older Populations. Value in Health, 2012, 15, A541.	0.1	2
647	Bewertung der Einsparpotenziale in der Arzneimitteltherapie durch Dosisanpassung an die Polymorphismen im Cytochrom P450. PharmacoEconomics - German Research Articles, 2012, 10, 69-85.	0.1	1
648	Effect of Medication Reconciliation on Medication Costs After Hospital Discharge in Relation to Hospital Pharmacy Labor Costs. Annals of Pharmacotherapy, 2012, 46, 329-338.	0.9	22
649	Adverse drug reactions in older patients during hospitalisation: are they predictable? Age and Ageing, 2012, 41, 771-776.	0.7	75
650	Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opinion on Drug Safety, 2012, 11, 83-94.	1.0	192
651	Drug-Related Problems and Hospital Admissions in Cardiac Transplant Recipients. Annals of Pharmacotherapy, 2012, 46, 1299-1307.	0.9	15
652	Pharmacokinetics and Pharmacodynamics: The Role of Sex and Gender. , 2012, , 183-194.		5
653	Applicability of an Adapted Medication Appropriateness Index for Detection of Drug-Related Problems in Geriatric Inpatients. American Journal of Geriatric Pharmacotherapy, 2012, 10, 101-109.	3.0	32
654	Running an NHS community homeopathy clinic – 10-year anniversary 2001–2011. Homeopathy, 2012, 101, 51-56.	0.5	5
655	Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. International Journal of Cardiology, 2012, 156, 69-75.	0.8	44
656	Medication-related problems occurring in people with diabetes during an admission to an adult teaching hospital: A retrospective cohort study. Diabetes Research and Clinical Practice, 2012, 97, 223-230.	1.1	28

#	Article	IF	CITATIONS
657	Study protocol of a mixed-methods evaluation of a cluster randomized trial to improve the safety of NSAID and antiplatelet prescribing: data-driven quality improvement in primary care. Trials, 2012, 13, 154.	0.7	14
658	An embedded longitudinal multi-faceted qualitative evaluation of a complex cluster randomized controlled trial aiming to reduce clinically important errors in medicines management in general practice. Trials, 2012, 13, 78.	0.7	36
659	A cluster randomised stepped wedge trial to evaluate the effectiveness of a multifaceted information technology-based intervention in reducing high-risk prescribing of non-steroidal anti-inflammatory drugs and antiplatelets in primary medical care: The DQIP study protocol. Implementation Science, 2012, 7, 24.	2.5	37
660	Geriatric pharmacology and pharmacotherapy education for health professionals and students: a systematic review. British Journal of Clinical Pharmacology, 2012, 74, 762-773.	1.1	45
661	The benefits of pharmacist-delivered warfarin education in the home. International Journal of Pharmacy Practice, 2012, 20, 384-389.	0.3	15
662	Targeting Outpatient Drug Safety. Drug Safety, 2012, 35, 245-259.	1.4	60
663	Methods for Assessing the Preventability of Adverse Drug Events. Drug Safety, 2012, 35, 105-126.	1.4	43
664	How are the Costs of Drug-Related Morbidity Measured?. Drug Safety, 2012, 35, 1.	1.4	14
665	Adverse Drug Reactions in Children – International Surveillance and Evaluation (ADVISE). Drug Safety, 2012, 35, 481-494.	1.4	47
666	Good Pharmacovigilance Practice and the Curate's Egg. Drug Safety, 2012, 35, 429-435.	1.4	7
668	An Update on Drug-induced Liver Injury. Journal of Clinical and Experimental Hepatology, 2012, 2, 247-259.	0.4	124
669	Design and evaluation of Ubiquitous Information Systems and use in healthcare. Decision Support Systems, 2012, 54, 597-609.	3.5	41
670	Challenges and solutions for personalizing medicines. Health Policy and Technology, 2012, 1, 50-57.	1.3	9
671	Costs of Adverse Drug Events in German Hospitals—A Microcosting Study. Value in Health, 2012, 15, 868-875.	0.1	63
675	Adverse Drug Reactions in Older People. Drugs and Aging, 2012, 29, 453-462.	1.3	82
677	Adverse Drug Reactions in a Population of Hospitalized Very Elderly Patients. Drugs and Aging, 2012, 29, 669-679.	1.3	39
678	Adverse Drug Reaction-Related Hospitalizations in Persons Aged 55 Years and Over. Drugs and Aging, 2012, 29, 225-232.	1.3	51
679	Human Pluripotent Stem Cells for Modeling Toxicity. Advances in Pharmacology, 2012, 63, 207-256.	1.2	23

#	Article	IF	CITATIONS
680	Adverse Drug Events as a Cause of Hospitalization in Older Adults. Drug Safety, 2012, 35, 29-45.	1.4	117
681	Estimating Renal Function to Reduce the Risk of Adverse Drug Reactions. Drug Safety, 2012, 35, 47-54.	1.4	12
682	Geriatric Conditions and the Risk of Adverse Drug Reactions in Older Adults. Drug Safety, 2012, 35, 55-61.	1.4	31
683	Impact of prescribed medications on patient safety in older people. Therapeutic Advances in Drug Safety, 2012, 3, 165-174.	1.0	39
684	DNA Genetic Testing. , 2012, , 81-115.		0
685	Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. European Journal of Clinical Pharmacology, 2012, 68, 1667-1676.	0.8	77
686	Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. European Journal of Clinical Pharmacology, 2012, 68, 1425-1433.	0.8	144
687	Adverse Drug Reactions in Hospitalised Children in Germany Are Decreasing: Results of a Nine Year Cohort-Based Comparison. PLoS ONE, 2012, 7, e44349.	1.1	16
688	Potential Drug-Drug Interactions in Prescriptions to Patients over 45 Years of Age in Primary Care, Southern Brazil. PLoS ONE, 2012, 7, e47062.	1.1	29
689	Adverse drug reactions in older patients: an Italian observational prospective hospital study. Drug, Healthcare and Patient Safety, 2012, 4, 75.	1.0	57
690	Improving Medication Reconciliation on the Surgical Wards of a District General Hospital. BMJ Quality Improvement Reports, 2012, 1, u200373.w323.	0.8	3
691	Diabetes medication incidents in the care home setting. Nursing Standard (Royal College of Nursing) Tj ${\sf ETQq1}$	1 0.784314 0.1	rgBT /Overl
693	Pharmacogenetics: transforming clinical medicine. Journal of the Royal College of Physicians of Edinburgh, The, 2012, 42, 244-247.	0.2	2
694	Altered Drug Metabolism and Transport in Pathophysiological Conditions. , 2012, , .		2
695	The Role of Genetics in Predictive and Personalized Medicine of Rheumatoid Arthritis. Hanyang Medical Reviews, 2012, 32, 59.	0.4	0
696	Pharmacogenomics-Guided Approaches to Avoiding Adverse Drug Reactions. Clinical Pharmacology & Biopharmaceutics, 2012, 01, .	0.2	2
697	General pharmacology., 2012,, 74-109.		1
698	Análise clÃnica e epidemiológica das internações hospitalares de idosos decorrentes de intoxicações e efeitos adversos de medicamentos, Brasil, de 2004 a 2008. Revista Brasileira De Epidemiologia, 2012, 15, 828-844.	0.3	19

#	Article	IF	CITATIONS
699	What Is The "Safest―Non-Steroidal Anti-Inflammatory Drugs?. American Medical Journal, 2012, 3, 115-123.	1.0	21
700	The role of genetics in pre-eclampsia and potential pharmacogenomic interventions. Pharmacogenomics and Personalized Medicine, 2012, 5, 37.	0.4	18
701	Medication managementâ€"the missing link in dementia interventions. International Journal of Geriatric Psychiatry, 2012, 27, 439-442.	1.3	24
702	Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors?. Journal of Genetic Counseling, 2012, 21, 527-535.	0.9	17
703	Severe drug eruptions revisited. Immunologic Research, 2012, 53, 162-167.	1.3	1
704	The importance of drug–drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. European Journal of Clinical Pharmacology, 2012, 68, 767-775.	0.8	34
705	Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. European Journal of Clinical Pharmacology, 2012, 68, 801-810.	0.8	94
706	Inappropriate prescribing for the elderly—a modern epidemic?. European Journal of Clinical Pharmacology, 2012, 68, 1085-1094.	0.8	67
707	A prospective analysis of the preventability of adverse drug reactions reported in Sweden. European Journal of Clinical Pharmacology, 2012, 68, 1183-1189.	0.8	15
708	Potentially inappropriate medications in the elderly: a comprehensive protocol. European Journal of Clinical Pharmacology, 2012, 68, 1123-1138.	0.8	38
709	Comparative evaluation of three clinical decision support systems: prospective screening for medication errors in 100 medical inpatients. European Journal of Clinical Pharmacology, 2012, 68, 1209-1219.	0.8	29
710	NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. British Journal of Pharmacology, 2012, 165, 67-74.	2.7	131
711	The population pharmacokinetics of <i>R</i> aê•and <i>S</i> aê•warfarin: effect of genetic and clinical factors. British Journal of Clinical Pharmacology, 2012, 73, 66-76.	1.1	70
712	Impact of genetic factors ( <i>VKORC1, CYP2C9, CYP4F2</i> and <i>EPHX1</i> ) on the anticoagulation response to fluindione. British Journal of Clinical Pharmacology, 2012, 73, 428-436.	1.1	14
715	A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 148-152.	0.7	41
716	Decision support for sensible dosing in electronic prescribing systems. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 415-419.	0.7	6
717	Integrated medicines management – can routine implementation improve quality?. Journal of Evaluation in Clinical Practice, 2012, 18, 807-815.	0.9	28
718	Drugâ€Induced Blood Consumption: The Impact of Adverse Drug Reactions on Demand for Blood Components in German Departments of Internal Medicine. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 240-247.	1.2	7

#	Article	IF	CITATIONS
719	Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients. International Journal of Rheumatic Diseases, 2012, 15, 315-321.	0.9	9
720	Prescribing medicines for older patients. Medicine, 2012, 40, 382-385.	0.2	2
721	Drug interactions that matter. Medicine, 2012, 40, 371-375.	0.2	2
722	The relative contribution of <scp>NSAIDs</scp> and <scp><i>H</i></scp> <i>elicobacter pylori</i> the aetiology of endoscopicallyâ€diagnosed peptic ulcer disease: observations from a tertiary referralhospital in the <scp>UK</scp> between 2005 and 2010. Alimentary Pharmacology and Therapeutics, 2012,36. 48-56.	1.9	54
723	Using textâ€mining techniques in electronic patient records to identify ADRs from medicine use. British Journal of Clinical Pharmacology, 2012, 73, 674-684.	1.1	80
724	An agenda for UK clinical pharmacology: Developing and delivering clinical pharmacology in the UK National Health Service. British Journal of Clinical Pharmacology, 2012, 73, 884-887.	1.1	3
725	An agenda for UK clinical pharmacology: Medication errors. British Journal of Clinical Pharmacology, 2012, 73, 912-916.	1.1	12
726	An agenda for UK clinical pharmacology: Pharmacovigilance. British Journal of Clinical Pharmacology, 2012, 73, 979-982.	1.1	32
727	Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement. BMC Clinical Pharmacology, 2012, 12, 5.	2.5	49
728	Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: A review of their methodologies and results. Arthritis and Rheumatism, 2012, 64, 21-32.	6.7	56
730	Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. European Journal of Clinical Pharmacology, 2012, 68, 179-188.	0.8	65
731	Pharmacovigilance teaching in UK undergraduate pharmacy programmes. Pharmacoepidemiology and Drug Safety, 2013, 22, 223-228.	0.9	21
732	Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Archives of Toxicology, 2013, 87, 407-420.	1.9	50
733	Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan. International Journal of Clinical Pharmacy, 2013, 35, 455-462.	1.0	39
734	Characterisation of non-warfarin-associated bleeding events reported to the Norwegian spontaneous reporting system. European Journal of Clinical Pharmacology, 2013, 69, 1445-1452.	0.8	5
735	Identification and weighting of the most critical "real-life―drug–drug interactions with acenocoumarol in a tertiary care hospital. European Journal of Clinical Pharmacology, 2013, 69, 617-627.	0.8	13
736	The continuing challenge of providing drug information services to diminish the knowledgeâ€"practice gap in medical practice. European Journal of Clinical Pharmacology, 2013, 69, 65-72.	0.8	39
737	Safety pharmacology â€" Current and emerging concepts. Toxicology and Applied Pharmacology, 2013, 273, 229-241.	1.3	56

#	Article	IF	Citations
738	Inter-rater reliability of the assessment of adverse drug reactions in the hospitalised elderly. Journal of Nutrition, Health and Aging, 2013, 17, 700-705.	1.5	7
739	Sex Differences in Human Lymphoblastoid Cells Sensitivities to Antipsychotic Drugs. Journal of Molecular Neuroscience, 2013, 49, 554-558.	1.1	13
740	Comparison of algorithms that detect drug side effects using electronic healthcare databases. Soft Computing, 2013, 17, 2381-2397.	2.1	22
742	Severity and Management of Drug–Drug Interactions in Acute Geriatric Patients. Drugs and Aging, 2013, 30, 721-727.	1.3	17
743	Polypharmacy and Potentially Inappropriate Medication in the Adult, Community-Dwelling Population in Switzerland. Drugs and Aging, 2013, 30, 561-568.	1.3	59
744	Information for Adequate Prescribing to Older Patients. Drugs and Aging, 2013, 30, 255-262.	1.3	19
745	Patients' Use of Information about Medicine Side Effects in Relation to Experiences of Suspected Adverse Drug Reactions: A Cross-Sectional Survey in Medical In-Patients. Drug Safety, 2013, 36, 673-680.	1.4	31
746	The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 183-192.	0.9	7
747	Medikamentöse Therapie bei Frauen – Was gilt es zu beachten?. Clinical Research in Cardiology Supplements, 2013, 8, 32-37.	2.0	0
748	Kounis syndrome triggered by diclofenac sodium injection which leads to myocardial infarction and cardiac arrest. Journal of Cardiology Cases, 2013, 8, e17-e19.	0.2	7
750	Prescripci $ ilde{A}^3$ n medicamentosa y iatrogenia en el anciano. EMC - Tratado De Medicina, 2013, 17, 1-9.	0.0	0
751	Medication-Related Emergency Department Visits and Hospital Admissions in Pediatric Patients: A Qualitative Systematic Review. Journal of Pediatrics, 2013, 163, 477-483.	0.9	40
752	Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal antiâ€inflammatory drugs. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1219-1232.	2.7	356
753	The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification. International Journal of Biochemistry and Cell Biology, 2013, 45, 1121-1132.	1.2	540
754	A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England Journal of Medicine, 2013, 369, 2294-2303.	13.9	735
755	Adverse drug reactions to local anesthetics: a systematic review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 319-327.	0.2	28
756	Clinically Relevant Drug-Drug and Drug-Food Interactions. Pharmaceutical Medicine, 2013, 27, 9-23.	1.0	8
757	Dermatology: Future Therapeutic Perspectives. Dermatology and Therapy, 2013, 3, 115-116.	1.4	0

#	Article	IF	CITATIONS
758	Frequency and Severity of Adverse Drug Reactions Due to Self-Medication: A Cross-Sectional Multicentre Survey in Emergency Departments. Drug Safety, 2013, 36, 1159-1168.	1.4	51
760	Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay – a systematic review. European Journal of Clinical Pharmacology, 2013, 69, 1985-1996.	0.8	62
761	Medication errors detected in elderly patients admitted to an internal medicine service. International Journal of Clinical Practice, 2013, 67, 282-289.	0.8	10
762	Correlating adverse drug reactions with biological pathways in humans. , 2013, , .		1
763	Automatic detection of drug interaction mismatches in package inserts. , 2013, , .		0
764	Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection. Scandinavian Journal of Infectious Diseases, 2013, 45, 239-240.	1.5	4
765	The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy, 2013, 14, 1119-1133.	0.9	5
766	Key Elements in Adverse Drug Interaction Safety Signals. Drug Safety, 2013, 36, 63-70.	1.4	7
767	Sex Differences in Drug Effects: Interaction with Sex Hormones in Adult Life. Handbook of Experimental Pharmacology, 2013, , 91-105.	0.9	43
768	The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Discovery Today, 2013, 18, 218-239.	3.2	130
769	Omics and Drug Response. Annual Review of Pharmacology and Toxicology, 2013, 53, 475-502.	4.2	130
772	Protecting patient safety in resource-poor settings. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2013, 27, 497-508.	1.4	7
774	Impact of Pharmacist Discharge Medication Therapy Counseling and Disease State Education. American Journal of Medical Quality, 2013, 28, 292-300.	0.2	45
776	Drugâ€Related Readmissions to Medical Units of Older Adults Discharged from Acute Geriatric Units: Results of the Optimization of Medication in <scp>AGE</scp> d Multicenter Randomized Controlled Trial. Journal of the American Geriatrics Society, 2013, 61, 113-121.	1.3	73
777	The Development and Evaluation of Triage Algorithms for Early Discovery of Adverse Drug Interactions. Drug Safety, 2013, 36, 371-388.	1.4	27
778	Severe drugâ€induced anaphylaxis: analysis of 333 cases recorded by the <scp>A</scp> llergy <scp>V</scp> igilance <scp>N</scp> etwork from 2002 to 2010. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 929-937.	2.7	118
779	Detection of adverse drug reactions using hospital databasesâ€"a nationwide study in Portugal. Pharmacoepidemiology and Drug Safety, 2013, 22, 907-913.	0.9	29
780	Risk Factors for Hospital Admissions Associated with Adverse Drug Events. Pharmacotherapy, 2013, 33, 827-837.	1.2	104

#	Article	IF	Citations
781	The Generation, Detection, and Effects of Reactive Drug Metabolites. Medicinal Research Reviews, 2013, 33, 985-1080.	5.0	73
782	The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. European Journal of Clinical Pharmacology, 2013, 69, 33-41.	0.8	14
783	Use of case–time–control design in pharmacovigilance applications: exploration with highâ€risk medications and unplanned hospital admissions in the Western Australian elderly. Pharmacoepidemiology and Drug Safety, 2013, 22, 1159-1170.	0.9	11
784	Practical Pharmacogenetics and Single Nucleotide Polymorphisms (SNPs) in Renal Transplantation. , 0,		1
785	How many potential drug–drug interactions cause adverse drug reactions in hospitalized patients?. European Journal of Internal Medicine, 2013, 24, 27-33.	1.0	50
786	Drug interactions and dual diagnosis. Advances in Dual Diagnosis, 2013, 6, 145-150.	0.3	4
787	Personalizing health care: feasibility and future implications. BMC Medicine, 2013, 11, 179.	2.3	81
788	Where to buy OTC medications? A cross-sectional survey investigating consumers' confidence in over-the-counter (OTC) skills and their attitudes towards the availability of OTC painkillers. BMJ Open, 2013, 3, e003455.	0.8	18
789	Sex and Gender in Adverse Drug Events, Addiction, and Placebo. Handbook of Experimental Pharmacology, 2013, , 107-126.	0.9	36
790	Epidemiologic Aspects. , 2013, , 11-19.		0
791	Attitudes and Opinion about Adverse Drug Events of Women Living in a City of South Italy. Pharmacology, 2013, 91, 173-177.	0.9	10
792	Adherence to antiretroviral drug therapy in adult patients who are HIV-positive in Northwest Ethiopia: a study protocol. BMJ Open, 2013, 3, e003559.	0.8	11
793	Under-representation of older adults in pharmacokinetic and pharmacodynamic studies: a solvable problem?. Expert Review of Clinical Pharmacology, 2013, 6, 35-39.	1.3	27
794	Dictionary construction and identification of possible adverse drug events in Danish clinical narrative text. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 947-953.	2.2	71
795	Introducing an adverse drug event manager. European Journal of Hospital Pharmacy, 2013, 20, 78-81.	0.5	13
796	Drug use and upper gastrointestinal complications in children: a case-control study. Archives of Disease in Childhood, 2013, 98, 218-221.	1.0	32
797	Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT). BMJ Open, 2013, 3, e002295.	0.8	22
798	Perceived causes of prescribing errors by junior doctors in hospital inpatients: a study from the PROTECT programme. BMJ Quality and Safety, 2013, 22, 97-102.	1.8	106

#	Article	IF	CITATIONS
799	Knowledge assessment in adverse drug reactions and reporting. Archives of Pharmacy Practice, 2013, 4, 104.	0.2	5
800	Paediatric pharmacogenomics: an overview. Archives of Disease in Childhood, 2013, 98, 232-237.	1.0	24
801	Frequency, Levels and Predictors of Potential Drug-Drug Interactions in a Pediatrics Ward of a Teaching Hospital in Pakistan. Tropical Journal of Pharmaceutical Research, 2013, 12, .	0.2	3
802	Personalizing healthcare: from genetics through payment to improving care?. Journal of the Royal Society of Medicine, 2013, 106, 41-44.	1.1	5
803	Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. Pathology, 2013, 45, 357-370.	0.3	4
804	Medication Reconciliation. Journal of Patient Safety, 2013, 9, 160-168.	0.7	2
805	Encouraging the reporting of adverse drug reactions. Adverse Drug Reaction Bulletin, 2013, 282, 1087-1090.	0.6	0
806	Orthopedic Surgery and Trauma. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 141-160.	0.7	1
807	DRUG INTERACTIONS AND ADVERSE DRUG REACTIONS IN THE OLDER PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENT. Acta Clinica Belgica, 2013, 68, 15-21.	0.5	32
808	Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial. BMJ Open, 2013, 3, e002361.	0.8	82
809	Colorectal cancer prevention: screening and the role of aspirin. Colorectal Cancer, 2013, 2, 429-439.	0.8	1
810	Underreported use of non-steroidal anti-inflammatory drugs in an outpatient gastroenterology practice: a prospective office-based survey. Gastroenterology Insights, 2013, 5, 3.	0.7	1
811	Clinical and economic burden of adverse drug reactions. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, S73-S77.	0.2	329
812	An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspectives in Clinical Research, 2013, 4, 204.	0.5	55
813	Community pharmacists' knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia. Therapeutic Advances in Drug Safety, 2013, 4, 45-51.	1.0	42
814	Preventing hospital admissions by reviewing medication (PHARM) in primary care: an open controlled study in an elderly population. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 379-387.	0.7	38
815	The cutaneous adverse drug reactions: risk factors, prognosis and economic impacts. International Journal of Clinical Practice, 2013, 67, 576-584.	0.8	9
816	Stem cellâ€derived hepatocytes as a predictive model for drugâ€induced liver injury: are we there yet?. British Journal of Clinical Pharmacology, 2013, 75, 885-896.	1.1	68

#	Article	IF	Citations
817	Proton pump inhibitors are associated with hypersensitivity reactions to drugs in hospitalized patients: a nested caseâ€control in a retrospective cohort study. Clinical and Experimental Allergy, 2013, 43, 344-352.	1.4	35
818	The Nordic prescription databases as a resource for pharmacoepidemiological researchâ€"a literature review. Pharmacoepidemiology and Drug Safety, 2013, 22, 691-699.	0.9	156
819	Drug–drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiology and Drug Safety, 2013, 22, 1054-1060.	0.9	53
820	A new approach to identify, classify and count drugâ€related events. British Journal of Clinical Pharmacology, 2013, 76, 56-68.	1.1	16
821	Mining Twitter Data for Potential Drug Effects. Lecture Notes in Computer Science, 2013, , 434-443.	1.0	47
822	Medication safety and knowledgeâ€based functions: a stepwise approach against information overload. British Journal of Clinical Pharmacology, 2013, 76, 14-24.	1.1	14
823	PRESCRIBING AND RESEARCH IN MEDICINES MANAGEMENT (UK & LAND). Pharmacoepidemiology and Drug Safety, 2013, 22, 670-690.	0.9	1
824	Prediction of hypersensitivity to antibiotics: what factors need to be considered? Expert Review of Clinical Immunology, 2013, 9, 1279-1288.	1.3	7
825	Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina. International Journal of Risk and Safety in Medicine, 2013, 25, 185-192.	0.3	18
826	Study Designs in Clinical Pharmacogenetic and Pharmacogenomic Research., 2013,, 309-341.		2
827	Hazards Associated with the Use of Herbal and Other Natural Products., 2013,, 335-356.		8
828	Use of femoral nerve blocks in adults with hip fractures. Nursing Standard (Royal College of Nursing) Tj ETQq $1\ 1$	0.784314 0.1	rgBT /Over
829	When Direct Health-Care Professional Communications Have an Impact on Inappropriate and Unsafe Use of Medicines. Clinical Pharmacology and Therapeutics, 2013, 93, 360-365.	2.3	33
830	Overview of geriatric emergency medicine., 0,, 1-7.		0
831	Pharmacology in the elderly. , 0, , 41-50.		0
832	Prescription peer academic detailing to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. British Journal of General Practice, 2013, 63, e554-e562.	0.7	40
833	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2013, , .	1.5	6
834	Genetic Bleeding Risk Score (GBRS) for Patients on Oral Anticoagulant Therapy. International Journal of Genomic Medicine, 2013, 1, .	0.0	1

#	Article	IF	CITATIONS
836	The prevalence and reliability of self-reported penicillin allergy in a community hospital. International Journal of General Medicine, 2013, 6, 905.	0.8	16
837	In vitro antioxidant, analgesic and cytotoxic activities of Sepia officinalis ink and Coelatura aegyptiaca extracts. African Journal of Pharmacy and Pharmacology, 2013, 7, 1512-1522.	0.2	27
838	Adverse Drug Events in Older Patients Admitted as an Emergency. Deutsches Ärzteblatt International, 2013, 110, 213-9.	0.6	73
839	Investigating and Learning Lessons from Early Experiences of Implementing ePrescribing Systems into NHS Hospitals: A Questionnaire Study. PLoS ONE, 2013, 8, e53369.	1.1	40
840	Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model. PLoS ONE, 2013, 8, e71505.	1.1	31
841	Prevalence and Perceived Preventability of Self-Reported Adverse Drug Events – A Population-Based Survey of 7099 Adults. PLoS ONE, 2013, 8, e73166.	1.1	37
842	Multi-Indication Carbamazepine and the Risk of Severe Cutaneous Adverse Drug Reactions in Korean Elderly Patients: A Korean Health Insurance Data-Based Study. PLoS ONE, 2013, 8, e83849.	1.1	15
843	Completing a Yellow Card report following an adverse reaction to a medicine. Journal of Aesthetic Nursing, 2013, 2, 386-389.	0.0	0
844	Toward a sustainable and wise healthcare approach: potential contributions from hospital Internal Medicine Departments to reducing inappropriate medical spending. Italian Journal of Medicine, 0, , 65-81.	0.2	6
845	Risk Factors of Severe Neutropenia during Cancer Chemotherapy. Iryo Yakugaku (Japanese Journal of) Tj ETQq1 1	0.78431	4 rgBT /Over
846	Completing a Yellow Card report following an adverse reaction. Journal of Aesthetic Nursing, 2014, 3, S28-S34.	0.0	0
847	Seriousness, preventability, and burden impact of reported adverse drug reactions in Lombardy emergency departments: a retrospective 2-year characterization. ClinicoEconomics and Outcomes Research, 2014, 6, 505.	0.7	23
848	Pharmacogenomics of Warfarin., 2014,, 497-507.		0
849	Adverse Drug Reactions of Spontaneous Reports in Shanghai Pediatric Population. PLoS ONE, 2014, 9, e89829.	1.1	38
850	Approaches to Recording Drug Allergies in Electronic Health Records: Qualitative Study. PLoS ONE, 2014, 9, e93047.	1.1	16
851	Development of an Adverse Drug Reaction Risk Assessment Score among Hospitalized Patients with Chronic Kidney Disease. PLoS ONE, 2014, 9, e95991.	1.1	31
852	"We have met the enemy". BMJ, The, 2014, 349, g5324-g5324.	3.0	1
853	Medication Monitoring for People with Dementia in Care Homes: The Feasibility and Clinical Impact of Nurse-Led Monitoring. Scientific World Journal, The, 2014, 2014, 1-11.	0.8	19

#	Article	IF	CITATIONS
854	HLA and the Pharmacogenomics of Drug Hypersensitivity., 2014, , 437-465.		5
855	A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clinical Interventions in Aging, 2014, 9, 2079.	1.3	202
856	Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Archives of Medical Science, 2014, 5, 920-932.	0.4	33
857	Predicting adverse drug reactions in older adults; a systematic review of the risk prediction models. Clinical Interventions in Aging, 2014, 9, 1581.	1.3	54
858	Monkey-based Research on Human Disease: The Implications of Genetic Differences. ATLA Alternatives To Laboratory Animals, 2014, 42, 287-317.	0.7	20
859	Reporting Adverse Drug Reactions Among Hospitalized Medical Patients: A Prospective Study From Tertiary Care Hospital in Western Nepal. Journal of College of Medical Sciences-Nepal, 2014, 4, 330-336.	0.2	3
860	Alleged Medical Malpractice: A Retrospective Study of Forensic Evaluation of Cases in Cairo and Giza regions-Egypt(2009-2011). Journal of Forensics Research, 2014, 05, .	0.1	1
861	Estratégias para a segurança do paciente no processo de uso de medicamentos após alta hospitalar. Physis, 2014, 24, 401-420.	0.1	7
862	Multimorbidity's research challenges and priorities from a clinical perspective: The case of â€~Mr Curran'. European Journal of General Practice, 2014, 20, 139-147.	0.9	26
863	Adverse drug reactions in neonates: could we be documenting more?. Expert Review of Clinical Pharmacology, 2014, 7, 807-820.	1.3	8
864	Pharmacodynamic Pharmacogenomics. , 2014, , 365-383.		4
865	Pharmacogenomics and Stratified Medicine. , 2014, , 3-25.		21
866	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opinion on Drug Safety, 2014, 13, 1305-1317.	1.0	8
867	Hospital pharmacists' roles and attitudes in providing information on the safety of non-steroidal anti-inflammatory drugs in Thailand. International Journal of Clinical Pharmacy, 2014, 36, 1205-1212.	1.0	15
868	Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. Expert Review of Clinical Pharmacology, 2014, 7, 645-653.	1.3	5
869	A limited number of prescribed drugs account for the great majority of drug-drug interactions. European Journal of Clinical Pharmacology, 2014, 70, 1375-1383.	0.8	32
870	Modeling hepatic drug metabolism and toxicity: where are we heading?. Future Medicinal Chemistry, 2014, 6, 725-727.	1.1	1
871	Through a Glass Darkly: Economics and Personalised Medicine. Pharmacoeconomics, 2014, 32, 1055-1061.	1.7	17

#	Article	IF	CITATIONS
872	Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. Pharmacogenomics Journal, 2014, 14, 316-321.	0.9	40
874	Direct health care costs of hospital admissions due to adverse events in the Netherlands. European Journal of Public Health, 2014, 24, 1028-1033.	0.1	18
875	Negligible Pharmacokinetic Interaction of Red Ginseng and Antihypertensive Agent Amlodipine in Sprague-Dawley Rats. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2014, 77, 1372-1383.	1,1	15
876	How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Frontiers in Pharmacology, 2014, 5, 231.	1.6	136
877	Patient stratification and identification of adverse event correlations in the space of 1190 drug related adverse events. Frontiers in Physiology, 2014, 5, 332.	1.3	15
878	Systems Level Metabolic Phenotype of Methotrexate Administration in the Context of Non-alcoholic Steatohepatitis in the Rat. Toxicological Sciences, 2014, 142, 105-116.	1.4	17
879	WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys. PLoS Medicine, 2014, 11, e1001724.	3.9	68
880	Sex and gender influences on pharmacological response: an overview. Expert Review of Clinical Pharmacology, 2014, 7, 469-485.	1.3	99
881	A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian Journal of Pharmacology, 2014, 46, 152.	0.4	43
882	Developing a complex intervention to improve prescribing safety in primary care: mixed methods feasibility and optimisation pilot study. BMJ Open, 2014, 4, e004153.	0.8	20
883	Development and application of indicators for the reduction of potentially preventable hospital admissions related to medications. Expert Opinion on Drug Safety, 2014, 13, 157-165.	1.0	3
884	Asthma Medications Should Be Available for Over-the-Counter Use: Pro. Annals of the American Thoracic Society, 2014, 11, 969-974.	1.5	13
885	Prevalence, nature and potential preventability of adverse drug events – a populationâ€based medical record study of 4970 adults. British Journal of Clinical Pharmacology, 2014, 78, 170-183.	1.1	58
886	A temporal interestingness measure for drug interaction signal detection in post-marketing surveillance., 2014, 2014, 2722-5.		0
887	Drug-Induced Disorders of the Nervous System. , 2014, , 685-711.		3
888	Histopathological Changes in the Gastrointestinal Tract Due to Drugs. International Journal of Surgical Pathology, 2014, 22, 120-128.	0.4	27
889	A systematic review of hospitalization resulting from medicineâ€related problems in adult patients. British Journal of Clinical Pharmacology, 2014, 78, 202-217.	1.1	147
890	Pharmacovigilance in Neonatal Intensive Care. Pediatric and Adolescent Medicine, 2014, , 28-40.	0.4	2

#	Article	IF	CITATIONS
891	Doseâ€response relationship between depressive symptoms and hospital readmission. Journal of Hospital Medicine, 2014, 9, 358-364.	0.7	30
892	Hypoglycemia After Antimicrobial Drug Prescription for Older Patients Using Sulfonylureas. JAMA Internal Medicine, 2014, 174, 1605.	2.6	55
894	Generalist solutions to overprescribing: a joint challenge for clinical and academic primary care. Primary Health Care Research and Development, 2014, 15, 72-79.	0.5	17
895	Rat engineered heart tissue: a novel tool in the safety pharmacology toolkit?. Basic Research in Cardiology, 2014, 109, 437.	2.5	3
896	Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. BMC Pharmacology & Empty Toxicology, 2014, 15, 54.	1.0	42
897	Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS) a pragmatic three-arm cluster randomised trial: designing the intervention (ClinicalTrials.gov registration NCT01602705). Implementation Science, 2014, 9, 133.	2.5	11
898	Linked health data for pharmacovigilance in children: perceived legal and ethical issues for stakeholders and data guardians: TableÂ1. BMJ Open, 2014, 4, e003875.	0.8	4
899	Drug Exposure and Risk of Microscopic Colitis. Inflammatory Bowel Diseases, 2014, 20, 1702-1707.	0.9	117
900	The Medication Minefield. Journal of Ambulatory Care Management, 2014, 37, 226-240.	0.5	3
901	Lower limb joint replacement in patients with a history of venous thromboembolism. Bone and Joint Journal, 2014, 96-B, 1515-1519.	1.9	12
902	District nurses' preventive home visits to 75-year-olds: An opportunity to identify factors related to unsafe medication management. Scandinavian Journal of Public Health, 2014, 42, 786-794.	1.2	56
904	Inappropriate drug use among older persons: is it time for action?. Age and Ageing, 2014, 43, 737-739.	0.7	7
905	Effect of Educational Intervention on Adverse Drug Reporting by Physicians: A Cross-Sectional Study. ISRN Pharmacology, 2014, 2014, 1-8.	1.6	25
906	Customer interest in and experience with various types of pharmacy counselling – a qualitative study. Health Expectations, 2014, 17, 852-862.	1.1	25
907	Costs and Length of Stay of Drug-Related Hospital Admissions in Cancer Patients. Clinical Therapeutics, 2014, 36, 588-592.	1.1	10
908	Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records. Drug Discovery Today, 2014, 19, 361-366.	3.2	8
909	Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake. Journal of Thrombosis and Thrombolysis, 2014, 38, 105-114.	1.0	11
910	Drug identification and interaction checker based on IoT to minimize adverse drug reactions and improve drug compliance. Personal and Ubiquitous Computing, 2014, 18, 5-17.	1.9	50

#	Article	IF	CITATIONS
911	Preventability analysis of adverse drug reactions detected in two internal medicine departments in Romania. Internal and Emergency Medicine, 2014, 9, 187-193.	1.0	8
912	Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. British Journal of Pharmacology, 2014, 171, 580-594.	2.7	184
913	Determination of anti-inflammatory activities of standardised preparations of plant- and mushroom-based foods. European Journal of Nutrition, 2014, 53, 335-343.	1.8	31
914	Intermediate Care: The Role of Medicines Management. Drugs and Aging, 2014, 31, 21-31.	1.3	7
917	Path-breaking target therapies for lung cancer and a far-sighted health policy to support clinical and cost effectiveness. Health Policy and Technology, 2014, 3, 74-82.	1.3	54
918	Integrated pharmaceutical care in the community: (how) can we turn vision into reality?. Drugs and Therapy Perspectives, 2014, 30, 65-71.	0.3	0
919	Irrational prescribing of over-the-counter (OTC) medicines in general practice: testing the feasibility of an educational intervention among physicians in five European countries. BMC Family Practice, 2014, 15, 34.	2.9	14
920	A Framework for Assessing the Economic Value of Pharmacovigilance in Low- and Middle-Income Countries. Drug Safety, 2014, 37, 127-134.	1.4	9
921	Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China. BMC Health Services Research, 2014, 14, 73.	0.9	26
922	Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients. Supportive Care in Cancer, 2014, 22, 1875-1881.	1.0	29
923	Self-Medication with Over-the-Counter and Prescribed Drugs Causing Adverse-Drug-Reaction-Related Hospital Admissions: Results of a Prospective, Long-Term Multi-Centre Study. Drug Safety, 2014, 37, 225-235.	1.4	85
924	Prevalence and predictors of potential drug-drug interactions. Open Medicine (Poland), 2014, 9, 348-356.	0.6	9
925	Genotyping for Severe Drug Hypersensitivity. Current Allergy and Asthma Reports, 2014, 14, 418.	2.4	35
927	Hospital admissions/visits associated with drug–drug interactions: a systematic review and metaâ€analysis. Pharmacoepidemiology and Drug Safety, 2014, 23, 489-497.	0.9	204
929	High-throughput determination of nonsteroidal anti-inflammatory drugs in human plasma by HILIC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 71-80.	1.4	31
930	Opposing effects of aspirin and anticoagulants on morbidity and mortality in patients with upper gastrointestinal bleeding. Journal of Digestive Diseases, 2014, 15, 283-292.	0.7	8
931	Community pharmacists' knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharmaceutical Journal, 2014, 22, 411-418.	1.2	59
932	An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds. Expert Opinion on Pharmacotherapy, 2014, 15, 153-157.	0.9	9

#	Article	IF	CITATIONS
933	Potentially inappropriate prescribing to the elderly: comparison of new protocol to Beers criteria with relation to hospitalizations for ADRs. European Journal of Clinical Pharmacology, 2014, 70, 483-490.	0.8	27
934	Evaluation of Serum Bile Acid Profiles as Biomarkers of Liver Injury in Rodents. Toxicological Sciences, 2014, 137, 12-25.	1.4	95
935	Understanding adverse drug reactions in older adults through drug–drug interactions. European Journal of Internal Medicine, 2014, 25, 843-846.	1.0	73
936	Overâ€theâ€Counter Medication Overuse and Bowel Obstruction. Journal of the American Geriatrics Society, 2014, 62, 400-402.	1.3	1
937	Medication Regimen Complexity and Hospital Readmission for an Adverse Drug Event. Annals of Pharmacotherapy, 2014, 48, 26-32.	0.9	77
938	Linking Biochemical Pathways and Networks to Adverse Drug Reactions. IEEE Transactions on Nanobioscience, 2014, 13, 131-137.	2.2	12
939	Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program. Pharmacogenomics, 2014, 15, 845-856.	0.6	9
940	Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reports. Journal of Nursing Management, 2014, 22, 322-330.	1.4	18
941	ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 547-557.	2.2	113
942	Dabigatran: how the drug company withheld important analyses. BMJ, The, 2014, 349, g4670-g4670.	3.0	90
943	Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank. Drug Safety, 2014, 37, 617-628.	1.4	83
944	A descriptive exploratory study of how admissions caused by medication-related harm are documented within inpatients' medical records. BMC Health Services Research, 2014, 14, 257.	0.9	6
945	Perspectives of carers on medication management in dementia: lessons from collaboratively developing a research proposal. BMC Research Notes, 2014, 7, 463.	0.6	43
946	Barriers and facilitators to implementing electronic prescription: a systematic review of user groups' perceptions. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 535-541.	2.2	78
947	Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions. Annual Review of Genomics and Human Genetics, 2014, 15, 349-370.	2.5	128
948	Adherence to therapy and adverse drug reactions: is there a link?. Expert Opinion on Drug Safety, 2014, 13, 41-55.	1.0	94
950	Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. European Journal of Clinical Pharmacology, 2014, 70, 361-367.	0.8	86
951	Adverse drug reactions in an emergency medical dispatching centre. European Journal of Clinical Pharmacology, 2014, 70, 881-887.	0.8	6

#	Article	IF	CITATIONS
952	A Novel Semisupervised Algorithm for Rare Prescription Side Effect Discovery. IEEE Journal of Biomedical and Health Informatics, 2014, 18, 537-547.	3.9	12
953	Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?. Current Medical Research and Opinion, 2014, 30, 1521-1528.	0.9	17
954	Vitamin D Therapy to Reduce Blood Pressure and Left Ventricular Hypertrophy in Resistant Hypertension. Hypertension, 2014, 63, 706-712.	1.3	57
955	Female gender as a susceptibility factor for drug-induced liver injury. Human and Experimental Toxicology, 2014, 33, 928-939.	1.1	76
956	Adverse Drug Effects and Their Clinical Management: A Personal View. Drug Safety, 2014, 37, 383-390.	1.4	6
957	The scale of repeat prescribing – time for an update. BMC Health Services Research, 2014, 14, 76.	0.9	21
958	Drug-Induced Liver Injury., 2014,, 467-477.		0
959	The practice of prescribing: Discovering differences in what we tell patients about prescription medications. Patient Education and Counseling, 2014, 94, 255-260.	1.0	5
960	Determining the frequency and preventability of adverse drug reaction-related admissions to an Irish University Hospital: a cross-sectional study. Emergency Medicine Journal, 2014, 31, 24-29.	0.4	42
961	Structured Pharmaceutical Analysis of the Systematic Tool to Reduce Inappropriate Prescribing Is an Effective Method for Final‥ear Medical Students to Improve Polypharmacy Skills: A Randomized Controlled Trial. Journal of the American Geriatrics Society, 2014, 62, 1353-1359.	1.3	29
962	Application of the Pareto principle to identify and address drug-therapy safety issues. European Journal of Clinical Pharmacology, 2014, 70, 727-736.	0.8	17
963	Risk factors associated with a thrombotic or bleeding event in patients treated with vitaminÂK antagonists. Journal Des Maladies Vasculaires, 2014, 39, 248-255.	0.6	1
964	A computational prospect to aspirin side effects: Aspirin and COX-1 interaction analysis based on non-synonymous SNPs. Computational Biology and Chemistry, 2014, 51, 57-62.	1.1	21
965	Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. British Journal of Clinical Pharmacology, 2014, 77, 201-210.	1.1	172
966	JADE: A tool for medical researchers to explore adverse drug events using health claims data. Applied Clinical Informatics, 2014, 05, 621-629.	0.8	6
968	Online Reporting of Adverse Drug Reactions: A Study from a French Regional Pharmacovigilance Center. Therapie, 2014, 69, 395-400.	0.6	24
970	Understanding adverse drug reactions: An overview. NursePrescribing, 2014, 12, 189-195.	0.1	6
971	Preventing harm: medication management. Nursing and Residential Care, 2014, 16, 622-627.	0.1	2

#	Article	IF	CITATIONS
973	Pharmacist-led medication reviews in primary care. Reviews in Clinical Gerontology, 2014, 24, 1-9.	0.5	12
974	Economic Impact Of Drug-Related Morbidity In Sweden. Value in Health, 2015, 18, A532.	0.1	1
975	Pharmaceutical care of older people: what do older people want from community pharmacy?. International Journal of Pharmacy Practice, 2015, 23, 121-130.	0.3	23
976	The burden of adverse drug events. British Journal of Clinical Pharmacology, 2015, 80, 785-787.	1.1	7
977	Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a crossâ€sectional survey. British Journal of Clinical Pharmacology, 2015, 80, 818-826.	1.1	66
978	Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review. British Journal of Clinical Pharmacology, 2015, 80, 808-817.	1.1	69
979	Social media and pharmacovigilance: A review of the opportunities and challenges. British Journal of Clinical Pharmacology, 2015, 80, 910-920.	1.1	103
980	Deprescribing: When and how to stop a medicine. NursePrescribing, 2015, 13, 358-361.	0.1	4
981	Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress. Biochemical Society Transactions, 2015, 43, 657-662.	1.6	40
982	Maintaining medication safety: understanding a complex process. Nursing and Residential Care, 2015, 17, 625-629.	0.1	0
983	Pattern of Adverse Drug Reactions in Children Attending the Department of Pediatrics in a Tertiary Care Center: A Prospective Observational Study. Clinical Medicine Insights Pediatrics, 2015, 9, CMPed.S29493.	0.7	12
985	Correlation of Incident Potentially Inappropriate Medication Prescriptions and Hospitalization: An Analysis Based on the PRISCUS List. Drugs - Real World Outcomes, 2015, 2, 249-259.	0.7	30
987	The Scottish patient safety programme in primary care: context, interventions and early outcomes. Scottish Medical Journal, 2015, 60, 192-195.	0.7	7
988	Overexpression of CYP3A5 attenuates inducibility and activity of CYP3A4 in HepG2 cells. Molecular Medicine Reports, 2015, 11, 2868-2874.	1.1	5
989	Increasing the Number of Spontaneous ADE Reports in a Danish Region: A Retrospective Analysis. Pharmaceutical Medicine, 2015, 29, 211-217.	1.0	7
990	A Delphi study among internal medicine clinicians to determine which therapeutic information is essential to record in a medical record. Journal of Clinical Pharmacology, 2015, 55, 1415-1421.	1.0	3
991	Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 466-471.	0.7	10
992	Prescribing of bisphosphonates and antibiotics in Pakistan: challenges and opportunities for the future. Journal of Pharmaceutical Health Services Research, 2015, 6, 111-121.	0.3	27

#	Article	IF	CITATIONS
993	Healthcare system intervention for safer use of medicines in elderly patients in primary care—a qualitative study of the participants' perceptions of self-assessment, peer review, feedback and agreement for change. BMC Family Practice, 2015, 16, 117.	2.9	8
994	Structure, importance and recording of therapeutic information in the medical record: a multicentre observational study. Journal of Evaluation in Clinical Practice, 2015, 21, 1129-1134.	0.9	3
995	Quick assessment of drug-related admissions over time (QUADRAT study). Pharmacoepidemiology and Drug Safety, 2015, 24, 495-503.	0.9	10
996	Examining variations in prescribing safety in UK general practice: cross sectional study using the Clinical Practice Research Datalink. BMJ, The, 2015, 351, h5501.	3.0	63
997	A systematic review of the emerging definition of †deprescribing†with network analysis: implications for future research and clinical practice British Journal of Clinical Pharmacology, 2015, 80, 1254-1268.	1.1	461
998	Decisional support to prevent adverse drug reactions of long latency: pilot randomized controlled intervention for glucocorticoidâ€induced diabetes. Journal of Evaluation in Clinical Practice, 2015, 21, 614-619.	0.9	4
999	Drugâ€Related Inadvertent Deaths in a University Hospital – A Declining Trend. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 421-426.	1.2	22
1000	Older Age and Steroid Use Are Associated with Increasing Polypharmacy and Potential Medication Interactions Among Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	43
1001	Strategies to Stimulate Actions for Pharmacovigilance Decentralization. Journal of Pharmacovigilance, 2015, 03, .	0.2	0
1003	A Rare Complication Related with Oral Anticoagulant (Warfarin) Use: Diffuse Alveolar Hemorrhage (above 65 Years 4 Case Reports). Journal of Pulmonary & Respiratory Medicine, 2015, 05, .	0.1	0
1004	Medication management: eliminating errors. Nursing and Residential Care, 2015, 17, 150-154.	0.1	1
1005	Seven Steps to the Diagnosis of NSAIDs Hypersensitivity: How to Apply a New Classification in Real Practice?. Allergy, Asthma and Immunology Research, 2015, 7, 312.	1.1	77
1006	Margaret McCartney: Honesty, placebos, and pain care. BMJ, The, 2015, 351, h5103.	3.0	0
1007	Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmacogenomics and Personalized Medicine, 2015, 8, 43.	0.4	27
1008	Systematic Review on Irrational Use of Medicines in China and Vietnam. PLoS ONE, 2015, 10, e0117710.	1.1	134
1009	Which Medication Is the Patient Taking at Admission to the Emergency Ward? Still Unclear Despite the Swedish Prescribed Drug Register. PLoS ONE, 2015, 10, e0128716.	1.1	2
1010	Identification of Adverse Drug Events from Free Text Electronic Patient Records and Information in a Large Mental Health Case Register. PLoS ONE, 2015, 10, e0134208.	1.1	62
1011	Differences between Drug-Induced and Contrast Media-Induced Adverse Reactions Based on Spontaneously Reported Adverse Drug Reactions. PLoS ONE, 2015, 10, e0142418.	1.1	9

#	Article	IF	CITATIONS
1012	Prescribing to fit the needs of older people – the NHS Scotland Polypharmacy Guidance, 2nd edition. Journal of the Royal College of Physicians of Edinburgh, The, 2015, 45, 108-113.	0.2	22
1013	Medicines adherence and coaching in cardiology. British Journal of Cardiac Nursing, 2015, 10, 390-393.	0.0	2
1014	Natural Products for Antithrombosis. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-17.	0.5	35
1015	Bridging Data Models and Terminologies to Support Adverse Drug Event Reporting Using EHR Data. Methods of Information in Medicine, 2015, 54, 24-31.	0.7	17
1016	A Cross-Sectional Study on Knowledge and Perceptions of Pharmacovigilance among Pharmacy Students of Selected Tertiary Institutions in Jordan. Tropical Journal of Pharmaceutical Research, 2015, 14, 1899.	0.2	10
1017	A Review of Pharmacovigilance. West Indian Medical Journal, 2014, 63, 771-4.	0.4	17
1018	Characteristics and drug utilization patterns for heavy users of prescription drugs among the elderly: a Danish register-based drug utilization study. European Journal of Clinical Pharmacology, 2015, 71, 751-758.	0.8	8
1019	Scanning the human genome and the horizon: the potential and pitfalls of pharmacogenetics and stratified medicine. British Journal of General Practice, 2015, 65, 284-285.	0.7	1
1020	Knowledge, attitude and practices toward pharmacovigilance and adverse drug reactions in postgraduate students of Tertiary Care Hospital in Gujarat. Journal of Advanced Pharmaceutical Technology and Research, 2015, 6, 29.	0.4	29
1021	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015, 135, 2632-2640.	0.3	318
1022	Oral anticoagulation: a critique of recent advances and controversies. Trends in Pharmacological Sciences, 2015, 36, 153-163.	4.0	70
1023	The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Medicine, 2015, 13, 74.	2.3	538
1024	Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital. Avicenna Journal of Medicine, 2015, 05, 29-35.	0.3	10
1025	Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 221-241.	6.6	57
1026	Chronic NSAIDs Use Increases the Risk of a Second Hip Fracture in Patients After Hip Fracture Surgery. Medicine (United States), 2015, 94, e1566.	0.4	12
1027	The importance of taking a thorough history. British Journal of Hospital Medicine (London, England:) Tj ETQq $1\ 1\ 0$	0.784314   0.2	rgBT /Overlo
1028	Development of a computerised decisions support system for renal risk drugs targeting primary healthcare. BMJ Open, 2015, 5, e006775.	0.8	10
1029	Medication incidents in primary care medicine: protocol of a study by the Swiss Federal Sentinel Reporting System. BMJ Open, 2015, 5, e007773-e007773.	0.8	5

#	Article	IF	CITATIONS
1030	A pilot survey of junior doctors' attitudes and awareness around medication review: time to change our educational approach?. European Journal of Hospital Pharmacy, 2015, 22, 243-248.	0.5	37
1031	Temporal weighting of clinical events in electronic health records for pharmacovigilance., 2015,,.		10
1032	Discovery of the relations between genetic polymorphism and adverse drug reactions. , 2015, , .		1
1033	Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. Arthritis Research and Therapy, 2015, 17, 375.	1.6	25
1034	Extraction of Clinical Phenotypic Information from Online Heterogeneous Healthcare Networks. , 2015, , .		0
1035	Antibiotics in frozen bone grafts can cause allergic reactions in recipient patients. Medical Hypotheses, 2015, 84, 107-108.	0.8	3
1036	Medication-Related Emergency Department Visits in Pediatrics: a Prospective Observational Study. Pediatrics, 2015, 135, 435-443.	1.0	35
1037	The quantified self: closing the gap between general knowledge and particular case?. Journal of Evaluation in Clinical Practice, 2015, 21, 398-403.	0.9	11
1038	Adverse drug reactions in special populations – the elderly. British Journal of Clinical Pharmacology, 2015, 80, 796-807.	1.1	366
1039	Safety of medication use in primary care. International Journal of Pharmacy Practice, 2015, 23, 3-20.	0.3	48
1040	Drugs in the elderly with chronic kidney disease: beware of potentially inappropriate medications. Nephrology Dialysis Transplantation, 2015, 30, 342-344.	0.4	14
1041	The harms of low-dose aspirin prophylaxis are overstated. Annals of Oncology, 2015, 26, 441-442.	0.6	4
1042	An in vitro study of anti-inflammatory activity of standardised Andrographis paniculata extracts and pure andrographolide. BMC Complementary and Alternative Medicine, 2015, 15, 18.	3.7	41
1043	Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 671-681.	2.2	415
1044	Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Saudi Pharmaceutical Journal, 2015, 23, 154-161.	1.2	59
1046	Evolving models of the immunopathogenesis of TÂcell–mediated drug allergy: The role of host, pathogens, and drug response. Journal of Allergy and Clinical Immunology, 2015, 136, 219-234.	1.5	185
1047	Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions?. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 357-368.	1.5	15
1048	Clinical pharmacists in general practice: value for patients and the practice of a new role. British Journal of General Practice, 2015, 65, 262-263.	0.7	26

#	Article	IF	CITATIONS
1049	Admissions for drug-related problems at the Emergency Department of a University Hospital in the Kingdom of Saudi Arabia. Journal of Family and Community Medicine, 2015, 22, 44.	0.5	23
1050	Knowledge, Attitude and Perception of Physicians towards Adverse Drug Reaction Reporting at King Khalid University Hospital, Riyadh, Saudi Arabia. Tropical Journal of Pharmaceutical Research, 2015, 14, 907.	0.2	6
1051	Accurate identification of UDP-glucuronosyltransferase 1A1 (UGT1A1) inhibitors using UGT1A1-overexpressing HeLa cells. Xenobiotica, 2015, 45, 945-953.	0.5	6
1052	Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. European Journal of Internal Medicine, 2015, 26, 399-406.	1.0	59
1054	Towards the development of mechanism-based biomarkers to diagnose drug hypersensitivity. Toxicology Research, 2015, 4, 777-795.	0.9	5
1055	Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis. Nature Communications, 2015, 6, 7101.	5.8	41
1056	A study of National Health Service management of chronic osteoarthritis and low back pain. Primary Health Care Research and Development, 2015, 16, 157-166.	0.5	23
1057	Clinical Association Between Pharmacogenomics and Adverse Drug Reactions. Drugs, 2015, 75, 589-631.	4.9	57
1058	Initiatives to Identify and Mitigate Medication Errors in England. Drug Safety, 2015, 38, 349-357.	1.4	12
1059	Role of dermatology in pharmacogenomics: drug-induced skin injury. Pharmacogenomics, 2015, 16, 401-412.	0.6	9
1060	Pharmacogenetic Markers of Drug Efficacy and Toxicity. Clinical Pharmacology and Therapeutics, 2015, 98, 61-70.	2.3	32
1062	Survey of patients' experiences and their certainty of suspected adverse drug reactions. International Journal of Clinical Pharmacy, 2015, 37, 168-174.	1.0	19
1063	Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. Drug Safety, 2015, 38, 437-453.	1.4	310
1064	NSAIDs Hypersensitivity: When and How to Desensitize?. Current Treatment Options in Allergy, 2015, 2, 124-140.	0.9	6
1065	Effectiveness of pharmaceutical care at discharge in the emergency department: study protocol of a randomized controlled trial. Trials, 2015, 16, 60.	0.7	11
1066	Advocacy for Integration. , 2015, , 1-25.		2
1067	Nonsteroidal Anti-inflammatory Drug Use in a Patient With Hypertension. JAMA Internal Medicine, 2015, 175, 892.	2.6	6
1068	Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest, 2015, 148, 701-710.	0.4	26

#	Article	IF	CITATIONS
1069	Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBaseâ,,¢. Regulatory Toxicology and Pharmacology, 2015, 72, 481-490.	1.3	46
1070	Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ, The, 2015, 350, h949-h949.	3.0	247
1071	Medicines management audit cycle, St. Brigid's Hospital Ballinasloe. Irish Journal of Psychological Medicine, 2015, 32, 219-225.	0.7	0
1072	Hospitalization for drug-induced hepatotoxicity: linking Y-codes with pharmaceutical claims data to identify implicated medicines. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 213-219.	0.7	2
1073	Ménière's Disease Treatment: A Patient-Centered Systematic Review. Audiology and Neuro-Otology, 2015, 20, 153-165.	0.6	18
1074	Translational Pharmacogenetics to Support Pharmacogenetically Driven Clinical Decision Making. , 2015, , 59-73.		O
1075	Factors that affect adverse drug reaction reporting among hospital pharmacists in Western China. International Journal of Clinical Pharmacy, 2015, 37, 457-464.	1.0	11
1076	"lt's very complicated― a qualitative study of medicines management in intermediate care facilities in Northern Ireland. BMC Health Services Research, 2015, 15, 216.	0.9	7
1077	Management of allergic disease in the elderly: key considerations, recommendations and emerging therapies. Expert Review of Clinical Immunology, 2015, 11, 1219-1228.	1.3	34
1078	Routine deprescribing of chronic medications to combat polypharmacy. Therapeutic Advances in Drug Safety, 2015, 6, 212-233.	1.0	88
1079	The expenditure of computer-related worktime using clinical decision support systems in chronic pain therapy. BMC Anesthesiology, 2015, 15, 113.	0.7	5
1080	Trends and Characteristics of Emergency Department Patients Prescribed Novel Oral Anticoagulants. Journal of Emergency Medicine, 2015, 49, 693-697.	0.3	20
1081	Quality Indicators as a Tool in Improving the Introduction of New Medicines. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 146-157.	1.2	29
1082	Nurses' selfâ€reported medication competence in relation to their pharmacovigilant activities in clinical practice. Journal of Evaluation in Clinical Practice, 2015, 21, 145-152.	0.9	12
1083	Enhanced clinical pharmacy service targeting tools: riskâ€predictive algorithms. Journal of Evaluation in Clinical Practice, 2015, 21, 187-197.	0.9	7
1084	Acute Hospital Admissions Because of Health Care–Related Adverse Events: A Retrospective Study of 5 Specialist Departments. Journal of the American Medical Directors Association, 2015, 16, 1055-1061.	1.2	3
1085	Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase. Expert Opinion on Drug Safety, 2015, 14, 1827-1833.	1.0	5
1086	Genetics, Genomics, and Pharmacogenomics. Annals of Surgical Oncology, 2015, 22, 3414-3417.	0.7	0

#	Article	IF	CITATIONS
1087	Adverse drug reactions experience in a teaching hospital in Jordan. International Journal of Clinical Pharmacy, 2015, 37, 1188-1193.	1.0	15
1088	Reducing errors through discharge medication reconciliation by pharmacy services. American Journal of Health-System Pharmacy, 2015, 72, S120-S126.	0.5	38
1089	New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. Journal of Allergy and Clinical Immunology, 2015, 136, 236-244.	1.5	80
1090	Analysis of drug interactions at the end of life. BMJ Supportive and Palliative Care, 2015, 5, 281-286.	0.8	17
1091	Gastrointestinal Safety Pharmacology in Drug Discovery and Development. Handbook of Experimental Pharmacology, 2015, 229, 291-321.	0.9	18
1092	Medicine â€~misuse': Implications for health and environmental sustainability. Social Science and Medicine, 2015, 143, 81-87.	1.8	17
1093	Frequency of ambulatory care adverse events in Latin American countries: the AMBEAS/PAHO cohort study. International Journal for Quality in Health Care, 2015, 27, 52-59.	0.9	26
1094	Use of Celecoxib Correlates With Increased Relative Risk of Acute Pancreatitis: A Case–Control Study in Taiwan. American Journal of Gastroenterology, 2015, 110, 1490-1496.	0.2	19
1095	Safety, trust, and money are uncomfortable bedfellows. BMJ, The, 2015, 351, h5750.	3.0	2
1096	Promoting Safer Use of High-Risk Pharmacotherapy: Impact of Pharmacist-Led Targeted Medication Reviews. Drugs - Real World Outcomes, 2015, 2, 261-271.	0.7	10
1097	Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model. Drug Metabolism and Disposition, 2015, 43, 1679-1690.	1.7	22
1098	Personalized medicine approaches in epilepsy. Journal of Internal Medicine, 2015, 277, 218-234.	2.7	71
1099	Improving Postapproval Drug Safety Surveillance: Getting Better Information Sooner. Annual Review of Pharmacology and Toxicology, 2015, 55, 75-87.	4.2	15
1100	Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 243-257.	1,5	69
1101	Traumatologie und gewaltsamer Tod., 2015, , 171-418.		0
1102	Adverse drug reaction-related hospitalisations among patients with heart failure at two hospitals in the United Arab Emirates. International Journal of Clinical Pharmacy, 2015, 37, 105-112.	1.0	10
1103	A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells. Drug Discovery Today, 2015, 20, 37-49.	3.2	40
1104	Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiology and Drug Safety, 2015, 24, 176-186.	0.9	55

#	Article	IF	CITATIONS
1105	Diclofenac sodium induced Stevens–Johnson syndrome in a hospitalized patient during treatment of splenic injury and mandibular fracture. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2015, 27, 29-32.	0.2	1
1106	Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharmaceutical Journal, 2015, 23, 147-153.	1.2	78
1107	Incidence of hospital admissions due to adverse drug reactions in <scp>F</scp> rance: the <scp>EMIR</scp> study. Fundamental and Clinical Pharmacology, 2015, 29, 106-111.	1.0	99
1108	Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Annals of the Rheumatic Diseases, 2015, 74, 718-723.	0.5	72
1109	Adverse drug reactions as a cause of admission to a Dublin-based university teaching hospital. Irish Journal of Medical Science, 2015, 184, 441-447.	0.8	8
1110	Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review. Clinical Reviews in Allergy and Immunology, 2015, 48, 165-175.	2.9	57
1111	QUALITY EVALUATION AND SURVEY OF THE ESSENTIAL NEED FOR DRUG INFORMATION CENTERS. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 8, 137.	0.3	6
1112	Genomics, New Drug Development, and Precision Medicines. , 2016, , 247-259.		0
1113	Safe use of NSAIDs and RAS-inhibitors at Agogo Presbyterian Hospital, Ghana. Ghana Medical Journal, 2016, 50, 22.	0.2	0
1114	Sex and Gender; Pharmacology, Efficacy, Toxicity, and Toxicology. , 2016, , 63-76.		1
1115	Identifying polypharmacy in the primary care setting. Practice Nursing, 2016, 27, 28-33.	0.1	1
1116	Profile of rheumatology patients willing to report adverse drug reactions: bias from selective reporting. Patient Preference and Adherence, 2016, 10, 115.	0.8	0
1117	Does hospital admission provide an opportunity for improving pharmacotherapy among elderly inpatients?. Brazilian Journal of Pharmaceutical Sciences, 2016, 52, 391-401.	1.2	4
1118	Gender differences in the adverse events' profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis. Drug Design, Development and Therapy, 2016, Volume 10, 2917-2927.	2.0	17
1119	EVOLVING TRENDS AND FUTURE PROSPECTS OF ADR MONITORING AND REPORTING: A LITERATURE REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 2016, 9, 126.	0.3	10
1120	A systematic review of observational studies evaluating costs of adverse drug reactions. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 413-426.	0.7	41
1121	Factors affecting the development of adverse drug reactions to & Discrete Factors in hospitalized cardiac patient population. Patient Preference and Adherence, 2016, Volume 10, 1461-1469.	0.8	9
1122	Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophrenia Research and Treatment, 2016, 2016, 1-12.	0.7	47

#	Article	IF	CITATIONS
1123	Hospitalization in older patients due to adverse drug reactions – the need for a prediction tool. Clinical Interventions in Aging, 2016, 11, 497.	1.3	110
1124	Pharmacology, pharmacy, and the aging adult: Implications for occupational therapy. , 2016, , 214-234.		1
1125	The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. International Journal of Molecular Sciences, 2016, 17, 1714.	1.8	73
1126	Irrational Use of Medicines—A Summary of Key Concepts. Pharmacy (Basel, Switzerland), 2016, 4, 35.	0.6	150
1127	Adverse Drug Reactions in a Tertiary Care Emergency Medicine Ward - Prevalence, Preventability and Reporting. PLoS ONE, 2016, 11, e0162948.	1.1	26
1128	Prediction of Hospitalization due to Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC Score). PLoS ONE, 2016, 11, e0165757.	1.1	53
1129	Methods to reduce prescribing errors in elderly patients with multimorbidity. Clinical Interventions in Aging, 2016, 11, 857.	1.3	121
1130	Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and Mouse. Journal of Toxicologic Pathology, 2016, 29, 18-1258.	0.3	109
1131	Potentially inappropriate prescribing and the risk of adverse drug reactions in critically ill older adults. Pharmacy Practice, 2016, 14, 818.	0.8	26
1132	Analysis of the effect of sentiment analysis on extracting adverse drug reactions from tweets and forum posts. Journal of Biomedical Informatics, 2016, 62, 148-158.	2.5	140
1133	Xenobiotic/medium chain fatty acid: CoA ligase $\hat{a}$ €" a critical review on its role in fatty acid metabolism and the detoxification of benzoic acid and aspirin. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1169-1179.	1.5	20
1134	Pressure ulcers induced by drug administration: A new concept and report of four cases in elderly patients. Journal of Dermatology, 2016, 43, 436-438.	0.6	12
1135	CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding. Pharmacogenetics and Genomics, 2016, 26, 66-73.	0.7	38
1136	A web resource for mining HLA associations with adverse drug reactions: HLA-ADR. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw069.	1.4	24
1137	Nurses' attitudes and spontaneous adverse drug reaction reporting: a case-control study in Portugal. Journal of Nursing Management, 2016, 24, 409-416.	1.4	21
1138	The effect of carbamazepine on warfarin anticoagulation: a registerâ€based nationwide cohort study involving the Swedish population. Journal of Thrombosis and Haemostasis, 2016, 14, 765-771.	1.9	26
1139	Rheumatic Diseases in Chihuahua, México. Journal of Clinical Rheumatology, 2016, 22, 188-193.	0.5	8
1140	Medicine's perception of reality - a split picture: critical reflections on apparent anomalies within the biomedical theory of science. Journal of Evaluation in Clinical Practice, 2016, 22, 496-501.	0.9	23

#	Article	IF	CITATIONS
1141	Older people remain on blood pressure agents despite being hypotensive resulting in increased mortality and hospital admission. Age and Ageing, 2016, 45, 783-788.	0.7	18
1145	Psychocardiology in the elderly. Wiener Klinische Wochenschrift, 2016, 128, 474-479.	1.0	6
1146	Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system. Expert Opinion on Drug Safety, 2016, 15, 69-75.	1.0	0
1147	A systematic review of approaches for calculating the cost of medication errors. European Journal of Hospital Pharmacy, 2016, 23, 294-301.	0.5	11
1148	Potential drug–drug interactions among elderly patients admitted to medical ward of Ayder Referral Hospital, Northern Ethiopia: a cross sectional study. BMC Research Notes, 2016, 9, 431.	0.6	30
1149	Pilot study to test the feasibility of a trial design and complex intervention on <i> PRI &lt; /i &gt; oritising <i> MU &lt; /i &gt; Itimedication in <i> M &lt; /i &gt; ultimorbidity in general practices (PRIMUM <i> pilot) &lt; /i &gt; . BMJ Open, 2016, 6, e011613.</i></i></i></i>	0.8	30
1150	Improving the management of behaviour that challenges associated with dementia in care homes: protocol for pharmacy–health psychology intervention feasibility study. BMJ Open, 2016, 6, e010279.	0.8	12
1151	A literature-based economic evaluation of healthcare preventable adverse events in Europe. International Journal for Quality in Health Care, 2016, 29, 9-18.	0.9	7
1152	Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data. Pharmacoepidemiology and Drug Safety, 2016, 25, 1434-1442.	0.9	14
1153	The need for a prescribing competency framework to address the burden of complex polypharmacy among multiple long-term conditions. Clinical Medicine, 2016, 16, 470-474.	0.8	13
1154	Practical multidisciplinary approaches to heart failure management for improved patient outcome. European Heart Journal Supplements, 2016, 18, G43-G52.	0.0	17
1155	Evaluation of a care transition program with pharmacist-provided home-based medication review for elderly Singaporeans at high risk of readmissions. International Journal for Quality in Health Care, 2016, 29, 200-205.	0.9	21
1157	Metabolic Network Prediction of Drug Side Effects. Cell Systems, 2016, 2, 209-213.	2.9	81
1158	Content Related to Older Adults in Canadian Innovator–Drug Product Monographs: An Exploratory Analysis. Pharmaceutical Medicine, 2016, 30, 149-155.	1.0	0
1159	Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities. Applied & Translational Genomics, 2016, 9, 3-5.	2.1	7
1160	Mechanism of Drug-Drug Interactions Between Warfarin and Statins. Journal of Pharmaceutical Sciences, 2016, 105, 1976-1986.	1.6	34
1161	Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. Journal of Pharmacological and Toxicological Methods, 2016, 81, 323-334.	0.3	49
1162	Potential drug-drug interactions in paediatric outpatient prescriptions in Nigeria and implications for the future. Expert Review of Clinical Pharmacology, 2016, 9, 1505-1515.	1.3	6

#	Article	IF	CITATIONS
1163	The Pharmacist's Perspective on Pharmacogenetics Implementation. Clinics in Laboratory Medicine, 2016, 36, 543-556.	0.7	1
1164	Conceptual models of drug-drug interactions: A summary of recent efforts. Knowledge-Based Systems, 2016, 114, 99-107.	4.0	15
1165	Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study. Drug Safety, 2016, 39, 1189-1195.	1.4	33
1166	Adverse drug reactions. Clinical Medicine, 2016, 16, 481-485.	0.8	208
1167	The epidemiology of polypharmacy. Clinical Medicine, 2016, 16, 465-469.	0.8	155
1168	Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. Chemical Research in Toxicology, 2016, 29, 1936-1955.	1.7	196
1169	Nature and frequency of drug therapy alerts generated by clinical decision support in community pharmacy. Pharmacoepidemiology and Drug Safety, 2016, 25, 82-89.	0.9	26
1170	A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. British Journal of Clinical Pharmacology, 2016, 81, 569-578.	1.1	23
1171	Reducing Hepatocyte Injury and Necrosis in Response to Paracetamol Using Noncoding RNAs. Stem Cells Translational Medicine, 2016, 5, 764-772.	1.6	36
1172	Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Annals of Oncology, 2016, 27, 1909-1915.	0.6	72
1173	No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region. Expert Opinion on Drug Safety, 2016, 15, 101-107.	1.0	9
1174	Hard to swallow: strategies to enable medication administration. Nursing and Residential Care, 2016, 18, 540-544.	0.1	0
1175	Making a difference: optimising medication management. Nursing and Residential Care, 2016, 18, 427-430.	0.1	1
1176	Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases. Expert Opinion on Drug Safety, 2016, 15, 1321-1328.	1.0	37
1177	Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. British Journal of Clinical Pharmacology, 2016, 82, 1636-1646.	1.1	67
1178	Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS A Journal of Integrative Biology, 2016, 20, 593-603.	1.0	20
1179	Potentially Serious Drug-Drug Interactions in Older Patients Hospitalized for Acute Ischemic and Hemorrhagic Stroke. European Neurology, 2016, 76, 161-166.	0.6	14
1180	Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors. Drug Safety, 2016, 39, 847-857.	1.4	105

#	Article	IF	CITATIONS
1181	Future Perspectives in Drug Therapy of Older Adults. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 737-757.	0.2	0
1182	Challenges in the Management of Hypertension in Older Populations. Advances in Experimental Medicine and Biology, 2016, 956, 167-180.	0.8	19
1183	Geriatric Pharmacotherapy: Optimisation Through Integrated Approach in the Hospital Setting. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 683-697.	0.2	0
1184	Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001–2010: content and utility analysis. British Journal of Clinical Pharmacology, 2016, 82, 1601-1612.	1.1	17
1185	Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Research, 2016, 4, 15040.	5.4	355
1186	Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trial. BMJ, The, 2016, 354, i4079.	3.0	52
1187	Qualitative evaluation of the Safety and Improvement in Primary Care (SIPC) pilot collaborative in Scotland: perceptions and experiences of participating care teams. BMJ Open, 2016, 6, e009526.	0.8	7
1188	Safer drug use in primary care - a pilot intervention study to identify improvement needs and make agreements for change in five Swedish primary care units. BMC Family Practice, 2016, 17, 140.	2.9	10
1189	Learning temporal weights of clinical events using variable importance. BMC Medical Informatics and Decision Making, 2016, 16, 71.	1.5	16
1190	Unplanned readmissions in younger and older adult patients: the role of healthcare-related adverse events. European Journal of Medical Research, 2016, 21, 35.	0.9	10
1191	<pre><scp>A</scp>ustralian and <scp>N</scp>ew <scp>Z</scp>ealand <scp>S</scp>ociety for <scp>G</scp>eriatric <scp>M</scp>edicine Position Statement Abstract: Pain in older people. Australasian Journal on Ageing, 2016, 35, 293-293.</pre>	0.4	2
1192	Towards Human–Machine Collaboration in Creating an Evaluation Corpus for Adverse Drug Events in Discharge Summaries of Electronic Medical Records. Big Data Research, 2016, 4, 37-43.	2.6	4
1193	Hospital re-admission associated with adverse drug reactions in patients over the age of 65Âyears. European Journal of Clinical Pharmacology, 2016, 72, 631-639.	0.8	17
1194	Prescribing medicines for older patients. Medicine, 2016, 44, 433-437.	0.2	3
1195	The dangers of NSAIDs: look both ways. British Journal of General Practice, 2016, 66, 172-173.	0.7	98
1196	Assessment of the impact of the Scottish public health campaign on patient reporting of adverse drug reactions. Drugs and Therapy Perspectives, 2016, 32, 209-218.	0.3	2
1197	Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics, 2016, 17, 917-924.	0.6	40
1198	Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial. BMC Family Practice, 2016, 17, 49.	2.9	14

#	Article	IF	Citations
1199	Protocol for a Prospective (P) study to develop a model to stratify the risk (RI) of medication (M) related harm in hospitalized elderly (E) patients in the UK (The PRIME study). BMC Geriatrics, 2016, 16, 22.	1.1	16
1200	Polypharmacy in chronic diseases–Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support (PRIMA-eDS): study protocol for a randomized controlled trial. Trials, 2016, 17, 57.	0.7	74
1201	The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 281-286.	0.6	4
1202	Refining adverse drug reaction signals by incorporating interaction variables identified using emergent pattern mining. Computers in Biology and Medicine, 2016, 69, 61-70.	3.9	11
1203	Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation. Drugs - Real World Outcomes, 2016, 3, 33-43.	0.7	36
1204	Precision Medicine and Rare Genetic Variants. Trends in Pharmacological Sciences, 2016, 37, 85-86.	4.0	52
1205	Advances in the Pharmacogenomics of Adverse Drug Reactions. Drug Safety, 2016, 39, 15-27.	1.4	29
1206	Prevention of Adverse Drug Reactions in Hospitalised Older Patients Using a Software-Supported Structured Pharmacist Intervention: A Cluster Randomised Controlled Trial. Drugs and Aging, 2016, 33, 63-73.	1.3	69
1207	A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. Pharmacoeconomics, 2016, 34, 771-793.	1.7	111
1208	Safer Prescribing â€" A Trial of Education, Informatics, and Financial Incentives. New England Journal of Medicine, 2016, 374, 1053-1064.	13.9	138
1209	Optimization of Geriatric Pharmacotherapy: Role of Multifaceted Cooperation in the Hospital Setting. Drugs and Aging, 2016, 33, 179-188.	1.3	47
1210	An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. Drug Safety, 2016, 39, 433-441.	1.4	30
1211	A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Medicine, 2016, 8, 2.	3.6	41
1212	A functional temporal association mining approach for screening potential drug–drug interactions from electronic patient databases. Informatics for Health and Social Care, 2016, 41, 387-404.	1.4	10
1213	Adverse drug reactions in neonates: a prospective study. Archives of Disease in Childhood, 2016, 101, 371-376.	1.0	20
1214	Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention. Drug Safety, 2016, 39, 491-500.	1.4	48
1215	Adverse Drug Reactions: Definitions, Classifications and Regulatory Aspects., 2016,, 9-25.		0
1216	Predicting risk of adverse drug reactions in older adults. Therapeutic Advances in Drug Safety, 2016, 7, 11-22.	1.0	276

#	Article	IF	CITATIONS
1217	Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clinical Infectious Diseases, 2016, 62, 561-567.	2.9	89
1218	Identifying high risk medications causing potential drug–drug interactions in outpatients: A prescription database study based on an online surveillance system. Research in Social and Administrative Pharmacy, 2016, 12, 559-568.	1.5	23
1219	Prescription errors in geriatric patients can be avoided by means of a computerized physician order entry (CPOE). Zeitschrift Fur Gerontologie Und Geriatrie, 2016, 49, 227-231.	0.8	6
1220	Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. European Heart Journal, 2016, 37, 24-34.	1.0	512
1221	Coagulation assessment with the new generation of oral anticoagulants. Emergency Medicine Journal, 2016, 33, 423-430.	0.4	58
1222	Pharmacy led medicine reconciliation at hospital: A systematic review of effects and costs. Research in Social and Administrative Pharmacy, 2017, 13, 300-312.	1.5	38
1223	Spinal Compression Fracture Management. Global Spine Journal, 2017, 7, 71-82.	1.2	35
1224	Human leucocyte antigen–adverse drug reaction associations: from a perspective of ethnicity. International Journal of Immunogenetics, 2017, 44, 7-26.	0.8	10
1225	Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan. Journal of Evaluation in Clinical Practice, 2017, 23, 608-613.	0.9	24
1226	Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 737-743.e3.	2.0	54
1227	Investigations on anti-inflammatory and analgesic activities of Alnus nitida Spach (Endl). stem bark in Sprague Dawley rats. Journal of Ethnopharmacology, 2017, 198, 407-416.	2.0	29
1228	Factors that Motivate Healthcare Professionals to Report Adverse Drug Events: A Systematic Review. Pharmaceutical Medicine, 2017, 31, 13-20.	1.0	1
1229	Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait. Saudi Pharmaceutical Journal, 2017, 25, 830-837.	1.2	48
1230	The effect of amiodarone on warfarin anticoagulation: a registerâ€based nationwide cohort study involving the Swedish population. Journal of Thrombosis and Haemostasis, 2017, 15, 446-453.	1.9	20
1231	2017, Sexual Dimorphism, Sexual Pluralism, and More. Clinical Therapeutics, 2017, 39, 1-5.	1.1	7
1232	Satisfaction with and adherence to warfarin treatment: A cross-sectional study among Sudanese patients. Journal of the Saudi Heart Association, 2017, 29, 169-175.	0.2	15
1233	Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. , 2017, 172, 181-194.		19
1234	Propacetamol poses a potential harm of adverse hypotension in male and older patients. Pharmacoepidemiology and Drug Safety, 2017, 26, 256-264.	0.9	10

#	Article	IF	CITATIONS
1235	DTB Select: 2   February 2017. Drug and Therapeutics Bulletin, 2017, 55, 14-17.	0.3	1
1236	Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms Assessed During Clinical Medication Reviews: A Cross-Sectional Observational Study. Drug Safety, 2017, 40, 419-430.	1.4	16
1237	Impact of an integrated medicines management service on preventable medicines-related readmission to hospital: a descriptive study. European Journal of Hospital Pharmacy, 2017, 24, 327-331.	0.5	7
1238	Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiology and Drug Safety, 2017, 26, 635-641.	0.9	67
1239	Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study. Drug Safety, 2017, 40, 409-418.	1.4	22
1240	Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms. Clinical and Molecular Allergy, 2017, 15, 2.	0.8	27
1241	Putting knowledge into practice: Does information on adverse drug interactions influence people's dosing behaviour?. British Journal of Health Psychology, 2017, 22, 330-344.	1.9	5
1242	Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?. Journal of Psychopharmacology, 2017, 31, 812-818.	2.0	10
1243	The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis. Drug Safety, 2017, 40, 263-272.	1.4	27
1244	Human biology-based drug safety evaluation: scientific rationale, current status and future challenges. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 567-574.	1.5	4
1245	The SENATOR project: developing and trialling a novel software engine to optimize medications and nonpharmacological therapy in older people with multimorbidity and polypharmacy. Therapeutic Advances in Drug Safety, 2017, 8, 81-85.	1.0	23
1246	Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 806-812.	2.2	50
1247	Patient Reporting in the EU: Analysis of EudraVigilance Data. Drug Safety, 2017, 40, 629-645.	1.4	57
1248	The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients. Advances in Therapy, 2017, 34, 1349-1363.	1.3	13
1249	Synthesis of conductive polymeric ionic liquid/Ni nanocomposite and its application to construct a nanostructure based electrochemical sensor for determination of warfarin in the presence of tramadol. Talanta, 2017, 171, 25-31.	2.9	23
1250	Medicines reconciliation pilot at transfer of care: admission to a community-based early supported discharge (â€~step-down') and prevention of admission (â€~step-up') service. European Journal of Hospital Pharmacy, 2017, 24, 152-156.	0.5	1
1251	Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation. Expert Opinion on Drug Safety, 2017, 16, 515-522.	1.0	17
1252	A decade of adverse drug events in Portuguese hospitals: space-time clustering and spatial variation in temporal trends. BMC Pharmacology & Empty 2017, 18, 34.	1.0	3

#	Article	IF	Citations
1253	Exploring the prevalence of and factors associated with advice on prescription medicines: A survey of community pharmacies in an English city. Health and Social Care in the Community, 2017, 25, 1774-1786.	0.7	8
1254	How do family medicine residents choose an anticoagulation regimen for patients with nonvalvular atrial fibrillation?. Primary Health Care Research and Development, 2017, 18, 472-481.	0.5	6
1255	Improving adverse drug event reporting by health care professionals. The Cochrane Library, 2017, , .	1.5	2
1256	Economic Impact of Emergency Visits due to Drug-Related Morbidity on a Brazilian Hospital. Value in Health Regional Issues, 2017, 14, 1-8.	0.5	14
1257	Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data. Drug Safety, 2017, 40, 133-144.	1.4	29
1258	Hospitalizations due to preventable adverse reactionsâ€"a systematic review. European Journal of Clinical Pharmacology, 2017, 73, 385-398.	0.8	47
1259	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia. BMJ Open, 2017, 7, e016276.	0.8	2
1260	Current and future perspectives on the management of polypharmacy. BMC Family Practice, 2017, 18, 70.	2.9	115
1261	Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. Journal of Rheumatology, 2017, 44, 835-843.	1.0	58
1262	Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions. Drugs, 2017, 77, 859-883.	4.9	85
1263	Association Between Psychotropic and Cardiovascular latrogenic Alerts and Risk of Hospitalizations in Elderly People Treated for Dementia: A Self-Controlled Case Series Study Based on the Matching of 2 French Health Insurance Databases. Journal of the American Medical Directors Association, 2017, 18, 549.e1-549.e13.	1.2	6
1264	Inflammation and pharmacokinetics: potential implications for HIV-infection. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 641-650.	1.5	24
1265	Evaluation of a complex intervention to improve primary care prescribing: a phase IV segmented regression interrupted time series analysis. British Journal of General Practice, 2017, 67, e352-e360.	0.7	15
1266	Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals. Drug Safety, 2017, 40, 597-606.	1.4	43
1267	Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 757-763.	2.0	64
1268	Personalized Medicine in Europe. Clinical and Translational Science, 2017, 10, 61-63.	1.5	50
1270	Potentially high-risk medication categories and unplanned hospitalizations: a case–time–control study. Scientific Reports, 2017, 7, 41035.	1.6	17
1271	A systematic review of the outcomes reported in trials of medication review in older patients: the need for a core outcome set. British Journal of Clinical Pharmacology, 2017, 83, 942-952.	1.1	49

#	Article	IF	CITATIONS
1272	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. Expert Opinion on Pharmacotherapy, 2017, 18, 123-131.	0.9	6
1273	Genomics of Adverse Drug Reactions. Trends in Pharmacological Sciences, 2017, 38, 100-109.	4.0	53
1274	More than meets the eye: the changing face of histopathology. Histopathology, 2017, 70, 4-9.	1.6	9
1275	Extracting Drug-Drug Interactions with Word and Character-Level Recurrent Neural Networks. , 2017, 2017, 5-12.		36
1276	Polypharmacy and Unplanned Hospitalizations in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2017, 44, 1786-1793.	1.0	25
1277	Severe Delayed Drug Reactions. Immunology and Allergy Clinics of North America, 2017, 37, 785-815.	0.7	27
1278	Assessment of the coding accuracy of warfarin-related bleeding events. Thrombosis Research, 2017, 159, 86-90.	0.8	29
1280	Knowledge, attitudes and perspective on adverse drug reaction reporting in a public sector hospital in South Africa: baseline analysis. Hospital Practice (1995), 2017, 45, 238-245.	0.5	29
1281	Comparing Methods for Estimating Direct Costs of Adverse Drug Events. Value in Health, 2017, 20, 1299-1310.	0.1	6
1282	Highâ€risk prescribing in an Irish primary care population: trends and variation. British Journal of Clinical Pharmacology, 2017, 83, 2821-2830.	1.1	11
1283	Améliorer la prescription et la surveillance médicamenteuse chez les résidents des EHPADÂ: rÃ1es du comité thérapeutique ville–hÃ′pital. Pharmacien Hospitalier Et Clinicien, 2017, 52, 269-275.	0.3	0
1284	Perspective of Saudi undergraduate pharmacy students on pharmacovigilance and adverse drug reaction reporting: A National Survey. Currents in Pharmacy Teaching and Learning, 2017, 9, 779-785.	0.4	8
1285	Oral warfarin intake affects skin inflammatory cytokine responses in rats. Environmental Toxicology and Pharmacology, 2017, 54, 93-98.	2.0	5
1286	Bleedingâ€related hospital admissions and 30â€day readmissions in patients with nonâ€valvular atrial fibrillation treated with dabigatran versus warfarin. Journal of Thrombosis and Haemostasis, 2017, 15, 1923-1933.	1.9	15
1287	Assessment of Oral Anticoagulant Use in Residents of Long-Term Care Homes: Evidence for Contemporary Suboptimal Use. Annals of Pharmacotherapy, 2017, 51, 1053-1062.	0.9	4
1288	Polypharmacy management programmes: the SIMPATHY Project. European Journal of Hospital Pharmacy, 2017, 24, 5-6.	0.5	23
1289	Physicians' Nonâ€Uniform Approach to Prescribing Drugs to Older Patients – A Qualitative Study. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 505-511.	1,2	3
1290	Barriers to early detection of cognitive impairment in the elderly despite the availability of simple cognitive screening tools and the pharmacist's role in early detection and referral. Journal of Pharmacy Practice and Research, 2017, 47, 287-293.	0.5	1

#	Article	IF	CITATIONS
1291	The key role of clinical and community health nurses in pharmacovigilance. European Journal of Clinical Pharmacology, 2017, 73, 1379-1387.	0.8	23
1292	Medication incidents in primary care medicine: a prospective study in the Swiss Sentinel Surveillance Network ( <i>Sentinella</i> ). BMJ Open, 2017, 7, e013658.	0.8	12
1293	Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics. Pharmacogenomics, 2017, 18, 1281-1297.	0.6	19
1294	Cost-effectiveness of <i>HLA-B*15:02</i> screening in Malaysia. British Journal of Dermatology, 2017, 177, 904-905.	1.4	5
1295	Prioritising the application of genomic medicine. Npj Genomic Medicine, 2017, 2, 35.	1.7	22
1296	The Many Faces of Medication-Related Injury in the Gastrointestinal Tract. Surgical Pathology Clinics, 2017, 10, 887-908.	0.7	11
1297	Enabling personalized medicine in Europe by the European Commission's funding activities. Personalized Medicine, 2017, 14, 355-365.	0.8	27
1298	Adverse Drug reactions in an Ageing PopulaTion (ADAPT) study protocol: a cross-sectional and prospective cohort study of hospital admissions related to adverse drug reactions in older patients. BMJ Open, 2017, 7, e017322.	0.8	9
1299	A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study. Implementation Science, 2017, 12, 58.	2.5	20
1300	A tailored programme to implement recommendations for multimorbid patients with polypharmacy in primary care practicesâ€"process evaluation of a cluster randomized trial. Implementation Science, 2017, 12, 31.	2.5	14
1301	Medication-related visits in a pediatric emergency department: an 8-years retrospective analysis. Italian Journal of Pediatrics, 2017, 43, 55.	1.0	8
1302	Development of a core outcome set for effectiveness trials aimed at optimising prescribing in older adults in care homes. Trials, 2017, 18, 175.	0.7	45
1303	A review of the National pharmacovigilance system in Malta $\hat{a}\in$ " implementing and operating a pharmacovigilance management system. Expert Opinion on Drug Safety, 2017, 16, 65-76.	1.0	3
1305	Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug–Drug Interactions and Co-medication Regimens. AAPS Journal, 2017, 19, 298-312.	2.2	28
1306	Trends in emergency hospital admissions in England due to adverse drug reactions: 2008-2015. Journal of Pharmaceutical Health Services Research, 2017, 8, 5-11.	0.3	39
1307	Stem cell–derived models to improve mechanistic understanding and prediction of human drugâ€induced liver injury. Hepatology, 2017, 65, 710-721.	3.6	54
1308	Attitudes and knowledge of community pharmacy professionals regarding the spontaneous reporting of adverse drug reactions: a preliminary study in Coimbra, Portugal. Drugs and Therapy Perspectives, 2017, 33, 88-94.	0.3	4
1309	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	3.2	24

#	Article	IF	CITATIONS
1310	Adverse drug events in patients with advanced chronic conditions who have a prognosis of limited life expectancy at hospital admission. European Journal of Clinical Pharmacology, 2017, 73, 79-89.	0.8	34
1311	The impact of serious adverse drug reactions: a populationâ€based study of a decade of hospital admissions in New South Wales, Australia. British Journal of Clinical Pharmacology, 2017, 83, 416-426.	1.1	25
1312	The importance of â€~appropriate' polypharmacy and the value of medicines. European Journal of Hospital Pharmacy, 2017, 24, 70.2-72.	0.5	2
1313	Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ: British Medical Journal, 2017, 359, j5058.	2.4	373
1314	Pharmacogenomics: The Scientific Basis of Rational Drug Development and Prescribing. Clinical Pharmacology & Biopharmaceutics, 2017, 06, .	0.2	1
1315	Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis. Toxicological Research, 2017, 33, 343-350.	1.1	1
1316	Data Requirements for the Correct Identification of Medication Errors and Adverse Drug Events in Patients Presenting at an Emergency Department. Methods of Information in Medicine, 2017, 56, 276-282.	0.7	7
1317	Gabapentin and Pregabalin: Do the Benefits Outweigh the Harms?. Journal of the Royal College of Physicians of Edinburgh, The, 2017, 47, 310-313.	0.2	38
1318	Development of a core outcome set for medication review in older patients with multimorbidity and polypharmacy: a study protocol. Clinical Interventions in Aging, 2017, Volume 12, 1379-1389.	1.3	12
1319	Personalized Medicine in Cardiovascular Disease. , 2017, , 457-471.		1
1320	Role of the pharmacist in reducing healthcare costs: current insights. Integrated Pharmacy Research & Practice, 2017, Volume 6, 37-46.	0.9	246
1321	Adverse Drug Events. , 2017, , 389-396.		1
1322	Safer Prescribing and Care for the Elderly (SPACE): feasibility of audit and feedback plus practice mail-out to patients with high-risk prescribing. Journal of Primary Health Care, 2017, 9, 145.	0.2	10
1323	Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting. Integrated Pharmacy Research & Practice, 2017, Volume 6, 91-98.	0.9	60
1324	ADEPt, a semantically-enriched pipeline for extracting adverse drug events from free-text electronic health records. PLoS ONE, 2017, 12, e0187121.	1.1	41
1325	Adverse drug reactions reported to the drug and poison information center of Tehran, Iran. PLoS ONE, 2017, 12, e0185450.	1.1	6
1326	Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatrics, 2017, 17, 227.	1.1	49
1327	Potentially inappropriate medication use in nursing homes: an observational study using the NORGEP-NH criteria. BMC Geriatrics, 2017, 17, 220.	1.1	33

#	Article	IF	CITATIONS
1328	Impact of pharmacist-led medication management in care transitions. BMC Health Services Research, 2017, 17, 722.	0.9	17
1329	Use of a trigger tool to detect adverse drug reactions in an emergency department. BMC Pharmacology & Emp; Toxicology, 2017, 18, 71.	1.0	19
1330	Knowledge graph prediction of unknown adverse drug reactions and validation in electronic health records. Scientific Reports, 2017, 7, 16416.	1.6	69
1331	Barriers to reporting of adverse drugs reactions: a cross sectional study among community pharmacists in United Kingdom. Pharmacy Practice, 2017, 15, 931-931.	0.8	21
1332	A Personalized and Learning Approach for Identifying Drugs with Adverse Events. Yonsei Medical Journal, 2017, 58, 1229.	0.9	1
1333	Physiology and Pathology of Drug Hypersensitivity: Role of Human Leukocyte Antigens. , 0, , .		4
1334	Adverse Effects and Drug Interactions of the Nonâ€Steroidal Antiâ€Inflammatory Drugs. , 0, , .		8
1335	Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines. Ecancermedicalscience, 2017, 11, 764.	0.6	2
1336	Farmacogenética de reacciones adversas a fármacos antiepilépticos. NeurologÃa, 2018, 33, 165-176.	0.3	27
1337	Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice. Journal of Clinical Pharmacology, 2018, 58, 704-716.	1.0	10
1338	The adverse drug reaction risk in older persons (ADRROP) prediction scale: derivation and prospective validation of an ADR risk assessment tool in older multi-morbid patients. European Geriatric Medicine, 2018, 9, 191-199.	1.2	23
1339	Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 261-274.	1.5	2
1340	Adverse drug reactions in primary care: a scoping review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 615-621.	1.7	3
1341	Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial. Therapeutic Drug Monitoring, 2018, 40, 362-368.	1.0	20
1342	Complex Drug–Drug–Gene–Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. Clinical Pharmacokinetics, 2018, 57, 1267-1293.	1.6	36
1343	Can Practical Nurses Identify Older Home Care Clients at Risk of Drug-Related Problems–Geriatricians' Appraisal of Their Risk Screenings: A Pilot Study. Journal of Pharmacy Technology, 2018, 34, 99-108.	0.5	2
1344	Osteoimmunology: Effects of Standard Orthopaedic Interventions on Inflammatory Response and Early Fracture Healing. Journal of the American Academy of Orthopaedic Surgeons, The, 2018, 26, 343-352.	1.1	13
1345	Methylxanthine Drug Monitoring with Wearable Sweat Sensors. Advanced Materials, 2018, 30, e1707442.	11.1	226

#	Article	IF	Citations
1346	No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. Biological Reviews, 2018, 93, 1518-1557.	4.7	92
1347	Psychiatrists' and dentists' knowledge and attitudes regarding adverse drug reactions of psychotropic drugs. Psychiatry Research, 2018, 266, 323-327.	1.7	2
1348	Direct oral anticoagulants versus warfarin: is new always better than the old? Open Heart, 2018, 5, e000712.	0.9	61
1349	Personalisation of warfarin therapy using thermal ink-jet printing. European Journal of Pharmaceutical Sciences, 2018, 117, 80-87.	1.9	71
1350	Avoidable hospitalizations due to adverse drug reactions in an acute geriatric unit. Analysis of 3,292 patients. Medicina ClÃnica (English Edition), 2018, 150, 209-214.	0.1	11
1351	The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. International Journal of Cardiology, 2018, 258, 126-132.	0.8	40
1352	Completed audit cycle to explore the use of the STOPP/START toolkit to optimise medication in psychiatric in-patients with dementia. BJPsych Bulletin, 2018, 42, 37-41.	0.7	8
1353	Prescribing for Older Patients. , 2018, , 299-313.		2
1354	Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission. JAMA Internal Medicine, 2018, 178, 375.	2.6	203
1355	Comprehensive Geriatric Assessment in the Emergency Department. , 2018, , 91-107.		4
1356	Public risk perception of non-prescription medicines and information disclosure during consultations: a suitable target for intervention?. International Journal of Pharmacy Practice, 2018, 26, 423-432.	0.3	15
1357	Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ Open, 2018, 8, e018404.	0.8	58
1358	Trends in the medication reviews of community pharmacies in Japan: a nationwide retrospective study. International Journal of Clinical Pharmacy, 2018, 40, 101-108.	1.0	4
1359	Effects of warfarin on biological processes other than haemostasis: A review. Food and Chemical Toxicology, 2018, 113, 19-32.	1.8	17
1360	Severe cutaneous adverse reactions due to inappropriate medication use. British Journal of Dermatology, 2018, 179, 329-336.	1.4	17
1361	Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery., 2018,, 119-172.		O
1362	Automated Detection of Adverse Drug Reactions from Social Media Posts withÂMachine Learning. Lecture Notes in Computer Science, 2018, , 3-15.	1.0	26
1363	Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting. Drug Safety, 2018, 41, 511-514.	1.4	34

#	Article	IF	CITATIONS
1364	Pharmacogenetics of adverse reactions to antiepileptic drugs. NeurologÃa (English Edition), 2018, 33, 165-176.	0.2	5
1365	Preventable ADRs leading to hospitalization â€" results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients. Expert Opinion on Drug Safety, 2018, 17, 125-137.	1.0	33
1367	Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Safety, 2018, 41, 603-613.	1.4	36
1368	Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial. International Journal of Clinical Pharmacy, 2018, 40, 126-134.	1.0	12
1369	Adverse drug reactions. Anaesthesia, 2018, 73, 76-84.	1.8	51
1370	Patients not patents: Drug research and development as a public enterprise. European Journal of Clinical Investigation, 2018, 48, e12875.	1.7	9
1371	Multifaceted Pharmacistâ€led Interventions in the Hospital Setting: A Systematic Review. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 363-379.	1.2	30
1372	Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. BMC Pharmacology & Empty Toxicology, 2018, 19, 16.	1.0	43
1373	Patient centric drug product design in modern drug delivery as an opportunity to increase safety and effectiveness. Expert Opinion on Drug Delivery, 2018, 15, 619-627.	2.4	13
1374	Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study. Pharmacology Research and Perspectives, 2018, 6, e00373.	1.1	23
1375	Opportunities and Challenges in Cardiovascular Pharmacogenomics. Circulation Research, 2018, 122, 1176-1190.	2.0	23
1376	Genotype-guided warfarin therapy: current status. Pharmacogenomics, 2018, 19, 667-685.	0.6	38
1377	Identification and management of drug allergy. Nursing Standard (Royal College of Nursing (Great) Tj ETQq0 0 0	rgBT/Ove	rlock 10 Tf 5
1378	Drug-Associated Risk Tool: development and validation of a self-assessment questionnaire to screen for hospitalised patients at risk for drug-related problems. BMJ Open, 2018, 8, e016610.	0.8	12
1379	Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. Medical Care, 2018, 56, 410-415.	1,1	2
1380	The impact of intravenous acetaminophen onÂpain after abdominal surgery: a meta-analysis. Journal of Surgical Research, 2018, 227, 234-245.	0.8	14
1381	Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. Molecular Diagnosis and Therapy, 2018, 22, 297-314.	1.6	15
1383	Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. European Journal of Clinical Pharmacology, 2018, 74, 819-832.	0.8	48

#	Article	IF	CITATIONS
1384	Pharmacovigilance Rapid Alert System for Consumer Reporting (PRASCOR): A Look at Its Quantitative Contribution to Spontaneous Reporting in Nigeria from August 2012 to February 2017. Pharmaceutical Medicine, 2018, 32, 131-141.	1.0	7
1385	Medication Review and Patient Outcomes in an Orthopedic Department: A Randomized Controlled Study. Journal of Patient Safety, 2018, 14, 74-81.	0.7	26
1386	Oral warfarin affects some aspects of systemic immunomodulation with topical dinitrochlorobenzene (DNCB) in rats. Cutaneous and Ocular Toxicology, 2018, 37, 29-35.	0.5	1
1387	Adverse Reactions to Radiopharmaceuticals: A Survey Based on Clinical Cases Using Criteria of Systematic Review. Therapeutic Innovation and Regulatory Science, 2018, 52, 109-113.	0.8	10
1388	Clinically relevant potential drug–drug interactions among outpatients: A nationwide database study. Research in Social and Administrative Pharmacy, 2018, 14, 572-580.	1.5	34
1389	Drug eruptions in the mature patient. Clinics in Dermatology, 2018, 36, 249-254.	0.8	4
1390	Next generation organoids for biomedical research and applications. Biotechnology Advances, 2018, 36, 132-149.	6.0	91
1391	Therapeutic challenges in the mature patient. Clinics in Dermatology, 2018, 36, 128-139.	0.8	3
1392	Biomarkers of adverse drug reactions. Experimental Biology and Medicine, 2018, 243, 291-299.	1.1	25
1393	Renal function monitoring in heart failure – what is the optimal frequency? A narrative review. British Journal of Clinical Pharmacology, 2018, 84, 5-17.	1.1	25
1394	Immune Mechanisms of Drug Allergy. , 2018, , 27-38.		0
1395	Hospitalizaciones evitables por reacciones adversas a medicamentos en una unidad geriátrica de agudos. Análisis de 3.292 pacientes. Medicina ClÃnica, 2018, 150, 209-214.	0.3	16
1396	HLAs: Key regulators of Tâ€cellâ€mediated drug hypersensitivity. Hla, 2018, 91, 3-16.	0.4	72
1397	Drug-related problems identified during geriatric medication review in the community pharmacy. International Journal of Clinical Pharmacy, 2018, 40, 109-118.	1.0	29
1398	Categorization and association analysis of risk factors for adverse drug events. European Journal of Clinical Pharmacology, 2018, 74, 389-404.	0.8	26
1399	Frail older people with multi-morbidities in primary care: a new integrated care clinical pharmacy service. International Journal of Clinical Pharmacy, 2018, 40, 41-47.	1.0	1
1400	Comment on: "Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals― Drug Safety, 2018, 41, 321-322.	1.4	1
1401	Application of process mapping to understand integration of high risk medicine care bundles within community pharmacy practice. Research in Social and Administrative Pharmacy, 2018, 14, 944-950.	1.5	8

#	Article	IF	CITATIONS
1403	La Farmacovigilancia en Cuba y la Infranotificaciones de Reacciones Adversas a los Medicamentos. Horizonte Sanitario, 2018, 18, .	0.1	1
1404	Knowledge, attitudes and practices of nurses and pharmacists towards adverse drug reaction reporting in the South African private hospital sector. Health SA Gesondheid, 2018, 23, 1064.	0.3	8
1405	Ageing well with chronic musculoskeletal pain: protocol for a systematic review of non-pharmacological interventions aimed at reducing pain in an ageing population. Physical Therapy Reviews, 2018, 23, 330-337.	0.3	2
1406	Toward Sustainable Virtualized Healthcare: Extracting Medical Entities from Chinese Online Health Consultations Using Deep Neural Networks. Sustainability, 2018, 10, 3292.	1.6	14
1407	History, Epidemiology and Clinical Characteristic of Adverse Events. Journal of Pharmacovigilance, 2018, 06, .	0.2	1
1408	Reliability, ease of use and usefulness of I-MeDeSA for evaluating drug-drug interaction alerts in an Australian context. BMC Medical Informatics and Decision Making, 2018, 18, 83.	1.5	9
1409	SMASH! The Salford medication safety dashboard. BMJ Health and Care Informatics, 2018, 25, 183-193.	1.4	19
1410	Type B adverse drug reactions reported by an immunoallergology department. Pharmacy Practice, 2018, 16, 1070.	0.8	3
1411	Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a caseâ€"control pharmacokinetic study. BMJ Open, 2018, 8, e020922.	0.8	8
1412	Zebrafish Larvae Are a Suitable Model to Investigate the Metabolic Phenotype of Drug-Induced Renal Tubular Injury. Frontiers in Pharmacology, 2018, 9, 1193.	1.6	13
1413	Polypharmacy in older people: The need for deprescribing. Practice Nursing, 2018, 29, 390-396.	0.1	1
1415	KNOWLEDGE, ATTITUDE AND PRACTICE OF YEMENI PHYSICIANS TOWARD PHARMACOVIGILANCE: A MIXED METHOD STUDY. International Journal of Pharmacy and Pharmaceutical Sciences, 2018, 10, 74.	0.3	161
1416	Which drugs cause treatment-related problems? Analysis of 10,672 problems within the outpatient setting. Therapeutics and Clinical Risk Management, 2018, Volume 14, 2273-2281.	0.9	3
1417	Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. Journal of Translational Medicine, 2018, 16, 304.	1.8	220
1418	Iron Dysregulation and Dormant Microbes as Causative Agents for Impaired Blood Rheology and Pathological Clotting in Alzheimer's Type Dementia. Frontiers in Neuroscience, 2018, 12, 851.	1.4	17
1419	Community pharmacy Medicines Use Review: current challenges. Integrated Pharmacy Research & Practice, 2017, Volume 7, 83-92.	0.9	37
1420	Interactive Attention Network for Adverse Drug Reaction Classification. Communications in Computer and Information Science, 2018, , 185-196.	0.4	6
1421	Evidence-based medication review in care homes. Nursing and Residential Care, 2018, 20, 32-36.	0.1	1

#	Article	IF	CITATIONS
1422	Caracterizaci $\tilde{A}^3$ n de las potenciales interacciones farmacol $\tilde{A}^3$ gicas en pacientes de una unidad de cuidados intensivos en un hospital de tercer nivel de Bogot $\tilde{A}_i$ . Biomedica, 2018, 38, 407-416.	0.3	5
1423	Releasing GP capacity with pharmacy prescribing support and New Ways of Working: a prospective observational cohort study. British Journal of General Practice, 2018, 68, e735-e742.	0.7	34
1424	Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients. Pharmacy (Basel, Switzerland), 2018, 6, 108.	0.6	25
1425	Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles. Pharmacy (Basel,) Tj ETQq1 1	0,784314	4 rgBT /Over
1426	The use of computer-interpretable clinical guidelines to manage care complexities of patients with multimorbid conditions: A review. Digital Health, 2018, 4, 205520761880492.	0.9	28
1427	Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mo>â^—</mml:mo></mml:math> 15:02. lournal of Immunology Research, 2018, 2018, 1-12.	0.9	19
1428	Potential drug-drug interactions in outpatient department of a tertiary care hospital in Pakistan: a cross-sectional study. BMC Health Services Research, 2018, 18, 762.	0.9	19
1429	An ontological analysis of drug prescriptions. Applied Ontology, 2018, 13, 273-294.	1.0	4
1430	Pediatric Pharmacovigilance: Current Practice and Future Perspectives. Methods in Pharmacology and Toxicology, 2018, , 67-85.	0.1	0
1431	Associations between Antibiotics for Non-tuberculous Mycobacterial Infection and Incident Sjögren's Syndrome: A Nationwide, Population-based Case-control Study. Scientific Reports, 2018, 8, 16007.	1.6	4
1432	Nurse-led medicines' monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines. BMJ Open, 2018, 8, e023377.	0.8	9
1433	Evaluation of Reported Adverse Drug Reactions in Antibiotic Usage: A Retrospective Study From a Tertiary Care Hospital, Malaysia. Frontiers in Pharmacology, 2018, 9, 809.	1.6	7
1434	Role of personality traits in reporting the development of adverse drug reactions: a prospective cohort study of the Estonian general population. BMJ Open, 2018, 8, e022428.	0.8	5
1435	Patient-Reported Treatment Satisfaction with Dabigatran versus Warfarin in Patients with Non-Valvular Atrial Fibrillation in China. Thrombosis and Haemostasis, 2018, 118, 1815-1822.	1.8	16
1436	Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. European Journal of Clinical Pharmacology, 2018, 74, 1165-1173.	0.8	45
1437	Survivability of hospitalized chronic kidney disease (CKD) patients with moderate to severe estimated glomerular filtration rate (eGFR) after experiencing adverse drug reactions (ADRs) in a public healthcare center: a retrospective 3 year study. BMC Pharmacology & Dixicology, 2018, 19, 52.	1.0	6
1438	Increase of 10% in the Rate of Adverse Drug Reactions for Each Drug Administered in Hospitalized Patients. Clinics, 2018, 73, 1-6.	0.6	17
1439	Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab. Drug Safety, 2018, 41, 1397-1410.	1.4	37

#	ARTICLE	IF	Citations
1440	Effectiveness of a complex intervention on Prioritising Multimedication in Multimorbidity (PRIMUM) in primary care: results of a pragmatic cluster randomised controlled trial. BMJ Open, 2018, 8, e017740.	0.8	63
1442	Drug-Drug Interactions and Psychiatric Medication. , 2018, , 181-200.		O
1443	A Combined InÂVitro/In Silico Approach to Identifying Off-Target Receptor Toxicity. IScience, 2018, 4, 84-96.	1.9	5
1444	Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK. British Journal of Clinical Pharmacology, 2018, 84, 1789-1797.	1.1	80
1446	Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature. European Journal of Clinical Pharmacology, 2018, 74, 1235-1248.	0.8	49
1447	Prediction of Drug-Related Risks Using Clinical Context Information in Longitudinal Claims Data. Value in Health, 2018, 21, 1390-1398.	0.1	8
1448	The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opinion on Drug Safety, 2018, 17, 681-695.	1.0	125
1449	Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine. CNS Drugs, 2018, 32, 559-565.	2.7	12
1450	Clinically relevant drug–drug interactions among elderly people with dementia. European Journal of Clinical Pharmacology, 2018, 74, 1351-1360.	0.8	57
1451	Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice. BMC Family Practice, 2018, 19, 131.	2.9	30
1452	The prevalence and determinants of polypharmacy at age 69: a British birth cohort study. BMC Geriatrics, 2018, 18, 118.	1.1	37
1453	Promoting quality use of medicines in South-East Asia: reports from country situational analyses. BMC Health Services Research, 2018, 18, 526.	0.9	9
1454	Integrating rare genetic variants into pharmacogenetic drug response predictions. Human Genomics, 2018, 12, 26.	1.4	166
1455	Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in) Tj ETQq1 1	l 0.78431 1.6	4 rgBT /Ove
1456	Pharmacist's interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. International Journal of Clinical Pharmacy, 2018, 40, 1078-1085.	1.0	20
1457	Implementing a non-steroidal anti-inflammatory drugs communication bundle in remote and rural pharmacies and dispensing practices. BMJ Open Quality, 2018, 7, e000303.	0.4	3
1458	Causality and preventability assessment of adverse drug events of antibiotics among inpatients having different lengths of hospital stay: a multicenter, cross-sectional study in Lahore, Pakistan. BMC Pharmacology & Drain (2018), 19, 34.	1.0	7
1459	Can doctors identify older patients at risk of medication harm following hospital discharge? A multicentre prospective study in the UK. British Journal of Clinical Pharmacology, 2018, 84, 2344-2351.	1.1	11

#	Article	IF	CITATIONS
1460	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents. Journal of Clinical Medicine, 2018, 7, 29.	1.0	29
1461	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. Journal of Personalized Medicine, 2018, 8, 1.	1.1	136
1462	Warfarin: The End or the End of One Size Fits All Therapy?. Journal of Personalized Medicine, 2018, 8, 22.	1,1	26
1463	Development of a standardized chart review method to identify drugâ€related hospital admissions in older people. British Journal of Clinical Pharmacology, 2018, 84, 2600-2614.	1.1	38
1464	Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. Journal of Medical Genetics, 2018, 55, 617-627.	1.5	24
1465	International core outcome set for clinical trials of medication review in multi-morbid older patients with polypharmacy. BMC Medicine, 2018, 16, 21.	2.3	84
1466	Finite Horizon Tracking Control of Boolean Control Networks. IEEE Transactions on Automatic Control, 2018, 63, 1798-1805.	3.6	42
1467	Adverse Drug Reactions Reported by Healthcare Professionals: Reaction Characteristics and Time to Reporting. Journal of Clinical Pharmacology, 2018, 58, 1332-1339.	1.0	15
1468	Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and hove community pharmacy service. BMC Health Services Research, 2018, 18, 91.	0.9	20
1469	Hospitalisation and morbidity due to adverse drug reactions in elderly patients: a singleâ€eentre study. Internal Medicine Journal, 2018, 48, 1192-1197.	0.5	8
1470	LC–MS/MS assay for assessing medical adherence in patients under warfarin maintenance therapy. Microchemical Journal, 2018, 141, 135-140.	2.3	4
1471	Hospital readmissions, mortality and potentially inappropriate prescribing: a retrospective study of older adults discharged from hospital. British Journal of Clinical Pharmacology, 2018, 84, 1757-1763.	1.1	70
1472	Evaluation of a Novel System to Enhance Clinicians' Recognition of Preadmission Adverse Drug Reactions. Applied Clinical Informatics, 2018, 09, 313-325.	0.8	7
1473	Mortality from adverse drug reaction-related hospitalizations in south-west Ethiopia: A cross-sectional study. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 790-798.	0.7	10
1474	A data-driven method to detect adverse drug events from prescription data. Journal of Biomedical Informatics, 2018, 85, 10-20.	2.5	9
1475	Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study. PLoS ONE, 2018, 13, e0200810.	1.1	27
1476	Toward safer prescribing: evaluation of a prospective drug utilization review system on inappropriate prescriptions, prescribing patterns, and adverse drug events and related health expenditure in South Korea. Public Health, 2018, 163, 128-136.	1.4	12
1477	Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action. Drug Safety, 2018, 41, 1285-1302.	1.4	17

#	Article	IF	CITATIONS
1478	Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. Hospital Practice (1995), 2018, 46, 221-228.	0.5	24
1479	Effects of medication reviews on use of potentially inappropriate medications in elderly patients; a cross-sectional study in Swedish primary care. BMC Health Services Research, 2018, 18, 616.	0.9	41
1480	Personalised Medicine and Medical Imaging: Opportunities and Challenges for Contemporary Health Care. Journal of Medical Imaging and Radiation Sciences, 2018, 49, 352-359.	0.2	12
1481	Reducing clinical risks associated with the pharmacological treatment of acute gout attacks. Drugs and Therapy Perspectives, 2018, 34, 377-385.	0.3	0
1482	Healthcare professionals' knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. International Journal of Clinical Pharmacy, 2018, 40, 895-902.	1.0	24
1483	The Tokyo Declaration on patient safety. BMJ: British Medical Journal, 2018, 362, k3424.	2.4	9
1485	Strengths and Weaknesses of Pharmaceutical Policy in Relation to Rational and Responsible Medicines Use., 2018,, 247-262.		1
1486	Pharmacogenetics of Adverse Drug Reactions. Advances in Pharmacology, 2018, 83, 155-190.	1.2	32
1487	What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects. Drug Safety, 2018, 41, 1003-1011.	1.4	42
1488	Drug Hypersensitivity., 2019,, 649-667.e1.		1
1489	Pharmacists' knowledge and perceptions about pharmacovigilance and barriers towards adverse drug reactions reporting in Yemen. Journal of Pharmaceutical Health Services Research, 2019, 10, 67-72.	0.3	3
1490	Can community pharmacy successfully bridge the gap in care for housebound patients?. Research in Social and Administrative Pharmacy, 2019, 15, 425-439.	1.5	7
1491	Effect of a medicines management model on medicationâ€related readmissions in older patients admitted to a medical acute admission unitâ€"A randomized controlled trial. Journal of Evaluation in Clinical Practice, 2019, 25, 88-96.	0.9	21
1492	Protecting those at risk of anaphylaxis. Journal of Prescribing Practice, 2019, 1, 328-331.	0.1	0
1493	Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Current Medical Research and Opinion, 2019, 35, 1873-1883.	0.9	20
1494	Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation. Stroke, 2019, 50, 2469-2476.	1.0	23
1495	Communication between primary and secondary care: deficits and danger. Family Practice, 2020, 37, 63-68.	0.8	13
1496	The observed effect of adverse drug reactions on the length of hospital stay among medical inpatients in a Nigerian University Teaching Hospital. Toxicology Research and Application, 2019, 3, 239784731985045.	0.7	7

#	Article	IF	CITATIONS
1497	Adverse Drug Events and Reactions Managed by Medical Toxicologists: an Analysis of the Toxicology Investigators Consortium (ToxIC) Registry, 2010–2016. Journal of Medical Toxicology, 2019, 15, 262-270.	0.8	1
1498	Pharmacogenomics. Lancet, The, 2019, 394, 521-532.	6.3	261
1499	Genomic medicine: time for health-care transformation. Lancet, The, 2019, 394, 454-456.	6.3	14
1500	Polypharmacy perspectives in general practice environments. Practice Nursing, 2019, 30, 342-347.	0.1	0
1501	Retrobulbar haematoma in the era of anticoagulants. Injury, 2019, 50, 1641-1648.	0.7	5
1502	A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes. Chemical Research in Toxicology, 2019, 32, 1707-1721.	1.7	6
1503	Earlier discontinuation of TNFâ€Î± inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Alimentary Pharmacology and Therapeutics, 2019, 50, 386-396.	1.9	21
1504	Emerging Trend in the Pharmacotherapy of Osteoarthritis. Frontiers in Endocrinology, 2019, 10, 431.	1.5	68
1505	Sex differences in the pharmacology of itch therapiesâ€"a narrative review. Current Opinion in Pharmacology, 2019, 46, 122-142.	1.7	9
1506	Barriers to adverse drug reaction reporting in community practice in the UAE. Journal of Pharmaceutical Health Services Research, $2019, \ldots$	0.3	1
1507	Pharmacy-supported interventions at transitions of care: an umbrella review. International Journal of Clinical Pharmacy, 2019, 41, 831-852.	1.0	8
1508	Medication errors in primary health care records; a cross-sectional study in Southern Sweden. BMC Family Practice, 2019, 20, 110.	2.9	13
1509	Drug-Induced Injury, Vascular, Congenital, Motility, Polyps, and Miscellaneous Disorders. , 2019, , 479-522.		0
1510	HLA Polymorphisms And TKI-Induced Liver Injury in Patients with Cancer: A Meta-analysis. Journal of Cancer, 2019, 10, 2161-2168.	1.2	3
1511	Medications., 2019,, 178-189.		0
1512	Electroconvulsive Therapy and Neurostimulation. , 2019, , 190-204.		0
1514	The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity. Pharmaceutics, 2019, 11, 536.	2.0	12
1515	Identifying  avoidable harm' in family practice: a RAND/UCLA Appropriateness Method consensus study. BMC Family Practice, 2019, 20, 134.	2.9	5

#	Article	IF	CITATIONS
1517	Immunomodulatory actions of a Polynesian herb Noni (Morinda citrifolia) and its clinical applications. Complementary Therapies in Medicine, 2019, 47, 102206.	1.3	20
1518	Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review. Seminars in Nuclear Medicine, 2019, 49, 382-410.	2.5	9
1519	Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis. MDM Policy and Practice, 2019, 4, 238146831986682.	0.5	9
1520	Pharmacists' influence on adverse reactions to warfarin: a randomised controlled trial in elderly rural patients. International Journal of Clinical Pharmacy, 2019, 41, 1166-1173.	1.0	8
1521	Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. Journal of Personalized Medicine, 2019, 9, 42.	1.1	2
1522	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 751-765.	1.5	0
1523	Nurse-led medicines' monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for mental health medicines: An observational and interview study. PLoS ONE, 2019, 14, e0220885.	1.1	21
1524	The Role of an Interventional Program for Improving Pharmacovigilance at a Pediatric Facility. Frontiers in Pharmacology, 2019, 10, 1004.	1.6	2
1525	Prescribing in 2019: what are the safety concerns?. Expert Opinion on Drug Safety, 2019, 18, 69-74.	1.0	7
1526	Optimization of Drug Use in Older People. , 2019, , 237-262.		3
1527	The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes. Current Clinical Pharmacology, 2019, 14, 152-156.	0.2	2
1528	Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Drugs. Allergy, Asthma and Immunology Research, 2019, 11, 212.	1.1	13
1529	Arthritic Conditions Affecting the Temporomandibular Joint., 2019, , 1919-1954.		0
1530	Safety profile of traditional Chinese herbal injection: An analysis of a spontaneous reporting system in China. Pharmacoepidemiology and Drug Safety, 2019, 28, 1002-1013.	0.9	38
1531	Healthcare personnel's experience of reporting adverse drug reactions in Baghdad city: cross-sectional study. International Journal of Clinical Pharmacy, 2019, 41, 1307-1313.	1.0	2
1532	New Insights in Computational Methods for Pharmacovigilance: E-Synthesis, a Bayesian Framework for Causal Assessment. International Journal of Environmental Research and Public Health, 2019, 16, 2221.	1.2	10
1533	Factors that facilitate reporting of adverse drug reactions by pharmacists in Saudi Arabia. Expert Opinion on Drug Safety, 2019, 18, 745-752.	1.0	18
1534	Adverse Drug Reaction (ADR) as a Cause of Hospitalization at a Government Hospital in Saudi Arabia: A Prospective Observational Study. Current Drug Safety, 2019, 14, 192-198.	0.3	11

#	Article	IF	Citations
1536	Adverse drug reaction reporting by community pharmacistsâ€"The barriers and facilitators. Pharmacoepidemiology and Drug Safety, 2019, 28, 1552-1559.	0.9	30
1537	Pitfalls in Geriatric Prescribing: Antidepressants and Extreme Sedation. Case Reports in Medicine, 2019, 2019, 1-3.	0.3	1
1538	Clinical relevance of alerts from a decision support system, PHARAO, for drug safety assessment in the older adults. BMC Geriatrics, 2019, 19, 164.	1.1	8
1539	Drug Toxicity: Personalising IBD Therapeutics– The Use of Genetic Biomarkers to Reduce Drug Toxicity. , 2019, , 257-269.		1
1540	Unusual localization of bleeding under acenocoumarol: Spinal subdural hematoma. International Journal of Surgery Case Reports, 2019, 59, 15-18.	0.2	2
1541	Sex-Gender Variable: Methodological Recommendations for Increasing Scientific Value of Clinical Studies. Cells, 2019, 8, 476.	1.8	65
1542	Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Frontiers in Pharmacology, 2019, 10, 206.	1.6	8
1543	Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. Pharmacogenomics, 2019, 20, 599-608.	0.6	4
1544	Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2019, 58, 1767-1776.	0.9	24
1545	Stem cell models as an <i>in vitro</i> model for predictive toxicology. Biochemical Journal, 2019, 476, 1149-1158.	1.7	21
1546	Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA. BMC Bioinformatics, 2019, 20, 97.	1.2	29
1547	Adverse Event Circumstances and the Case of Drug Interactions. Healthcare (Switzerland), 2019, 7, 45.	1.0	9
1548	A comprehensive overview of common polymorphic variants that cause missense mutations in human CYPs and UGTs. Biomedicine and Pharmacotherapy, 2019, 111, 983-992.	2.5	9
1549	A mixed methods analysis of clozapine errors reported to the National Reporting and Learning System. Pharmacoepidemiology and Drug Safety, 2019, 28, 657-664.	0.9	4
1550	A Case for n-of-1 Trials. JAMA Internal Medicine, 2019, 179, 452.	2.6	5
1551	A systematic approach to polypharmacy review. BMJ: British Medical Journal, 2019, 364, l1034.	2.4	1
1552	Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions. International Journal of Data Science and Analytics, 2019, 8, 113-135.	2.4	52
1553	Machine learning on adverse drug reactions for pharmacovigilance. Drug Discovery Today, 2019, 24, 1332-1343.	3.2	44

#	Article	IF	CITATIONS
1554	Identifying Adverse Drug Events in Older Community-Dwelling Patients. Annals of Family Medicine, 2019, 17, 133-140.	0.9	15
1555	Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study. Frontiers in Pharmacology, 2019, 10, 265.	1.6	31
1558	Preliminary phytochemical and biological investigations of ethanolic extract of Grewia hirsute Vahl. Oriental Pharmacy and Experimental Medicine, 2019, 19, 145-156.	1.2	1
1559	INTREPAD. Neurology, 2019, 92, e2070-e2080.	1.5	76
1560	Use of prescription drugs in the older adult populationâ€"a nationwide pharmacoepidemiological study. European Journal of Clinical Pharmacology, 2019, 75, 1125-1133.	0.8	23
1561	Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. Therapeutic Advances in Drug Safety, 2019, 10, 204209861982943.	1.0	77
1562	Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015. PLoS ONE, 2019, 14, e0212046.	1.1	54
1563	Efficiency versus thoroughness in medication review: a qualitative interview study in UK primary care. British Journal of General Practice, 2019, 69, e190-e198.	0.7	33
1564	Mechanisms of idiosyncratic drug-induced liver injury. Advances in Pharmacology, 2019, 85, 133-163.	1.2	26
1565	Adverse Drug Event Detection Using a Weakly Supervised Convolutional Neural Network and Recurrent Neural Network Model. Information (Switzerland), 2019, 10, 276.	1.7	10
1566	Evaluation of a prescription support-tool for chronic management of oral antithrombotic combinations in adults using clinical vignettes: protocol of a randomised controlled trial. BMJ Open, 2019, 9, e025544.	0.8	2
1567	Importance of potentially inappropriate medications, number of chronic conditions and medications for the risk of hospitalisation in elderly in Sweden: a case–control study. BMJ Open, 2019, 9, e029477.	0.8	19
1568	Role of nurses in supporting proactive deprescribing. Nursing Standard (Royal College of Nursing) Tj ETQq0 0 0 rg	gBT /Overlo	ock 10 Tf 50
1569	Evaluation of a Novel Audit Tool for Medication Reconciliation at Hospital Discharge. Canadian Journal of Hospital Pharmacy, 2019, 72, .	0.1	0
1570	Pharmacist integration into general practice in New Zealand. Journal of Primary Health Care, 2019, 11, 159.	0.2	19
1572	Adverse Drug Reactions in Paediatric In-Patients in a South African Tertiary Hospital. Journal of Tropical Pediatrics, 2019, 65, 389-396.	0.7	6
1573	Approaches to managing older people using opiates and their risk of dependence. Nursing Older People, 2019, 31, 40-48.	0.1	1
1574	Patient-centric medication history recording system using blockchain. , 2019, , .		9

#	Article	IF	Citations
1575	Using the WHO database of spontaneous reports to build joint vector representations of drugs and adverse drug reactions, a promising avenue for pharmacovigilance. , 2019, , .		2
1576	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2019, 7, CD010891.	1.5	7
1577	Drugs Reviews Sentiment Analysis using Weakly Supervised Model. , 2019, , .		12
1578	Impact of a Prescription Support Tool to Improve Adherence to the Guidelines for the Prescription of Oral Antithrombotics: The Combi-AT Randomized Controlled Trial Using Clinical Vignettes. Journal of Clinical Medicine, 2019, 8, 1919.	1.0	3
1580	Adverse Drug Reactions, still masquerading after all these years?. Adverse Drug Reaction Bulletin, 2019, 314, 1215-1218.	0.6	0
1581	Allergic Reactions Captured by Voluntary Reporting. Journal of Patient Safety, 2019, Publish Ahead of Print, e1595-e1604.	0.7	8
1582	Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BMC Health Services Research, 2019, 19, 926.	0.9	45
1583	Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine, 2019, 17, 100188.	3.2	113
1584	Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability. Oncologist, 2019, 24, e968-e977.	1.9	27
1585	Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 78-83.	0.7	6
1586	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 2019, 180, 1069-1076.	1.4	74
1587	Medication safety knowledge, attitude, and practice among hospital pharmacists in Lebanon. Journal of Evaluation in Clinical Practice, 2019, 25, 323-339.	0.9	18
1588	Characterisation of a functional rat hepatocyte spheroid model. Toxicology in Vitro, 2019, 55, 160-172.	1.1	32
1589	Applying DoTS adverse drug reactions classification to reports from hospital stimulated reporting. European Journal of Clinical Pharmacology, 2019, 75, 433-435.	0.8	1
1590	Cutaneous adverse drug reactions to psychotropic drugs and their risk factors – a case-control study. European Neuropsychopharmacology, 2019, 29, 111-121.	0.3	15
1591	Effectiveness and safety of 110 or 150Âmg dabigatran vs . vitamin K antagonists in nonvalvular atrial fibrillation. British Journal of Clinical Pharmacology, 2019, 85, 432-441.	1.1	19
1592	Assessment tool for hospital admissions related to medications: development and validation in older patients. International Journal of Clinical Pharmacy, 2019, 41, 198-206.	1.0	19
1593	Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 197-208.	0.7	20

#	Article	IF	CITATIONS
1594	Preventing Future Deaths from Medicines: Responses to Coroners' Concerns in England and Wales. Drug Safety, 2019, 42, 445-451.	1.4	19
1595	Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 439-448.	1.2	22
1596	Trends in adverse drug reactionâ€related hospitalisations over 13 years in New South Wales, Australia. Internal Medicine Journal, 2019, 49, 84-93.	0.5	16
1597	Defining and classifying terminology for medication harm: a call for consensus. European Journal of Clinical Pharmacology, 2019, 75, 137-145.	0.8	35
1598	Patient prioritization for pharmaceutical care in hospital: A systematic review of assessment tools. Research in Social and Administrative Pharmacy, 2019, 15, 767-779.	1.5	28
1599	Medication-related risk factors and its association with repeated hospital admissions in frail elderly: A case control study. Research in Social and Administrative Pharmacy, 2020, 16, 1318-1322.	1.5	11
1600	Do user preferences align with human factors assessment scores of drug–drug interaction alerts?. Health Informatics Journal, 2020, 26, 563-575.	1.1	6
1601	Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort. Journal of Geriatric Oncology, 2020, 11, 586-592.	0.5	22
1602	Addressing the Challenge of Polypharmacy. Annual Review of Pharmacology and Toxicology, 2020, 60, 661-681.	4.2	35
1603	Medicines reconciliation at the community mental health team–general practice interface: quality improvement study. BJPsych Bulletin, 2020, 44, 12-18.	0.7	4
1604	Shared parameter model for competing risks and different data summaries in metaâ€analysis: Implications for common and rare outcomes. Research Synthesis Methods, 2020, 11, 91-104.	4.2	8
1605	Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. European Journal of Human Genetics, 2020, 28, 88-94.	1.4	71
1607	Cost implications of adverse drug event-related emergency department visits – a multicenter study in South Korea. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 139-146.	0.7	3
1608	Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation. Research in Social and Administrative Pharmacy, 2020, 16, 928-934.	1.5	3
1609	Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and metaâ€analysis. British Journal of Clinical Pharmacology, 2020, 86, 698-710.	1.1	30
1610	Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 247-253.	1.2	6
1611	Interventions to Reduce Adverse Drug Event-Related Outcomes in Older Adults: AÂSystematic Review and Meta-analysis. Drugs and Aging, 2020, 37, 91-98.	1.3	23
1612	An investigation into the avoidability of adverse drug reactions using the LAAT and modified Hallas tools. Medicine (United States), 2020, 99, e18569.	0.4	5

#	Article	IF	CITATIONS
1613	Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission. International Journal of Clinical Pharmacy, 2020, 42, 150-157.	1.0	4
1614	Do computerized clinical decision support systems improve the prescribing of oral anticoagulants? A systematic review. Thrombosis Research, 2020, 187, 79-87.	0.8	16
1615	Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metabolism Reviews, 2020, 52, 44-65.	1.5	17
1617	Undergraduate and postgraduate pharmacovigilance education: A proposal for appropriate curriculum content. British Journal of Clinical Pharmacology, 2020, 86, 779-790.	1.1	16
1618	Improving prescribing through big data approachesâ€"Ten years of the Scottish Prescribing Information System. British Journal of Clinical Pharmacology, 2020, 86, 250-257.	1.1	6
1619	Adverse Medication Events Related to Hospitalization in the United States: A Comparison Between Adults With Intellectual and Developmental Disabilities and Those Without. American Journal on Intellectual and Developmental Disabilities, 2020, 125, 37-48.	0.8	11
1620	Fascia Iliaca Block Decreases Hip Fracture Postoperative Opioid Consumption: A Prospective Randomized Controlled Trial. Journal of Orthopaedic Trauma, 2020, 34, 49-54.	0.7	27
1621	A prospective observational pilot study of adverse drug reactions contributing to hospitalization in a cohort of middle-aged adults aged 45–64 years. Drugs and Therapy Perspectives, 2020, 36, 123-130.	0.3	5
1622	Assessment of Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting Among Healthcare Professionals working in Primary, Secondary and Tertiary Healthcare Facilities in Ekiti State, South-West Nigeria. Hospital Pharmacy, 2021, 56, 751-759.	0.4	6
1623	Prevalence and incidence rate of hospital admissions related to medication between 2008 and 2013 in The Netherlands. Pharmacoepidemiology and Drug Safety, 2020, 29, 1659-1668.	0.9	6
1624	Precision Medicine Using Pharmacogenomic Panel-Testing. Advances in Molecular Pathology, 2020, 3, 131-142.	0.2	1
1625	Assessing quality of life using WHOQOL-BREF: A cross-sectional insight among patients on warfarin in Malaysia. Saudi Pharmaceutical Journal, 2020, 28, 936-942.	1.2	6
1626	Development of the Ketamine Side Effect Tool (KSET). Journal of Affective Disorders, 2020, 266, 615-620.	2.0	28
1627	A Feasibility Study of Drug–Drug Interaction Signal Detection in Regular Pharmacovigilance. Drug Safety, 2020, 43, 775-785.	1.4	13
1628	Rapid and convenient biotransformation procedure for human drug metabolizing enzymes using permeabilized fission yeast cells. Analytical Biochemistry, 2020, 607, 113704.	1.1	12
1629	The <scp>PINCER</scp> initiative: reducing medication errors in primary care. The Prescriber, 2020, 31, 11-14.	0.1	2
1630	Pharmacogenomics for Primary Care: An Overview. Genes, 2020, 11, 1337.	1.0	30
1631	Rosanortriterpenes A–B, Two Promising Agents from Rosa laevigata var. leiocapus, Alleviate Inflammatory Responses and Liver Fibrosis in In Vitro Cell Models. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-9.	0.5	0

#	ARTICLE	IF	CITATIONS
1632	Restricted access supramolecular solvent based magnetic solvent bar liquid-phase microextraction for determination of non-steroidal anti-inflammatory drugs in human serum coupled with high performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 2020, 1634, 461700.	1.8	19
1633	Risk factors for hospital readmission in older adults within 30 days of discharge – a comparative retrospective study. BMC Geriatrics, 2020, 20, 467.	1.1	50
1634	Incident adverse drug reactions and their effect on the length of hospital stay in older inpatients. International Journal of Clinical Pharmacy, 2020, 43, 839-846.	1.0	8
1635	Medication management in older adults. Clinics in Integrated Care, 2020, 1, 100002.	0.3	0
1636	Knowledge and Barriers Among Physicians Toward Adverse Drug Reaction Reporting at a Tertiary Care Hospital in Saudi Arabia. Hospital Pharmacy, 2020, 56, 001857872091038.	0.4	1
1637	Nonsteroidal anti-inflammatory drugs (NSAIDs) consideration by dermatologists during the COVID19 pandemic. Journal of Dermatological Treatment, 2020, , 1-2.	1.1	0
1638	Neurology and the clinical historian. Medicine, 2020, 48, 493-496.	0.2	0
1639	Non-dispensing pharmacist integrated in the primary care team: effect on the quality of physician's prescribing, a non-randomised comparative study. International Journal of Clinical Pharmacy, 2020, 42, 1293-1303.	1.0	2
1640	Multi-Morbidity and Polypharmacy in Older People: Challenges and Opportunities for Clinical Practice. Geriatrics (Switzerland), 2020, 5, 85.	0.6	51
1641	Polypharmacy: A general review of definitions, descriptions and determinants. Therapie, 2020, 75, 407-416.	0.6	38
1642	Pharmacist and Data-Driven Quality Improvement in Primary Care (P-DQIP): a qualitative study of anticipated implementation factors informed by the Theoretical Domains Framework. BMJ Open, 2020, 10, e033574.	0.8	3
1643	Pharmacovigilance and radiologists: How well do they get along?. British Journal of Radiology, 2020, 93, 20200596.	1.0	2
1644	Discovering Drug-Drug and Drug-Disease Interactions Inducing Acute Kidney Injury Using Deep Rule Forests. , 2020, , .		2
1645	Primary care management of patients with pain complaints and the influence of physician training in mechanical diagnosis and therapy. Zeitschrift Fur Gesundheitswissenschaften, 2020, , 1.	0.8	0
1646	Pharmacogenetic information in Swiss drug labels – a systematic analysis. Pharmacogenomics Journal, 2021, 21, 423-434.	0.9	15
1647	Looking for the "Little Things― A Multi-Disciplinary Approach to Medicines Monitoring for Older People Using the ADRe Resource. Geriatrics (Switzerland), 2020, 5, 79.	0.6	3
1648	Study of Natural products Adverse Reactions (SONAR) in children seen in mental health clinics: a cross-sectional study. BMJ Paediatrics Open, 2020, 4, e000674.	0.6	5
1649	What do patients ask when using a medicines helpline service?. The Prescriber, 2020, 31, 23-26.	0.1	0

#	ARTICLE	IF	Citations
1650	Predicting the frequencies of drug side effects. Nature Communications, 2020, 11, 4575.	5.8	54
1651	Investigating the characteristics and needs of frequently admitting hospital patients: a cross-sectional study in the UK. BMJ Open, 2020, 10, e035522.	0.8	2
1652	From Rat Poison to Medicine: Medical Applications of Coumarin Derivatives. , 0, , .		2
1653	Potential statin drug interactions in elderly patients: a review. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 1133-1145.	1.5	17
1654	A Gentle Introduction to Reinforcement Learning and its Application in Different Fields. IEEE Access, 2020, 8, 209320-209344.	2.6	73
1655	Identifying side effects of commonly used drugs in the treatment of Covid 19. Scientific Reports, 2020, 10, 21508.	1.6	25
1656	What influences prescribing decisions in a multimorbidity and polypharmacy context on the acute medical unit? An interprofessional, qualitative study. Journal of Evaluation in Clinical Practice, 2021, 27, 1076-1084.	0.9	1
1657	A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes, 2020, 11, 1295.	1.0	120
1658	The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study. British Journal of Clinical Pharmacology, 2020, 86, 2144-2154.	1.1	14
1659	A multifactorial intervention to lower potentially inappropriate medication use in older adults in Argentina. Aging Clinical and Experimental Research, 2021, 33, 3313-3320.	1.4	10
1660	Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie, 2020, 75, 355-362.	0.6	74
1661	Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatology, 2020, 59, 1253-1261.	0.9	15
1662	Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial. Age and Ageing, 2020, 49, 605-614.	0.7	68
1663	A multimodal deep learning framework for predicting drug–drug interaction events. Bioinformatics, 2020, 36, 4316-4322.	1.8	202
1664	latrogenesis and neurological manifestations in the elderly. Revue Neurologique, 2020, 176, 710-723.	0.6	4
1665	Retrospective assessment of acute poisoning incidents by pharmaceutical agents in Jordan: Data from Pharmacy Oneâ,,¢ Poison Call Center, 2014 to 2018â€"Part II. Pharmacology Research and Perspectives, 2020, 8, e00583.	1.1	5
1666	The development of a scoring and ranking strategy for a patient-tailored adverse drug reaction prediction in polypharmacy. Scientific Reports, 2020, 10, 9552.	1.6	5
1667	Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?—Results from the ADRED Study. Journal of Clinical Medicine, 2020, 9, 1801.	1.0	8

#	ARTICLE	IF	CITATIONS
1668	Polypharmacy: the whys, the so whats and the what nexts. British Journal of Hospital Medicine (London, England: 2005), 2020, 81, 1-7.	0.2	3
1669	Using pharmacogenetics to structure individual pain management protocols in total knee arthroplasty. Bone and Joint Journal, 2020, 102-B, 73-78.	1.9	5
1670	Why women are not small men: sex-related differences in perioperative cardiopulmonary exercise testing. Perioperative Medicine (London, England), 2020, 9, 18.	0.6	6
1671	Pharmacovigilance of anti-cancer medicines: opportunities and challenges. Expert Opinion on Drug Safety, 2020, 19, 849-860.	1.0	7
1672	Determinants of health-related quality of life among warfarin patients in Pakistan. PLoS ONE, 2020, 15, e0234734.	1.1	5
1673	Intervention protocol: OPtimising the Rapy to prevent avoidable hospital Admission in the Multi-morbid elderly (OPERAM): a structured medication review with support of a computerised decision support system. BMC Health Services Research, 2020, 20, 220.	0.9	23
1674	Clinical and economic impact of medication reconciliation in cancer patients: a systematic review. Supportive Care in Cancer, 2020, 28, 3557-3569.	1.0	19
1675	Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 1702-1708.	0.6	9
1676	A patent review of anticancer glucocorticoid receptor modulators (2014-present). Expert Opinion on Therapeutic Patents, 2020, 30, 313-324.	2.4	3
1677	Family conferences and shared prioritisation to improve patient safety in the frail elderly (COFRAIL): study protocol of a cluster randomised intervention trial in primary care. Trials, 2020, 21, 285.	0.7	8
1678	Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. International Journal of Colorectal Disease, 2020, 35, 1489-1500.	1.0	3
1679	Oral non-steroidal anti-inflammatory drug use in recreational runners participating in Parkrun UK: Prevalence of use and awareness of risk. International Journal of Pharmacy Practice, 2020, 28, 561-568.	0.3	10
1680	Are patients on oral anticoagulation therapy aware of its effects? A cross-sectional study from Karachi, Pakistan. BMC Research Notes, 2020, 13, 279.	0.6	6
1681	EUPRON: nurses' practice in interprofessional pharmaceutical care in Europe. A cross-sectional survey in 17 countries. BMJ Open, 2020, 10, e036269.	0.8	25
1682	Medication-related hospital admissions and readmissions in older patients: an overview of literature. International Journal of Clinical Pharmacy, 2020, 42, 1243-1251.	1.0	38
1683	Adverse Drug Reactions in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1090-1102.	2.2	47
1684	Optimising Medications for Patients With Cancer and Multimorbidity: The Case for Deprescribing. Clinical Oncology, 2020, 32, 609-617.	0.6	20
1685	Identifying the most effective essential medicines policies for quality use of medicines: A replicability study using three World Health Organisation data-sets. PLoS ONE, 2020, 15, e0228201.	1.1	7

#	Article	IF	CITATIONS
1686	High-risk medication in community care: a scoping review. European Journal of Clinical Pharmacology, 2020, 76, 623-638.	0.8	3
1687	Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study. BMC Geriatrics, 2020, 20, 22.	1.1	19
1688	Pharmacotherapy for knee osteoarthritis: current and emerging therapies. Expert Opinion on Pharmacotherapy, 2020, 21, 797-809.	0.9	51
1689	<p>Calycosin Influences the Metabolism of Five Probe Drugs in Rats</p> . Drug Design, Development and Therapy, 2020, Volume 14, 429-434.	2.0	4
1691	Prevalence of Psychotropic Drugs in Cases of Severe Adverse Drug Reactions Leading to Unplanned Emergency Visits in General Hospitals. Pharmacopsychiatry, 2020, 53, 133-137.	1.7	6
1692	The New Genomics Era: Integration of genomics into mainstream oncology and implications for psychoâ€oncological care. Psycho-Oncology, 2020, 29, 453-460.	1.0	3
1693	Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. Pharmacogenomics Journal, 2020, 20, 621-628.	0.9	10
1694	Personalising drug safety—results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED). European Journal of Clinical Pharmacology, 2020, 76, 439-448.	0.8	15
1695	Deprescribing in older people. British Journal of Hospital Medicine (London, England: 2005), 2020, 81, 1-9.	0.2	2
1696	Prevalence and treatment of neurological and psychiatric disorders among tertiary hospitals in Pakistan; findings and implications. Hospital Practice (1995), 2020, 48, 145-160.	0.5	7
1697	Medical Toxicology and COVID-19: Our Role in a Pandemic. Journal of Medical Toxicology, 2020, 16, 245-247.	0.8	14
1698	Clustering-Based Hybrid Approach for Identifying Quantitative Multidimensional Associations Between Patient Attributes, Drugs and Adverse Drug Reactions. Interdisciplinary Sciences, Computational Life Sciences, 2020, 12, 237-251.	2.2	4
1699	National Cross-Sectional Study of Community-Based Adverse Drug Reactions in Saudi Arabia. Drugs - Real World Outcomes, 2020, 7, 161-170.	0.7	7
1700	HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review. Diagnostics, 2020, 10, 244.	1.3	27
1701	Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. Yonsei Medical Journal, 2020, 61, 4.	0.9	11
1702	Exploiting adversarial transfer learning for adverse drug reaction detection from texts. Journal of Biomedical Informatics, 2020, 106, 103431.	2.5	18
1703	Impact of medication review via tele-expertise on unplanned hospitalizations at 3  months of nursing homes patients (TEM-EHPAD): study protocol for a randomized controlled trial. BMC Geriatrics, 2020, 20, 147.	1.1	5
1704	The effect of an intervention program on the knowledge and attitudes among medical staff regarding adverse drug reaction reporting. Pharmacoepidemiology and Drug Safety, 2020, 29, 1246-1253.	0.9	4

#	Article	IF	CITATIONS
1705	Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district. European Journal of Clinical Pharmacology, 2020, 76, 991-1001.	0.8	27
1706	Goal-setting with patients with multi-morbidity. InnovAiT, 2020, 13, 179-185.	0.0	3
1707	Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Quality and Safety, 2021, 30, 96-105.	1.8	161
1708	Cohort study on adverse drug reactions in adults admitted to the medical wards of a tertiary hospital in Nigeria: Prevalence, incidence, risk factors and fatality. British Journal of Clinical Pharmacology, 2021, 87, 1878-1889.	1.1	8
1709	A Survey on Knowledge Gaps in Assessment and Management of Severe Drug Hypersensitivity Reactions: Multicenter Crossâ€Sectional Study of Australian Health Care Providers. Journal of Clinical Pharmacology, 2021, 61, 25-31.	1.0	3
1710	Impact of pharmacists' training on oral anticoagulant counseling: A randomized controlled trial. Patient Education and Counseling, 2021, 104, 1253-1259.	1.0	5
1711	Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Metaâ€Analysis. Clinical and Translational Science, 2021, 14, 645-655.	1.5	7
1712	Adverse Drug Reactions Spontaneously Reported at a Tertiary Care Hospital and Preventable Measures Implemented. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 460-469.	0.7	10
1713	Pharmacogenomics: Prescribing based on genetic variation. InnovAiT, 2021, 14, 116-123.	0.0	1
1715	Polypharmacy and emergency readmission to hospital after critical illness: a population-level cohort study. British Journal of Anaesthesia, 2021, 126, 415-422.	1.5	23
1716	Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review. Pharmacogenomics Journal, 2021, 21, 20-36.	0.9	10
1717	The Clinical Utility and Ecological Validity of the Medication Management Ability Assessment in Older Adults with and without Dementia. Archives of Clinical Neuropsychology, 2021, 36, 37-50.	0.3	2
1718	Health-care Professionals' Knowledge and Perception of Adverse Drug Reaction Reporting and Pharmacovigilance in a Tertiary Care Teaching Hospital of Nepal. Hospital Pharmacy, 2021, 56, 178-186.	0.4	12
1719	Hospital Admissions Associated With Medication-Related Problems in Thai Older Patients: A Multicenter Prospective Observational Study. Journal of Patient Safety, 2021, 17, 15-22.	0.7	3
1720	Drug Reactions, Resistance, and Polypharmacy. , 2021, , 1-7.		0
1721	Ivan Illich, latrogenesis and Pharmacogenetics. , 0, , .		0
1722	Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital. Cancer Treatment and Research Communications, 2021, 26, 100277.	0.7	10
1723	Medication $\hat{a} \in A$ boon or bane: Emergencies due to medication-related visits. Indian Journal of Pharmacology, 2021, 53, 103.	0.4	0

#	Article	IF	Citations
1724	Incorporating pharmacokinetic data into personalised prescribing for older people: challenges and opportunities. European Geriatric Medicine, 2021, 12, 435-442.	1.2	6
1726	Characterising polypharmacy in the very old: Findings from the Newcastle 85+ Study. PLoS ONE, 2021, 16, e0245648.	1.1	15
1727	Drug Reaction with Eosinophilia and Systemic Symptoms: A Complex Interplay between Drug, T Cells, and Herpesviridae. International Journal of Molecular Sciences, 2021, 22, 1127.	1.8	7
1728	Medication safety in primary care—from measurement to action. Drug and Therapeutics Bulletin, 2021, 59, 24-28.	0.3	8
1729	Patient harm from cardiovascular medications. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110274.	1.0	5
1730	Prevalence of Adverse Drug Reactions to Second Line Anti Tuberculosis Drugs in Nigeria: A Cross-Sectional Study. Journal of Tuberculosis Research, 2021, 09, 90-102.	0.1	3
1731	Personalized Medicine Through GPCR Pharmacogenomics. , 2021, , .		2
1732	How effective are social norms interventions in changing the clinical behaviours of healthcare workers? A systematic review and meta-analysis. Implementation Science, 2021, 16, 8.	2.5	22
1733	The Impact of Medication Reviews Conducted in Primary Care on Hospital Admissions and Mortality: An Observational Follow-Up of a Randomized Controlled Trial. Drug, Healthcare and Patient Safety, 2021, Volume 13, 1-9.	1.0	2
1734	Detecting medication errors associated with the use of beta-lactams in the Russian Pharmacovigilance database. BMC Pharmacology & Detecting medication errors associated with the use of beta-lactams in the Russian Pharmacovigilance database. BMC Pharmacology & Detecting medication errors associated with the use of beta-lactams in the Russian Pharmacovigilance database. BMC Pharmacovigilance database database. BMC Pharmacovigilance database datab	1.0	1
1735	Polypharmacy and Integrated Care. , 2021, , 453-477.		0
1736	Modeling the Bioactivation and Subsequent Reactivity of Drugs. Chemical Research in Toxicology, 2021, 34, 584-600.	1.7	11
1737	Diclofenac in adolescents: diagnosing and treating gastrointestinal adverse drug reactions can prevent future deaths. BMJ Evidence-Based Medicine, 2021, 26, 196-199.	1.7	14
1738	Nicorandil―nduced colovesical fistula in a patient with diverticular disease. Clinical Case Reports (discontinued), 2021, 9, 1737-1741.	0.2	4
1739	Medication-Related Problems in Older People with Multimorbidity in Catalonia: A Real-World Data Study with 5 Years' Follow-Up. Journal of Clinical Medicine, 2021, 10, 709.	1.0	11
1740	Batı Karadeniz Bölgesinde Bir Üniversite Hastanesine Başvuran Hasta ve Hasta Yakınlarının Akılcı Kullanımına Yönelik Bilgi ve Davranışlarının DeÄŸerlendirilmesi. Dù¼zce Üniversitesi SaÄŸlık Bilir Enstitù¼sù¼ Dergisi, 0, , .	İlaç n <b>læ.s</b>	1
1741	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia, 2021, 64, 1309-1319.	2.9	5
1742	A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach. British Journal of Clinical Pharmacology, 2022, 88, 1471-1481.	1.1	2

#	Article	IF	CITATIONS
1743	Deprescribing in mental health: pragmatic steps for a better quality of life. Journal of Prescribing Practice, 2021, 3, 60-66.	0.1	1
1744	Professional Competence Among Registered Nurses Working in Hospitals in Saudi Arabia and Their Experiences of Quality of Nursing Care and Patient Safety. Journal of Transcultural Nursing, 2021, 32, 425-433.	0.6	8
1745	Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations. Pain Research and Management, 2021, 2021, 1-9.	0.7	13
1746	Hybrid Deep Learning for Medication-Related Information Extraction From Clinical Texts in French: MedExt Algorithm Development Study. JMIR Medical Informatics, 2021, 9, e17934.	1.3	17
1747	Cannabidiol Does Not Impair Anabolic Signaling Following Eccentric Contractions in Rats. International Journal of Sport Nutrition and Exercise Metabolism, 2021, 31, 93-100.	1.0	7
1748	Epidemiology and associated factors of polypharmacy in older patients in primary care: a northern Italian cross-sectional study. BMC Geriatrics, 2021, 21, 197.	1.1	11
1749	Medical students as adverse drug event managers, learning about side effects while improving their reporting in clinical practice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1467-1476.	1.4	7
1750	Predicting negative health outcomes in older general practice patients with chronic illness: Rationale and development of the PROPERmed harmonized individual participant data database. Mechanisms of Ageing and Development, 2021, 194, 111436.	2.2	3
1751	Health professionals' perspectives regarding polypharmacy in older patients with cancer: A mixed-design exploratory study. Journal of Geriatric Oncology, 2021, 12, 881-887.	0.5	3
1752	Interâ€rater reliability of assessments regarding the quality of drug treatment, and drugâ€related hospital admissions. British Journal of Clinical Pharmacology, 2021, 87, 3825-3834.	1.1	5
1753	Does DDI-Predictor Help Pharmacists to Detect Drug-Drug Interactions and Resolve Medication Issues More Effectively?. Metabolites, 2021, 11, 173.	1.3	8
1754	PharmaKU: A Web-Based Tool Aimed at Improving Outreach and Clinical Utility of Pharmacogenomics. Journal of Personalized Medicine, 2021, 11, 210.	1.1	6
1755	Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports, 2021, 11, 6403.	1.6	27
1756	Pain management in hemophilia: expert recommendations. Wiener Klinische Wochenschrift, 2021, 133, 1042-1056.	1.0	15
1757	Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database. Frontiers in Pharmacology, 2020, 11, 624562.	1.6	9
1758	Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database. British Journal of Clinical Pharmacology, 2021, 87, 4334-4340.	1.1	38
1760	End-to-end drug entity recognition and adverse effect relation extraction via principal neighbourhood aggregation network. Journal of Physics: Conference Series, 2021, 1848, 012110.	0.3	1
1761	Blood Pressure Changes Following Antihypertensive Medication Reduction, by Drug Class and Dose Chosen for Withdrawal: Exploratory Analysis of Data From the OPTiMISE Trial. Frontiers in Pharmacology, 2021, 12, 619088.	1.6	8

#	Article	IF	CITATIONS
1762	Surface modified multifaceted nanocarriers for oral non-conventional cancer therapy; synthesis and evaluation. Materials Science and Engineering C, 2021, 123, 111940.	3.8	12
1763	Custos hospitalares associados aos eventos adversos medicamentosos: Revisão sistemática. Research, Society and Development, 2021, 10, e21510414030.	0.0	0
1765	Investigating the Utility of Humanized PXR-CAR-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction. Drug Metabolism and Disposition, 2021, 49, DMD-AR-2021-000439.	1.7	2
1766	Potentially inappropriate medications and medication combinations before, during and after hospitalizations: an analysis of pathways and determinants in the Swiss healthcare setting. BMC Health Services Research, 2021, 21, 522.	0.9	1
1767	Inappropriate Use of Oral Antithrombotic Combinations in an Outpatient Setting and Associated Risks: A French Nationwide Cohort Study. Journal of Clinical Medicine, 2021, 10, 2367.	1.0	1
1768	Pharmacogenetic testing to guide therapeutic decisionâ€making and improve outcomes for children undergoing anthracyclineâ€based chemotherapy. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 95-99.	1.2	8
1769	Drug–drug interactions with warfarin: A systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 4051-4100.	1.1	37
1770	Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions. Journal of Personalized Medicine, 2021, 11, 383.	1.1	8
1771	CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous Systemâ€"Results From the ADRED Study. Frontiers in Pharmacology, 2021, 12, 624104.	1.6	6
1772	Ambulatory drug changes in the elderly after hospital discharge: A cohort study. Therapie, 2021, 76, 587-595.	0.6	2
1773	Detection of Drug–Drug and Drug–Disease Interactions Inducing Acute Kidney Injury Using Deep Rule Forests. SN Computer Science, 2021, 2, 1.	2.3	2
1774	An Overview on Patient-Centered Clinical Services. Borneo Journal of Pharmacy, 2021, 4, 157-170.	0.1	0
1775	Determinants of Satisfaction with Services, and Trust in the Information Received in Community Pharmacies: A Comparative Analysis to Foster Pharmaceutical Care Adoption. Healthcare (Switzerland), 2021, 9, 562.	1.0	5
1776	Evaluation of anticoagulant therapy management in a teaching hospital in Tunisia: information and education for vitamin k antagonist newly treated patients need to be improved. International Journal of Pharmacy Practice, 2021, 29, 389-393.	0.3	0
1777	Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions. Clinical Pharmacology and Therapeutics, 2021, 110, 392-400.	2.3	25
1778	The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions. Pharmacological Reviews, 2021, 73, 861-896.	7.1	18
1779	Prevalence of adverse drug reactions in the primary care setting: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0252161.	1.1	43
1780	HLAâ€associated adverse drug reactions ―scoping review. Clinical and Translational Science, 2021, 14, 1648-1658.	1.5	10

#	Article	IF	CITATIONS
1781	The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review. Frontiers in Genetics, 2021, 12, 675053.	1.1	6
1782	Pharmacovigilance in Older Adults., 0, , .		2
1783	Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity. Frontiers in Pharmacology, 2021, 12, 684162.	1.6	30
1784	Medicines Related Problems (MRPs) Originating in Primary Care Settings in Older Adults - A Systematic Review. Journal of Pharmacy Practice, 2023, 36, 357-369.	0.5	6
1785	Pharmacology, polypharmacy and the older adult: a review. British Journal of Community Nursing, 2021, 26, 290-295.	0.2	3
1786	High-throughput framework forÂgenetic analyses of adverse drug reactions using electronic health records. PLoS Genetics, 2021, 17, e1009593.	1.5	5
1787	EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING SECONDARY TO PEPTIC DISEASE IN A TERTIARY REFERRAL BRAZILIAN HOSPITAL. Arquivos De Gastroenterologia, 2021, 58, 202-209.	0.3	5
1788	Physicians' Knowledge and Attitudes Regarding Point-of-Care Pharmacogenetic Testing: A Hospital-Based Cross-Sectional Study. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 655-665.	0.4	4
1789	Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey. Expert Opinion on Drug Safety, 2021, 20, 979-985.	1.0	5
1790	Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds. Frontiers in Pharmacology, 2021, 12, 713178.	1.6	2
1791	The Impact of Pharmaceutical Care in Multidisciplinary Teams on Health Outcomes: Systematic Review and Meta-Analysis. Journal of the American Medical Directors Association, 2021, 22, 2518-2526.	1.2	15
1792	Knowledge, attitudes and practices of pharmacists about pharmacovigilance, Libya. Eastern Mediterranean Health Journal, 2021, 27, 693-697.	0.3	2
1793	Study of Natural Products Adverse Reactions (SONAR) in Adults with Mental Health Conditions: A Cross-Sectional Study. Drug Safety, 2021, 44, 999-1006.	1.4	2
1794	Variability of Pharmacogenomics Information in Drug Labels Approved by Different Agencies and Its Ethical Implications. Current Drug Safety, 2021, 16, .	0.3	0
1795	Potentially inappropriate medication (PIM) use and severe drug interactions (SDIs) in older adults with cancer. Journal of Geriatric Oncology, 2021, 12, 872-880.	0.5	8
1796	Mesenchymal Stem Cells: Current Concepts in the Management of Inflammation in Osteoarthritis. Biomedicines, 2021, 9, 785.	1.4	18
1797	Current Perspectives on Severe Drug Eruption. Clinical Reviews in Allergy and Immunology, 2021, 61, 282-298.	2.9	23
1799	Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial. BMJ, The, 2021, 374, n1585.	3.0	84

ARTICLE **CITATIONS** Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs. Diseases (Basel,) Tj ETQq0 0 0 rgBT (Overlock 10 Tf 50 1800 Let's talk about sex: Differences in drug therapy in males and females. Advanced Drug Delivery Reviews, 6.6 74 2021, 175, 113804. Efficacy and Safety of Topical Dosage Forms of Non-Steroidal Anti-Inflammatory Drugs and their 1802 2 0.3Pharmacokinetic Determinants (Review). Pharmaceutical Chemistry Journal, 2021, 55, 490-493. Facile and Straightforward Synthesis of Racemic Version of Substituted 3-[3-(2-Hydroxyphenyl)-3-oxo-1-arylpropyl]-4-hydroxycoumarins: Easy Access to a Series of Biorelevant Warfarin Analogues. Synthesis, 2022, 54, 451-464. 1803 1.2 Potential Drug-Drug Interactions in Hospitalized Medical Patients: Data From Low Resource Settings. 1804 0.2 3 Cureus, 2021, 13, e17336. Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review. Therapeutics and Clinical Risk Management, 2021, Volume 17, 927-949. Prevalence, Incidence, and Characteristics of Adverse Drug Reactions Among Older Adults 1807 Hospitalized at Mbarara Regional Referral Hospital, Uganda: A Prospective Cohort Study. Clinical 1.3 7 Interventions in Aging, 2021, Volume 16, 1705-1721. What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental 1808 1.1 28 Health Care Settings?. Frontiers in Genetics, 2021, 12, 740216. Drug-Related Deaths in a Tertiary Hospital: Characteristics of Spontaneously Reported Cases and 1809 1.0 3 Comparison to Cases Detected from a Retrospective Study. Journal of Clinical Medicine, 2021, 10, 4053. Systems analysis of miRNA biomarkers to inform drug safety. Archives of Toxicology, 2021, 95, 1.9 14 3475-3495. Chronic polypharmacy at all age: A populationâ€based drug utilization study. Fundamental and Clinical 1811 4 1.0 Pharmacology, 2022, 36, 405-413. Identifying adverse drug reaction entities from social media with adversarial transfer learning model. 3.5 Neurocomputing, 2021, 453, 254-262. Knowledge, Attitude, and Practice of Medical, Pharmacy, and Nursing Students Towards Pharmacovigilance and Adverse Drug Reaction Reporting at University of Gondar College of Medicine 1813 4 and Health Sciences, Northwest Ethiopia: A Cross-Sectional Study. Advances in Medical Education and Practice, 2021, Volume 12, 1129-1139 Evaluation of potential herb-drug interactions based on the effect of Suxiao Jiuxin Pill on CYP450 1814 enzymes and transporters. Journal of Ethnopharmacology, 2021, 280, 114408. Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma 1815 patients treated with platinum and pemetrexed doublet chemotherapy. Therapeutic Advances in Drug 1.0 1 Safety, 2021, 12, 204209862199128. Preventable adverse drug events causing hospitalisation: identifying root causes and developing a surveillance and learning system at an urban community hospital, a cross-sectional observational study. BMJ Open Quality, 2021, 10, e001161. The Contribution of Clinical Pharmacologists in Precision Medicine: An Opportunity for Health Care 1817 0.5 3 Improvement. Current Therapeutic Research, 2021, 94, 100628. Performance of a trigger tool for detecting drug-related hospital admissions in older people: analysis from the OPERAM trial. Age and Ageing, 2022, 51, .

#	Article	IF	CITATIONS
1819	General practitioner practice-based pharmacist input to medicines optimisation in the UK: pragmatic, multicenter, randomised, controlled trial. Journal of Pharmaceutical Policy and Practice, 2021, 14, 4.	1.1	10
1820	Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana. Pan African Medical Journal, 2021, 38, 191.	0.3	2
1821	Translational pharmacogenetics: pharmacogenetically driven clinical decision making., 2021,, 71-83.		0
1825	Arzneimitteltherapieinformationsdienste f $\tilde{A}^{1}/4$ r $\tilde{A}_{,,r}$ rzte. , 0, , 25-34.		1
1826	Pharmacogenomics and Pharmacoepigenomics in Pediatric Medicine. Methods in Molecular Biology, 2014, 1175, 671-685.	0.4	5
1827	T Cell Responses to Drugs and Drug Metabolites. Exs, 2014, 104, 137-163.	1.4	5
1828	Personalized Medicine., 2016,, 4235-4249.		1
1829	Arthritic Conditions Affecting the Temporomandibular Joint. , 2017, , 1-36.		4
1830	Digitalisierte Arzneimittelversorgung am Beispiel des bundeseinheitlichen patientenbezogenen Medikationsplans – eine Frage der Stakeholderakzeptanz. , 2017, , 149-164.		2
1831	Medicines Safety in the Globalized Context. , 2020, , 1-28.		1
1832	HETEROGENEITY OF DRUG RESPONSES AND INDIVIDUALIZATION OF THERAPY. , 2009, , 225-238.		1
1833	ADVERSE DRUG REACTIONS AND INTERACTIONS. , 2009, , 265-273.		3
1834	Geriatric Pharmacotherapy and Polypharmacy. , 2010, , 880-885.		12
1835	Drug-related problems in geriatric rehabilitation patients after discharge $\hat{a} \in ``A prevalence analysis and clinical case scenario-based pilot study. Research in Social and Administrative Pharmacy, 2018, 14, 628-637.$	1.5	7
1837	Prevalence of hospital admission due to adverse drug reaction in Salvador, Bahia. Revista Da Associação Médica Brasileira, 2011, 57, 42-45.	0.3	2
1839	Independent and Supplementary Prescribing. , 2010, , .		13
1840	Applied pharmacology. , 0, , 65-85.		1
1843	Making individualized drugs a reality. Nature Biotechnology, 2017, 35, 507-513.	9.4	35

#	ARTICLE	IF	CITATIONS
1844	Investigating the importance of individual mitochondrial genotype in susceptibility to drug-induced toxicity. Biochemical Society Transactions, 2020, 48, 787-797.	1.6	13
1845	Provision of home medicines reviews in Australia: linking population need with service provision and available pharmacist workforce. Australian Health Review, 2020, 44, 973.	0.5	7
1846	Medication Management Performance and Associated Cognitive Correlates in Healthy Older Adults and Older Adults with aMCI. Archives of Clinical Neuropsychology, 2019, 34, 290-300.	0.3	16
1847	An Over-the-counter Omission. Southern Medical Journal, 2006, 99, 1005-1006.	0.3	5
1848	Improper Renal Dosing in Long-Term Care Facilities. Southern Medical Journal, 2008, 101, 802-805.	0.3	13
1851	Avoiding harm from overprescribing: What are the challenges and how do we overcome them?. British Journal of Clinical Pharmacology, 2021, 87, 6-8.	1.1	4
1852	No medicine is sometimes the best medicine. BMJ Case Reports, 2015, 2015, bcr2014207152-bcr2014207152.	0.2	4
1853	Adverse drug reactions as cause of admission to hospital: Not all drugs that cause adverse reactions are actually prescribed by doctors. BMJ: British Medical Journal, 2004, 329, 459.2.	2.4	1
1854	Adverse drug reactions as cause of admission to hospital: Definition of adverse drug reactions needs to include overdose. BMJ: British Medical Journal, 2004, 329, 459.3-460.	2.4	3
1855	Assessing drug safety. BMJ: British Medical Journal, 2005, 330, 539.3-540.	2.4	9
1856	Readmissions as a result of adverse drug reactions in older people. BMJ: British Medical Journal, 2009, 338, a2436-a2436.	2.4	4
1857	Time to rethink aspirin in diabetes?. BMJ: British Medical Journal, 2009, 339, b5588-b5588.	2.4	1
1858	Bad apples or spoiled barrels? Multilevel modelling analysis of variation in high-risk prescribing in Scotland between general practitioners and between the practices they work in. BMJ Open, 2015, 5, e008270.	0.8	19
1859	Rationale and design of OPtimising the Rapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial. BMJ Open, 2019, 9, e026769.	0.8	36
1860	National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program. Pan African Medical Journal, 2017, 26, 48.	0.3	4
1862	A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle. Blood, 2020, 136, 898-908.	0.6	8
1863	Adverse reactions of Amiodarone. Journal of Geriatric Cardiology, 2019, 16, 552-566.	0.2	32
1864	Safety Pharmacology. , 2006, , 33-78.		4

#	Article	IF	CITATIONS
1865	A study of the use of medicine lists in medicines reconciliation: please remember this, a list is just a list. International Journal of Pharmacy Practice, 2010, 18, 116-121.	0.3	22
1866	Teucrium polium and kidney. Journal of Renal Injury Prevention, 2013, 2, 3-4.	0.6	26
1869	Why Drug Safety Should Not Take a Back Seat to Efficacy. PLoS Medicine, 2011, 8, e1001097.	3.9	8
1870	Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes. PLoS ONE, 2009, 4, e4439.	1.1	527
1871	Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions–ÂA Meta-Analysis. PLoS ONE, 2012, 7, e33236.	1.1	224
1872	Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study. PLoS ONE, 2012, 7, e42418.	1.1	19
1873	Medication Monitoring in a Nurse-Led Respiratory Outpatient Clinic: Pragmatic Randomised Trial of the West Wales Adverse Drug Reaction Profile. PLoS ONE, 2014, 9, e96682.	1.1	9
1874	Adherence to Guidelines for Avoiding Drug Interactions Associated with Warfarin - A Nationwide Swedish Register Study. PLoS ONE, 2014, 9, e97388.	1.1	9
1875	Inconsistencies among European Union Pharmaceutical Regulator Safety Communications: A Cross-Country Comparison. PLoS ONE, 2014, 9, e109100.	1.1	18
1876	A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction. PLoS ONE, 2014, 9, e114896.	1.1	12
1877	Nurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised Trial. PLoS ONE, 2015, 10, e0140203.	1.1	51
1878	Adverse drug events—Analysis of a decade. A Portuguese case-study, from 2004 to 2013 using hospital database. PLoS ONE, 2017, 12, e0178626.	1.1	29
1879	Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials. PLoS ONE, 2017, 12, e0183821.	1.1	10
1880	The side effect profile of Clozapine in real world data of three large mental health hospitals. PLoS ONE, 2020, 15, e0243437.	1.1	28
1881	Recording of adverse events in English general practice: analysis of data from electronic patient records. Journal of Innovation in Health Informatics, 2010, 18, 117-124.	0.9	16
1882	Non-steroidal Anti-inflammatory Drug Induced Injury to the Small Intestine. Acta Medica (Hradec) Tj ETQq $1\ 1\ 0.7$	84314 rgE 0.2	BT /Overlock
1883	VKORC1-1639 G> A Polymorphism and the Risk of Non-Variceal Upper Gastrointestinal Bleeding. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 13-18.	0.5	7
1888	Assessment of the consistency among three drug compendia in listing and ranking of drug-drug interactions. Bosnian Journal of Basic Medical Sciences, 2017, 13, 253.	0.6	6

#	Article	IF	CITATIONS
1889	Immune mechanisms of idiosyncratic drug-induced liver injury. Journal of Clinical and Translational Research, 2017, , .	0.3	11
1890	Physicians' Perceptions of Electronic Prescribing with Electronic Medical Records in Kuwaiti Primary Healthcare Centres. Sultan Qaboos University Medical Journal, 2019, 18, 476.	0.3	8
1891	Relationship of Drug-Drug Interactions with Hospital Diagnoses Associated to Adverse Drug Reactions: a Retrospective Study of Billing Data in Austria. International Journal of Clinical Pharmacology & Toxicology, 0, , 1-6.	1.0	2
1892	The use of pharmacogenetics to increase the safety of colorectal cancer patients treatedwith fluoropyrimidines., 2019, 2, 116-130.		3
1893	Refining Adverse Drug Reaction Signals by Incorporating Interaction Variables Identified Using Emergent Pattern Mining. SSRN Electronic Journal, 0, , .	0.4	2
1894	Polypharmacy in elderly patients at discharge from the acute care hospital. Therapeutics and Clinical Risk Management, 2007, 3, 197-203.	0.9	67
1895	Safety and tolerability of nsaids: focus on aceclofenac. Meditsinskiy Sovet, 2019, , 110-120.	0.1	1
1896	Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments. Drug Safety, 2012, 35, 769-781.	1.4	19
1897	Safety Monitoring of Herb-Drug Interactions. Drug Safety, 2012, 35, 785-791.	1.4	8
1898	Adverse Drug Reactions in a Population of Hospitalized Very Elderly Patients. Drugs and Aging, 2012, 29, 669-679.	1.3	40
1899	Epidemiology and Risk Factors for Severe Delayed Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3799-3812.	0.9	11
1900	Perception of the Usefulness of Drug/Gene Pairs and Barriers for Pharmacogenomics in Latin America. Current Drug Metabolism, 2014, 15, 202-208.	0.7	31
1901	A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients. Current Drug Safety, 2016, 11, 156-163.	0.3	17
1902	Signal Detection and their Assessment in Pharmacovigilance. Open Pharmaceutical Sciences Journal, 2015, 2, 66-73.	2.1	8
1903	Extraction of Information Related to Drug Safety Surveillance From Electronic Health Record Notes: Joint Modeling of Entities and Relations Using Knowledge-Aware Neural Attentive Models. JMIR Medical Informatics, 2020, 8, e18417.	1.3	20
1904	Adverse Drug Reaction Identification and Extraction in Social Media: A Scoping Review. Journal of Medical Internet Research, 2015, 17, e171.	2.1	101
1905	Consumer Mobile Apps for Potential Drug-Drug Interaction Check: Systematic Review and Content Analysis Using the Mobile App Rating Scale (MARS). JMIR MHealth and UHealth, 2018, 6, e74.	1.8	77
1907	Pharmacogenomics in the UK National Health Service: opportunities and challenges. Pharmacogenomics, 2020, 21, 1237-1246.	0.6	15

#	Article	IF	CITATIONS
1908	Ley de Zipf/Mandelbrot y teorÃa de la probabilidad aplicadas a la caracterización de reacciones adversas a medicamentos en adultos mayores. Revista Lasallista De Investigacion, 2016, 13, 27-34.	0.2	6
1909	Adverse drug reactions in hospitalized cardiac patients: Characteristics and risk factors. Vojnosanitetski Pregled, 2015, 72, 975-981.	0.1	13
1910	FREQUENCIES OF POLYMORPHISMS IN THE CYTOCHROME'S P450 GENES OF WARFARIN TRANSFORMATION A EUROPEAN POPULATION OF EASTERN SIBERIA. Acta Biomedica Scientifica, 2018, 3, 39-48.	IN 0.1	3
1911	Pharmacogenetics of Adverse Drug Reactions. , 2006, , 65-89.		1
1912	"Hopefully, I will never forget that again" - sensitizing medical students for drug safety by working on cases and simulating doctor-patient communication. GMS Journal for Medical Education, 2019, 36, Doc17.	0.1	4
1913	Identification of Adverse Drug Events. Deutsches Ärzteblatt International, 2010, 107, 23-9.	0.6	39
1914	Bleeding Complications and Liver Injuries During Phenprocoumon Treatment. Deutsches Ärzteblatt International, 2013, 110, 244-52.	0.6	13
1915	Adverse Drug Reactions (ADR) and Emergencies. Deutsches Ärzteblatt International, 2018, 115, 251-258.	0.6	55
1916	Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy. Deutsches Ärzteblatt International, 2019, 116, 508-518.	0.6	28
1917	Measuring prevalence, reliability and variation in high-risk prescribing in general practice using multilevel modelling of observational data in a population database. Health Services and Delivery Research, 2015, 3, 1-140.	1.4	12
1918	Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. Health Services and Delivery Research, 2017, 5, 1-150.	1.4	18
1919	Evaluation of patient reporting of adverse drug reactions to the UK †Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technology Assessment, 2011, 15, 1-234, iii-iv.	1.3	222
1920	A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technology Assessment, 2011, 15, 1-202, iii-iv.	1.3	94
1921	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment, 2017, 21, 1-386.	1.3	117
1922	ADRIC: Adverse Drug Reactions In Children – a programme of research using mixed methods. Programme Grants for Applied Research, 2014, 2, 1-184.	0.4	17
1923	Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. Croatian Medical Journal, 2020, 61, 147-158.	0.2	4
1924	A Machine Learning Approach to Identify Predictors of Potentially Inappropriate Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Use in Older Adults with Osteoarthritis. International Journal of Environmental Research and Public Health, 2021, 18, 155.	1,2	12
1925	GPs' views and experiences of prescribing non-steroidal anti-inflammatory drugs: a qualitative study. BJGP Open, 2017, 1, bjgpopen17X100869.	0.9	9

#	Article	IF	CITATIONS
1926	Are patients in heart failure trials representative of primary care populations? A systematic review. BJGP Open, 2018, 2, bjgpopen18X101337.	0.9	6
1927	Data Analysis for Anti-Neoplastic Chemotherapy-Related Adverse Events Reported to the Korean Pharmacovigilance Regional Network. Korean Journal of Medicine, 2013, 85, 385.	0.1	2
1928	Adverse Drug Reactions and Pattern Use of Cephalosporins: A Retrospective Review of Hospitalized Patients During 5 Years. International Journal of Pharmacology, 2012, 9, 66-73.	0.1	11
1929	Frequency and nature of adverse drug reactions in elderly in-patients of two Indian medical college hospitals. Journal of Postgraduate Medicine, 2011, 57, 189-195.	0.2	39
1930	Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian Journal of Pharmaceutical Sciences, 2015, 77, 687.	1.0	30
1931	Pharmacovigilance Programme of India: Recent developments and future perspectives. Indian Journal of Pharmacology, 2016, 48, 624.	0.4	58
1932	Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study. Journal of Natural Science, Biology and Medicine, 2013, 4, 191.	1.0	60
1933	Factors associated with the reporting of adverse drug reactions by health workers in Nnewi Nigeria. International Journal of Preventive Medicine, 2015, 6, 25.	0.2	8
1934	Pediatric hospital admission due to adverse drug reactions: Report from a tertiary center. Journal of Research in Pharmacy Practice, 2015, 4, 212.	0.2	6
1935	Attitude of nurses and pharmacists on adverse drug reactions reporting in selected hospitals in Sokoto, Northwest Nigeria. Journal of Research in Pharmacy Practice, 2016, 5, 219.	0.2	2
1936	Medication errors: Is it the hidden part of the submerged iceberg in our health-care system?. International Journal of Applied & Basic Medical Research, 2019, 9, 135.	0.2	16
1937	Knowledge and attitude of health-care professionals toward adverse drug reactions reporting at King Saud Medical City. Journal of Pharmacy and Bioallied Sciences, 2018, 10, 29.	0.2	10
1938	Assessment of Knowledge, Attitude and Practices of Adverse Drug Reaction Reporting among Doctors and Pharmacists in Primary Healthcare. Advances in Pharmacoepidemiology & Drug Safety, 2016, 5, .	0.1	5
1939	Development of a Consensus List of Potentially Inappropriate Medications for Korean Older Adults. Annals of Geriatric Medicine and Research, 2018, 22, 121-129.	0.7	26
1940	Impact of educational intervention on the pattern and incidence of potential drug-drug interactions in Nepal. Pharmacy Practice, 2009, 7, 242-7.	0.8	13
1941	Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more. Pharmacy Practice, 2012, 10, 9-16.	0.8	7
1942	Educating patients about warfarin therapy using information technology: A survey on healthcare professionals´ perspectives. Pharmacy Practice, 2012, 10, 97-104.	0.8	3
1944	Global Trigger Tool: Proficient Adverse Drug Reaction Autodetection Method in Critical Care Patient Units. Indian Journal of Critical Care Medicine, 2020, 24, 172-178.	0.3	8

#	Article	IF	CITATIONS
1945	Adverse drug events in hospitalized patients with chronic kidney disease. International Journal of Clinical Pharmacology and Therapeutics, 2010, 48, 571-576.	0.3	18
1946	Users' Knowledge About Adverse Effects of Non-steroidal Anti-inflammatory Drugs in Tirana, Albania. Materia Socio-medica, 2017, 29, 138.	0.3	7
1947	Future Directions of Pharmacovigilance Studies Using Electronic Medical Recording and Human Genetic Databases. Toxicological Research, 2019, 35, 319-330.	1.1	10
1948	Ongoing activities to influence the prescribing of proton pump inhibitors within the Scottish National Health Service: their effect and implications. GaBI Journal, 2018, 7, 142-151.	0.4	12
1949	Topics on Drug Metabolism. , 2012, , .		9
1950	Drug Hypersensitivity Reactions in Hospital-Admitted Children: A Single Center Study in Southern Iran. Jundishapur Journal of Natural Pharmaceutical Products, 2018, 13, .	0.3	1
1951	Predictors of Drug Calculation Competence of Nursing Students. Daehan Gicho Ganho Jayeon Gwahag Hoeji, 2012, 14, 174-182.	0.4	3
1952	Case management for long-term conditions. Nursing Management, 2009, 15, 22-27.	0.1	1
1953	Use of Mobile Phones for Monitoring Adverse Drug Reaction in Pharmacy and Drug Stores in Ishaka, Uganda - a Pilot Assessment of Willingness to Report. British Journal of Pharmaceutical Research, 2014, 4, 2245-2260.	0.4	1
1954	Assessment of Knowledge, Attitude and Perception of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting among the Pharmacy Students in South India. IOSR Journal of Pharmacy and Biological Sciences, 2014, 9, 34-37.	0.1	5
1955	Prevalence and characteristics of antidepressant prescribing in adults with comorbid depression and type 2 diabetes mellitus: A systematic review and meta-analysis. Health Sciences Review, 2021, 1, 100002.	0.6	3
1956	Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron, 2021, 109, 3914-3929.	3.8	25
1957	Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)–Never Change a Running System?. Pharmaceuticals, 2021, 14, 1056.	1.7	0
1958	Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners' case reports. BJGP Open, 2022, 6, BJGPO.2021.0150.	0.9	11
1959	Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. Human Genetics, 2022, 141, 1113-1136.	1.8	17
1961	Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis. BMC Health Services Research, 2021, 21, 1062.	0.9	3
1962	Small Molecule/HLA Complexes Alter the Cellular Proteomic Content. , 0, , .		1
1964	Adverse drug reactions as cause of admission to hospital: Alcohol and other non-prescribed drugs may have impact on adverse drug reactions. BMJ: British Medical Journal, 2004, 329, 459.1.	2.4	1

#	Article	IF	CITATIONS
1965	Adverse drug reactions as cause of admission to hospital: Only part of the picture was reported for aspirin. BMJ: British Medical Journal, 2004, 329, 459.4.	2.4	0
1966	Pharmacological and Pharmaceutical Profiling. , 2006, , 103-134.		1
1967	Pharmacogenomics: A New Frontier for the Evergreening of Pharmaceutical Drugs. SSRN Electronic Journal, 0, , .	0.4	0
1968	Harmful effects of drugs., 2007,, 751-764.		4
1969	Chapter 11. Preventing Drug Administration Errors. , 2007, , .		1
1970	Farmacotherapie bij ouderen. , 2007, , 41-52.		0
1971	Adverse drug reactions:reducing the burden of treatment. Nursing Standard (Royal College of) Tj ETQq0 0 0 rgBT	/Overlock 0.1	10 Tf 50 502
1972	The medic's guide to prescribing: Minimising adverse drug reactions. BMJ, The, 2007, 334, 0706222.	3.0	1
1974	Why should your Hospital have a Department of Clinical Pharmacology? Experience from the UK. Japanese Journal of Clinical Pharmacology and Therapeutics, 2008, 39, 1415-144S.	0.1	0
1975	Reacciones adversas a medicamentos como causa de consulta en el servicio de emergencias del Hospital San Juan de Dios. Revista Médica De La Universidad De Costa Rica, 2008, 2, .	0.0	1
1976	Epilepsy Predisposition and Pharmacogenetics. , 2009, , 1243-1255.		0
1977	Toxicological Consequences of Drug–Drug Interactions. , 2010, , 651-664.		0
1979	Pediatric Pharmacogenomics. Issues in Clinical Child Psychology, 2010, , 437-456.	0.2	0
1980	Pharmaceutical drug safety., 2010,, 263-279.		0
1981	Fundamentos de farmacogenética. , 2010, , 55-111.		0
1984	Issues in Translation of Pharmacogenomics into Clinical Practice. , 2011, , 3-14.		0
1985	ï¼ʿī¼Ž 藬物治ç™,ã«é—¢ãJ™ã,‹åŒ»å¦æ•™è,²ã®ç¾çжã•今後. Japanese Journal of Clinical Pharmacolo	g <b>y.a</b> nd Th	e <b>c</b> apeutics, 2
1986	Human Immunodefieciency Virus: Pharmacogenetics of Antiretroviral Treatment. Journal of Pharmacogenomics & Pharmacoproteomics, 2011, 01, .	0.2	O

#	ARTICLE	IF	CITATIONS
1987	What errors can be identified by Pharmacy led medicines reconciliation? A prospective study. Acute Medicine, 2011, 10, 18-21.	0.1	3
1988	Adverse events induced by anti-infectives in hospitalized patients. Serbian Journal of Experimental and Clinical Research, 2011, 12, 97-101.	0.2	O
1989	Pharmacokinetic and Pharmacodynamic Interactions Between Alcohol and Other Drugs. , 2012, , 499-586.		0
1992	Harmful effects of drugs. , 2012, , 698-709.		1
1993	Arzneimittel- und MedizinprodukteschÄ <b>d</b> en. , 2012, , 789-795.		0
1995	Recherche clinique et personnes $\tilde{A}^{\xi}g\tilde{A}^{\otimes}$ es: Consid $\tilde{A}^{\otimes}$ rations m $\tilde{A}^{\otimes}$ thodologiques et statistiques. R $\tilde{A}^{\otimes}$ f $\tilde{A}^{\otimes}$ rences En R $\tilde{A}^{\otimes}$ animation, 2012, , 149-163.	0.0	O
1996	Patient safety management in the medication use process: prevention and management of medication error. Journal of the Korean Medical Association, 2012, 55, 835.	0.1	3
1997	Survey of Drug Allergy Testing, Challenge, and Desensitization Practice. , 2012, 02, .		O
1998	The Role of Pharmacovigilance Center in Sudan in Reporting Adverse Drug Reactions. Advances in Bioinformatics and Biomedical Engineering Book Series, 2012, , 344-354.	0.2	0
1999	Drug Allergy. , 2012, , 1638-1640.		O
2000	Towards a Better Understanding of Health and Disease. , 0, , .		0
2001	S13-3. Drug-Drug Interactions Management in Clinical Situations. Japanese Journal of Clinical Pharmacology and Therapeutics, 2012, 43, 257-258.	0.1	O
2002	Aspekte der Polypharmazie beim alten Patienten., 2013,, 473-488.		1
2003	Comparison of Algorithms That Detect Drug Side Effects Using Electronic Healthcare Databases. SSRN Electronic Journal, 0, , .	0.4	1
2004	A Prospective Study on Adverse Drug Reactions in an Indian Hospital. Journal of Pharmacy and Nutrition Sciences (discontinued), 2013, 3, 149-162.	0.2	0
2005	Application of Clearance Theory to the Evaluation and Provision of Drug Information on Renal Dysfunction and Drug-drug Interactions. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health) Tj ETQq1 1 0.7	7 <b>84</b> 314 rg	BT /Overlo
2006	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs., 2013,, 469-506.		0
2007	Medicolegal Autopsies and Pharmacogenetics. , 2014, , 89-104.		O

#	ARTICLE	IF	CITATIONS
2008	A Novel Semi-Supervised Algorithm for Rare Prescription Side Effect Discovery. SSRN Electronic Journal, $0,  ,  .$	0.4	0
2009	Farmacovigilantie., 2014, , 79-98.		0
2010	Social Burden of Drug Allergy and its Prevention. Korean Journal of Medicine, 2014, 87, 647.	0.1	3
2011	İlaç İlaç Etkileşimlerinin Jordan Elman Ağları Kullanılarak Sınıflandırılması. Journal of the Fac Engineering and Architecture of Gazi University, 2014, 29, .	culty of	O
2014	Reporting Adverse Drug Reactions: Evaluations of Knowledge, Attitude and Practice among Community Pharmacists in UAE. IOSR Journal of Pharmacy, 2014, 04, 17-23.	0.1	5
2015	Perspectives on Women's Health and Medicines in Developing Countries. , 2015, , 497-529.		1
2016	Self-Reporting of Adverse Drug Reactions in Iraqi Hospitals: Patient's Perspectives. Pharmacology & Pharmacy, 2015, 06, 566-572.	0.2	1
2017	Pharmakovigilanz., 2015, , 1-9.		0
2018	Protective effect of Nigella sativa against paracetamol induced hepatic and renal damages. International Journal of Basic and Clinical Pharmacology, 0, , 503-509.	0.0	2
2019	The pattern and risk factors associated with adverse drug reactions induced by Reteplase in patients with acute ST-elevation myocardial infarction: The first report from Iranian population. Journal of Research in Pharmacy Practice, 2015, 4, 206.	0.2	2
2020	Anodic oxidation of etodolac and its linear sweep, square wave and differential pulse voltammetric determination in pharmaceuticals. Indian Journal of Pharmaceutical Sciences, 2015, 77, 413.	1.0	0
2022	Pharmacogenetics of Adverse Drug Reactions. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 109-156.	0.6	0
2023	Personalized Medicine., 2015, , 1-16.		0
2024	Drug Safety Surveillance: Modern Trends and Industrial Action. Journal of Young Pharmacists, 2015, 7, 69-75.	0.1	3
2026	Effect of Amoxicillin And Cefalexin on The Pharmacokinetics of Diclofenac Sodium in Healthy Volunteers. The Medical Journal of Basrah University, 2015, 33, 1-9.	0.1	0
2027	Innovations in Dispensing. , 2015, , 264-273.		O
2028	Pharmacovigilance awareness among interns in a tertiary care teaching hospital. Asian Pacific Journal of Health Sciences, 2015, 2, 1-3.	0.0	0
2030	Pediatric adverse drug reactions collected by an electronic reporting system in a single tertiary university hospital. Allergy Asthma & Respiratory Disease, 2016, 4, 354.	0.3	6

#	ARTICLE	IF	CITATIONS
2031	PHARMACOVIGILANCE AND ADVERSE DRUG REPORTING SYSTEM. The Professional Medical Journal, 2018, 23, 085-092.	0.0	0
2032	Encoding Medication Episodes for Adverse Drug Event Prediction. , 2016, , 245-250.		1
2034	Sources of Harm. , 2016, , 133-173.		0
2035	Chronifizierter Substanzmissbrauch im Alter – Probleme und Herausforderungen. , 2016, , 313-329.		1
2036	Pharmacovigilance Informatics. , 2016, , 299-315.		0
2037	Initiatives among Authorities to Improve the Quality and Efficiency of Prescribing and the Implications. Journal of Pharmaceutical Care & Health Systems, 2016, $1$ , .	0.1	5
2038	Pharmacotherapeutics knowledge of some nonemergency and emergency conditions among medical undergraduates in an Indian medical college. Indian Journal of Pharmacology, 2016, 48, 252.	0.4	1
2039	Variations in our genome: From disease to individualized cure. , 2016, , 289-301.		0
2040	Discriminating Power of Organization Related Variables on Intention to Medication Error Reporting. Journal of Health Informatics and Statistics, 2016, 41, 155-164.	0.1	1
2041	INVESTIGATION OF NEW NSAIDS FOR THE TREATMENT OF INFLAMMATORY DISEASES OF KIDNEY AND URINARY TRACT. Jurnal Teknologi (Sciences and Engineering), 2016, 78, .	0.3	0
2042	Caracterizaci $\tilde{A}^3$ n de los diferentes tipos de reacciones adversas relacionadas con el uso de medicamentos en un hospital de segundo nivel de complejidad de Itag $\tilde{A}^1/4\tilde{A}_7$ Antioquia. Investigar Y Aprender, 2016, , 96-103.	0.0	0
2043	AWARENESS OF PHARMACOVIGILANCE AMONG MEDICAL STUDENTS. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 5273-5276.	0.1	0
2044	Incidence of Potential Drug-Drug Interactions in a Limited and Stereotyped Prescription Setting - Comparison of Two Free Online Pharmacopoeias. Cureus, 2016, 8, e886.	0.2	6
2045	Les Effets Indésirables Digestifs De La Chimiothérapie : Cas Des Patients De L'institut National D'oncologie De Rabat (Maroc). European Scientific Journal, 2016, 12, 454.	0.0	0
2046	Possibility of Drug-Drug Interaction through Prescription Analysis at the National Institute of Cardiovascular Disease (NICVD), Bangladesh., 0,, 007-010.		1
2047	A Qualitative Study of Knowledge, Attitude and Practice towards Pharmacovigilance among Doctors and Nursing Staff in a Tertiary Care Hospital in India. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, FC01-FC03.	0.8	1
2048	Detection of adverse drug reaction (ADR)-related hospital admissions: A pilot study using administrative database for ADR monitoring in Thailand. Pharmaceutical Sciences Asia, 2017, 44, 142-153.	0.2	1
2049	Knowledge and Perception about Pharmacovigilance among Pharmacy Students of Universities in Sana'a Yemen. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, FC09-FC13.	0.8	7

#	Article	IF	CITATIONS
2050	Evaluation of Knowledge, Attitude and Practices of Resident Doctors, Interns and Nurses on Adverse Drug Reaction Monitoring and Reporting In a Tertiary Care Hospital. Journal of Medical Science and Clinical Research, 2017, 05, 19052-19059.	0.0	0
2051	Analysis of Antineoplastics, Immunomodulators, Antibiotics and Analgesics Adverse Drug Reactions Reports Submitted to the Pharmacovigilance Database in Jordan. Biosciences, Biotechnology Research Asia, 2017, 14, 541-546.	0.2	0
2052	Assessment of Knowledge, Attitude and Practice of Pharmacovigilance among the Interns in a Tertiary Care Hospital in Northern India-A Questionnaire Based Study. International Journal of Medical and Dental Sciences, 2017, 6, 1498.	0.1	0
2056	Analysis of L-asparaginase Related Adverse Reaction. Korean Journal of Clinical Pharmacy, 2017, 27, 143-149.	0.0	1
2057	Arthritic Conditions Affecting the Temporomandibular Joint. , 2018, , 1-36.		0
2059	The mechanisms of adverse reactions to medication. Pediatru Ro, 2018, 3, 6.	0.0	0
2060	Exploring Linguistic and Graph Based Features for the Automatic Classification and Extraction of Adverse Drug Effects. Lecture Notes in Computer Science, 2018, , 463-474.	1.0	1
2061	Jalaukavacharana (Leech Application) in Pain Management: A Pilot Open-Label Clinical Trial. Journal of Research in Ayurvedic Sciences, 2018, 2, 99-107.	0.1	0
2062	Trends in pharmacotherapy for elderly patients. Praktické LékárenstvÃ, 2018, 14, 8-10.	0.0	1
2063	Knowledge and perception towards pharmacovigilance and adverse drug reactions reporting among medical students at a teaching hospital in South India. International Journal of Basic and Clinical Pharmacology, 2018, 7, 866.	0.0	0
2064	Safer Prescribing and Care for the Elderly (SPACE): Protocol of a Cluster Randomized Controlled Trial in Primary Care. JMIR Research Protocols, 2018, 7, e109.	0.5	6
2067	Safer Prescribing and Care for the Elderly (SPACE): a pilot study in general practice. BJGP Open, 2018, 2, bjgpopen18X101594.	0.9	7
2068	Reporting Adverse Drug Reactions in a Tertiary Care Hospital in Istanbul. Turkish Thoracic Journal, 2018, 19, 237-239.	0.2	2
2069	Safe and effective management of analgesics in patients presenting to hospital with acute illness. Nursing Standard (Royal College of Nursing (Great Britain): 1987), 2018, 33, 31-37.	0.1	0
2070	How to Manage Drug Interactions in Clinical Settings (2). Iryo Yakugaku (Japanese Journal of) Tj ETQq0 0 0 rgBT	/Oyerlock	10 <sub>0</sub> Tf 50 182
2071	An Explainable Approach of Inferring Potential Medication Effects from Social Media Data. Lecture Notes in Computer Science, 2019, , 82-92.	1.0	1
2072	Antithrombotic/antiplatelet therapy and colonoscopy results in patients over 50 with iron-deficiency anemia. Archives of Medical Science - Civilization Diseases, 2019, 4, 28-33.	0.1	0
2073	Drug Reactions, Resistance, and Polypharmacy. , 2019, , 1-6.		0

#	Article	IF	CITATIONS
2074	Concurrent prescribing: Evaluation of its knowledge among dentists. National Journal of Maxillofacial Surgery, 2019, 10, 73.	0.1	3
2075	HEALTH CARE WORKERS' KNOWLEDDGE AND PERCEPTIONS ABOUT PHARMACOVIGILANCE AND ADVERSE DRUG REACTIONS REPORTING. International Journal of Pharmaceutical Science and Health Care, 2019, 1,	0.0	0
2077	Preparing for Vanessa's Law: Collaboration between the Medical Records and Pharmacy Departments at a Canadian Hospital Center. Journal of Population Therapeutics and Clinical Pharmacology, 2019, 26, e5-e13.	1.9	1
2079	To investigate the feasibility of predicting, identifying and mitigating latent system failures in a UK NHS paediatric hospital., 2019, , 387-415.		0
2080	An Update on the Immunological, Metabolic and Genetic Mechanisms in Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3813-3828.	0.9	2
2081	Potential drug-drug interactions in the psychiatric hospital: Frequency analysis. Research Results in Pharmacology, 2019, 5, 1-6.	0.1	6
2082	Reducing the risk of NSAID related gastrointestinal problems: an update. Drug and Therapeutics Bulletin, 2020, 58, 89-92.	0.3	3
2083	Evaluation and Management of Drug-Drug Interactions in Patients Hospitalized in Nephrology and Post-Transplant Wards in a Teaching Hospital. Journal of Pharmaceutical Care, 0, , .	0.0	0
2084	Nontraumatic warfarin-related intrapulmonary hemorrhage presenting as a lung mass. Surgical Case Reports, 2020, 6, 70.	0.2	2
2085	Application of Natural Language Processing with Supervised Machine Learning Techniques to Predict the Overall Drugs Performance. AJIT-e Online Academic Journal of Information Technology, 2020, 11, 8-23.	0.3	1
2086	The Effect of Omeprazole on the Pharmacokinetics of Piroxicam Profiles with High Performance Liquid Chromatography (HPLC) Method. Indonesian Journal of Pharmaceutical and Clinical Research, 2020, 3, 36-41.	0.1	0
2087	Low risk of intracranial emergency in patients with minor head injury treated with antiplatelet therapy. European Journal of Emergency Medicine, 2021, 28, 481-482.	0.5	0
2088	Hospitalizations and deaths related to adverse drug events worldwide: Systematic review of studies with national coverage. European Journal of Clinical Pharmacology, 2022, 78, 435-466.	0.8	13
2089	Adverse Drug Reactions and Drug Interactions. , 2020, , 89-114.		0
2091	Hazards of Hospitalization. , 2020, , 403-423.		3
2092	Potential of drug interactions as a cause of adverse drug reactions in patients with kidney diseases. Journal of Research in Pharmacy Practice, 2020, 9, 121.	0.2	0
2093	Challenges of Anticoagulation in Total Joint Arthroplasty. Open Journal of Orthopedics, 2020, 10, 289-294.	0.0	1
2094	Frequency of ADRs and their Economic Impact in a Tertiary Care Public Sector Hospital in South India. SBV Journal of Basic Clinical and Applied Health Science, 2020, 3, 23-31.	0.2	1

#	Article	IF	Citations
2095	Le programme éducatif OMAGE. , 2020, , 307-318.		0
2096	Drug identification and interaction checking using the Internet of Things. , 2020, , 87-115.		1
2097	Non-Surgical Management of Pre-Arthritic Dysplastic Hip Pain. , 2020, , 111-128.		0
2098	Pharmacogenetics in anesthesiology: what to look for. Review. Alexander Saltanov Intensive Care Herald, 2020, , 63-72.	0.2	0
2099	Patient with Polypharmacy., 2020,, 459-470.		0
2100	Patients' claims regarding drug allergies. Hospital Pharmacology, 2020, 7, 875-882.	0.1	1
2101	Pharmacology and Therapeutics. , 2020, , 406-424.		0
2104	The Characteristics of Adverse Drug Reactions in Cancer Patients: An Analysis of Spontaneously Reported Cases. Korean Journal of Medicine, 2020, 95, 104-113.	0.1	0
2105	Global research output in pharmacovigilance (2015–2020). Library Hi Tech News, 2021, 38, 13-16.	0.5	2
2106	Characterising risk of non-steroidal anti-inflammatory drug-related acute kidney injury: a retrospective cohort study. BJGP Open, 2022, 6, BJGPO.2021.0208.	0.9	4
2107	Detection and Reporting of Adverse Drug Reactions Related to Antibiotics in Primary Healthcare in Greece. Current Drug Safety, 2022, 17, 217-224.	0.3	1
2108	Comparative Theoretical Study of Stability, Lypophilicity, Dipole Moments, Acidity and Spectroscopic Properties of Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Ketoprofen and Flurbiprofen. Chemical Science International Journal, 0, , 51-60.	0.3	0
2109	Assessment of Knowledge, Attitude and Practices of Healthcare Professionals Towards Adverse Drug Reactions Monitoring and Reporting: A Cross-Sectional Study in Lahore, Pakistan. Modern Care Journal, 2020, 17, .	0.2	0
2110	Model-based Meta-analysis to Compare Primary Efficacy-endpoint, Efficacy-time Course, Safety, and Tolerability of Opioids Used in the Management of Osteoarthritic Pain in Humans. Current Drug Metabolism, 2020, 21, 390-399.	0.7	1
2111	Adverse Drug Events and Reactions Managed by Medical Toxicologists: an Analysis of the Toxicology Investigators Consortium (ToxIC) Registry, 2010–2016. Journal of Medical Toxicology, 0, , .	0.8	0
2112	Arzneimittel- und MedizinprodukteschÃ <b>d</b> en. , 2008, , 793-798.		0
2115	Role of Genetics and Genomics in Clinical Trials in Osteoarthritis and Rheumatoid Arthritis. , 2008, , 275-287.		0
2116	"Medikamentenmix" beim alten Patienten: Richtige Auswahl zur Vermeidung von gefÃĦrlichen Wechselwirkungen. , 2007, , 271-280.		0

#	Article	IF	CITATIONS
2117	Adverse Drug Effects., 2008,, 37-39.		0
2119	Adverse Drug Reactions. Drug Safety, 2012, 35, 977-981.	1.4	8
2120	Knowledge and Attitudes of Resident Physicians About Adverse Drug Reactions. Konuralp Tip Dergisi, 2020, 12, 498-502.	0.1	2
2121	Social norms interventions to change clinical behaviour in health workers: a systematic review and meta-analysis. Health Services and Delivery Research, 2020, 8, 1-138.	1.4	5
2122	Establishing a service to tackle problematic polypharmacy. Future Healthcare Journal, 2020, 7, 208-211.	0.6	6
2123	The pharmacoepidemiology of potential drug-drug interactions in patients with psychiatric disorders. Kachestvennaya Klinicheskaya Praktika, 2020, , 85-92.	0.2	0
2124	Interactive exploration of population scale pharmacoepidemiology datasets. , 2020, , .		0
2125	Interest of a general practitioner pharmacovigilance network to provide drug information: A comparative study in France. Therapie, 2020, 75, 617-622.	0.6	2
2127	Role of regulatory agencies in translating pharmacogenetics to the clinics. Clinical Cases in Mineral and Bone Metabolism, 2009, 6, 29-34.	1.0	3
2128	Pharmacovigilance training with focus on India. Indian Journal of Pharmacology, 2008, 40, S28-30.	0.4	5
2129	Prevalence of adverse drug reactions at a private tertiary care hospital in south India. Journal of Research in Medical Sciences, 2011, 16, 16-25.	0.4	19
2130	Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention. Canadian Family Physician, 2013, 59, 55-61.	0.1	7
2131	A Survey of Knowledge, Attitude and Practice of Nurses towards Pharamacovigilance in Taleqani Hospital. Iranian Journal of Pharmaceutical Research, 2010, 9, 199-206.	0.3	14
2133	Increasing the number of adverse drug reactions reporting: the role of clinical pharmacy residents. Iranian Journal of Pharmaceutical Research, 2014, 13, 291-7.	0.3	12
2134	Critical views in gastroenterology & hepatology: aspirin prophylaxis: putting gut bleeds into perspective. Gastroenterology and Hepatology, 2014, 10, 61-3.	0.2	3
2136	Management of drug interactions with beta-blockers: continuing education has a short-term impact. Pharmacy Practice, 2006, 4, 143-50.	0.8	0
2138	Handling Temporality of Clinical Events for Drug Safety Surveillance. AMIA Annual Symposium proceedings, 2015, 2015, 1371-80.	0.2	7
2139	Content and Usability Evaluation of Patient Oriented Drug-Drug Interaction Websites. AMIA Annual Symposium proceedings, 2015, 2015, 287-96.	0.2	5

#	Article	IF	CITATIONS
2142	Pharmacovigilance: A public health priority for South Africa. South African Health Review, 2017, 2017, 125-133.	0.0	3
2143	Warfarin: better the devil you know. Cardiovascular Journal of Africa, 2017, 28, 344-345.	0.2	0
2144	Bullous Fixed Drug Eruption Following Ibuprofen Ingestion. Journal of Research in Pharmacy Practice, 2018, 7, 51-56.	0.2	2
2145	The Streptokinase Therapy Complications and its Associated Risk Factors in Patients with Acute ST Elevation Myocardial Infarction. Iranian Journal of Pharmaceutical Research, 2018, 17, 53-63.	0.3	4
2147	Immune mechanisms of idiosyncratic drug-induced liver injury. Journal of Clinical and Translational Research, 2017, 3, 145-156.	0.3	16
2148	Evaluation of a Novel Audit Tool for Medication Reconciliation at Hospital Discharge. Canadian Journal of Hospital Pharmacy, 2019, 72, 421-427.	0.1	1
2149	Calculated parenteral initial therapy of bacterial infections: Antibiotic treatment in the elderly. GMS Infectious Diseases, 2020, 8, Doc05.	0.5	1
2150	Prevalence, attitude and practice of self-medication among adolescents and the paradigm of dysmenorrhea self-care management in different countries. Acta Biomedica, 2020, 91, 182-192.	0.2	3
2152	Determination of potential drug–drug interactions in prescription orders dispensed in a community pharmacy setting using Micromedex® and Lexicomp®: a retrospective observational study. International Journal of Clinical Pharmacy, 2022, 44, 348-356.	1.0	8
2153	Regulation Awareness and Experience of Additional Monitoring among Healthcare Professionals in Finland. Healthcare (Switzerland), 2021, 9, 1540.	1.0	2
2154	Editorial: NSAIDs Pharmacogenomics. Frontiers in Pharmacology, 2021, 12, 798447.	1.6	1
2155	Emerging technologies and their impact on regulatory science. Experimental Biology and Medicine, 2022, 247, 1-75.	1.1	22
2156	Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial. BMC Geriatrics, 2021, 21, 659.	1.1	12
2157	Analgesia Prescribing in Patients with Inflammatory Arthritis in England: An Observational Study Using Electronic Healthcare Record Data. Rheumatology, 2021, , .	0.9	4
2158	Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration. EBioMedicine, 2021, 74, 103728.	2.7	5
2159	Prognostic Impact of Polypharmacy at Discharge in Patients Hospitalized with Heart Failure. SSRN Electronic Journal, 0, , .	0.4	0
2160	Effect of Vitamin D Supplementation on the Regulation of Blood Pressure in Iranian Patients with Essential Hypertension: A Clinical Trial. Advances in Experimental Medicine and Biology, 2021, 1328, 501-511.	0.8	4
2161	Cutaneous adverse drug reactions in a tertiary care hospital: An observational study. Journal of Pharmacovigilance and Drug Research, 2020, $1$ , 6-9.	0.1	1

#	Article	IF	CITATIONS
2162	Drug prevalence and comparison interaction between numbers of patients admitted at two teaching hospitals; Quetta, Pakistan. Archives of Nursing Practice and Care, 2020, , 055-059.	0.0	0
2163	Investigation of Potential Drug-Drug Interactions in an Intensive Care Unit Using Lexicomp Drug Interactions. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2020, 46, 576-583.	0.0	1
2164	Drug Reactions, Resistance, and Polypharmacy. , 2021, , 1524-1530.		0
2165	Prescription errors: How to overcome?. Telangana Journal of Psychiatry, 2021, 7, 77.	0.0	0
2167	Farmacogenética en psiquiatrÃa: estudio de variantes alélicas del CYP450 en pacientes chilenos con patologÃa psiquiátrica. Revista Médica ClÃnica Las Condes, 2022, 33, 58-67.	0.2	0
2168	Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews. Frontiers in Pharmacology, 2021, 12, 792877.	1.6	8
2169	DSGAT: predicting frequencies of drug side effects by graph attention networks. Briefings in Bioinformatics, 2022, 23, .	3.2	7
2170	Pharmacogenomic alerts: Developing guidance for use by healthcare professionals. British Journal of Clinical Pharmacology, 2022, 88, 3201-3210.	1.1	3
2172	Effects of home drug delivery on drug-related problems: preliminary evidence for improved patient outcomes during the COVID-19 pandemic in Thailand. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 1206-1213.e3.	0.7	8
2173	Assessment of Information Sharing on Adverse Drug Reactions by Community Pharmacies with Other Medical Institutions. Pharmacy (Basel, Switzerland), 2022, 10, 25.	0.6	1
2174	Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study. Annals of Medicine, 2022, 54, 379-392.	1.5	2
2175	Projected number of osteoarthritis patients in Austria for the next decades – quantifying the necessity of treatment and prevention strategies in Europe. BMC Musculoskeletal Disorders, 2022, 23, 133.	0.8	6
2176	Estimated Costs of Severe Adverse Drug Reactions Resulting in Hospitalization in the Veterans Health Administration. JAMA Network Open, 2022, 5, e2147909.	2.8	7
2177	Adverse drug reactions among major depressive disorders: patterns by age and gender. Heliyon, 2021, 7, e08655.	1.4	8
2179	A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England. In Vivo, 2022, 36, 780-800.	0.6	3
2180	Characterisation of seriousness and outcome of adverse drug reactions in patients received cancer chemotherapy drugs – A prospective observational study. Current Medicine Research and Practice, 2022, 12, 20.	0.1	1
2181	The Immunogenetics of Cutaneous Drug Reactions. Advances in Experimental Medicine and Biology, 2022, 1367, 411-431.	0.8	1
2184	Development and Validation of â€ <sup>P</sup> rediction of Adverse Drug Reactions in Older Inpatients (PADROI)' Risk Assessment Tool. Clinical Interventions in Aging, 2022, Volume 17, 195-210.	1.3	2

#	Article	IF	CITATIONS
2185	The Potential of Metabolomics in Biomedical Applications. Metabolites, 2022, 12, 194.	1.3	63
2186	Drug-Related Deaths in China: An Analysis of a Spontaneous Reporting System. Frontiers in Pharmacology, 2022, 13, 771953.	1.6	3
2187	Severity and Hospitalization Cost Related to Warfarin-Related Adverse Events in a Tertiary Malaysian Hospital. Hospital Pharmacy, 0, , 001857872110701.	0.4	1
2188	Emergency department admissions induced by drug–drug interactions in the elderly: A crossâ€sectional study. Clinical and Translational Science, 2022, 15, 1472-1481.	1.5	6
2189	Inconsistent Country-Wide Reporting of Adverse Drug Reactions to Antimicrobials in Sierra Leone (2017–2021): A Wake-Up Call to Improve Reporting. International Journal of Environmental Research and Public Health, 2022, 19, 3264.	1.2	4
2191	Similarity and consistency assessment of three major online drug–drug interaction resources. British Journal of Clinical Pharmacology, 2022, 88, 4067-4079.	1.1	7
2192	Pharmacist's Knowledge and Behaviors Toward Pharmacovigilance and Adverse Drug Reactions Reporting Process in Turkey. Turkish Journal of Pharmaceutical Sciences, 2022, .	0.6	0
2193	Analysing electronic prescribing data to detect potential undocumented adverse reactions to medications. European Journal of Hospital Pharmacy, 2024, 31, 76-78.	0.5	0
2194	Co-designing a community pharmacy pharmacogenomics testing service in the UK. BMC Health Services Research, 2022, 22, 378.	0.9	7
2195	A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China. BMC Health Services Research, 2022, 22, 318.	0.9	3
2196	Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of a National Reporting Indicator. British Journal of Clinical Pharmacology, 2022, , .	1.1	2
2197	Global research output in †pharmacovigilance' during 2010†2020. Therapie, 2022, 77, 273-290.	0.6	6
2198	Safer prescription of drugs: impact of the PREFASEG system to aid clinical decision-making in primary care in Catalonia. BMC Medical Informatics and Decision Making, 2021, 21, 349.	1.5	4
2199	Intervention fidelity and process outcomes of the IMMENSE study, a pharmacistâ€led interdisciplinary intervention to improve medication safety in older hospitalized patients. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 619-627.	0.7	3
2200	Medication related to pigmentation of oral mucosa. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2020, , 0-0.	0.7	3
2201	Adverse Drug Reactions Due to Opioid Use in Oldest-Old Patients Visiting the Emergency Unit of the Geneva Geriatric Hospital. Journal of Frailty & Description of Strailty & D	0.8	1
2202	Budget impact analysis of a pilot polypharmacy clinic. British Journal of Health Care Management, 2022, 28, 1-9.	0.1	0
2203	Cost-effectiveness of a structured medication review approach for multimorbid older adults: Within-trial analysis of the OPERAM study. PLoS ONE, 2022, 17, e0265507.	1.1	6

#	Article	IF	CITATIONS
2211	Prescribing Authority and Medication Management in Mental Health and Addiction Nursing. , 0, , 196-208.		0
2216	Cutaneous Adverse Drug Reactions in a Tertiary Teaching Hospital: A Prospective, Observational Study Indian Journal of Dermatology, 2021, 66, 573.	0.1	1
2218	Knowledge, attitude and practice of hospital pharmacists towards pharmacovigilance and adverse drug reaction reporting in Najran, Saudi Arabia. Saudi Pharmaceutical Journal, 2022, 30, 1018-1026.	1.2	3
2219	Impact of educational intervention on the knowledge, attitude and practice of pharmacovigilance among nurses at a tertiary care public hospital. Current Drug Safety, 2022, 17, .	0.3	0
2220	An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. Frontiers in Pharmacology, 2022, 13, 886377.	1.6	14
2221	Evaluation of Factors Associated With Appropriate Drug Prescription and Effectiveness of Informative and Educational Interventionsâ€"The EDU.RE.DRUG Project. Frontiers in Pharmacology, 2022, 13, 832169.	1.6	2
2222	Medication compliance aids unpackaged: A national survey. British Journal of Clinical Pharmacology, 2022, 88, 4595-4606.	1.1	4
2223	NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study. Virology Journal, 2022, 19, 84.	1.4	19
2224	Risk factors for gastrointestinal bleeding: a hospital-based case-control study. Swiss Medical Weekly, 0, , .	0.8	7
2225	Machine Learning in Causal Inference: Application in Pharmacovigilance. Drug Safety, 2022, 45, 459-476.	1.4	7
2226	Incidence of adverse drug events in patients hospitalized in the medical wards of a teaching referral hospital in Ethiopia: a prospective observational study. BMC Pharmacology & Ethiopia: a prospective observational study. BMC Pharmacology & Ethiopia: 30.	1.0	6
2227	Teaching pharmacovigilance to undergraduate students: Our experience in poor-resource setting. Journal of Pharmacy and Bioallied Sciences, 2022, 14, 31.	0.2	1
2228	Inappropriate Prescriptions in Older People—Translation and Adaptation to Portuguese of the STOPP/START Screening Tool. International Journal of Environmental Research and Public Health, 2022, 19, 6896.	1.2	6
2229	A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators. Therapeutic Innovation and Regulatory Science, 2022, 56, 717-743.	0.8	8
2232	A preliminary investigation into the use of amino acids as potential ion pairs for diclofenac transdermal delivery. International Journal of Pharmaceutics, 2022, 623, 121906.	2.6	5
2233	Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research, 0, Volume 15, 1691-1706.	0.8	26
2234	Advances in Our Understanding of the Interaction of Drugs with T-cells: Implications for the Discovery of Biomarkers in Severe Cutaneous Drug Reactions. Chemical Research in Toxicology, 2022, 35, 1162-1183.	1.7	2
2235	Pharmacovigilance study of spontaneous adverse drug reaction in a tertiary care centre. Current Medicine Research and Practice, 2022, 12, 106.	0.1	0

#	Article	IF	CITATIONS
2236	Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: does age matter?. Archive of Clinical Cases, 2022, 9, 80-88.	0.1	1
2237	Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model. Frontiers in Pharmacology, 0, $13$ , .	1.6	9
2238	Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open, 2022, 12, e055551.	0.8	33
2239	India's Opportunities and Challenges in Establishing a Twin Registry: An Unexplored Human Resource for the World's Second-Most Populous Nation. Twin Research and Human Genetics, 0, , 1-9.	0.3	0
2240	Evaluation of Phytochemistry and Pharmacological Properties of Alnus nitida. Molecules, 2022, 27, 4582.	1.7	3
2241	Medication Errors Require Intensive Care Unit Admission. Egyptian Journal of Critical Care Medicine, 2022, 9, 16-21.	0.2	1
2243	Fatal adverse drug reactions in children: A descriptive study in the World Health Organization pharmacovigilance database, 2010â€2019. British Journal of Clinical Pharmacology, 0, , .	1.1	1
2245	A Questionnaire based Cross-sectional Study to assess Knowledge, Attitude and Practice of Pharmacovigilance and Adverse Drug Reaction Reporting among Postgraduate Medical students in a Tertiary Care Teaching Hospital of South India. Research Journal of Pharmacy and Technology, 2022, , 2391-2394.	0.2	0
2246	Possible futures of acute medical care in the NHS: a multispecialty approach. Future Healthcare Journal, 2022, 9, 125-132.	0.6	2
2247	Barriers and facilitators to pharmacovigilance activities in Pakistan: A healthcare professionals-based survey. PLoS ONE, 2022, 17, e0271587.	1.1	4
2248	Prescribing at 95 years of age: cross-sectional findings from the Newcastle 85+ study. International Journal of Clinical Pharmacy, 2022, 44, 1072-1077.	1.0	0
2250	Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review. Frontiers in Medicine, 0, 9, .	1.2	7
2251	Dual-antithrombotic therapy and gastroprotection in atrial fibrillation: An observational primary care study. BJGP Open, 0, , BJGPO.2022.0048.	0.9	0
2252	The Impact of Pharmacist-Led Medication Management Services on the Quality of Life and Adverse Drug Reaction Occurrence. Pharmacy (Basel, Switzerland), 2022, 10, 102.	0.6	3
2253	Omega-3 Fatty Acids for the Management of Osteoarthritis: A Narrative Review. Nutrients, 2022, 14, 3362.	1.7	8
2254	Perceptions and barriers of adverse drug reaction reporting within inpatient state psychiatric facilities. Mental Health Clinician, 2022, 12, 247-253.	0.5	1
2255	Conjugation of human serum albumin and flucloxacillin provokes specific immune response in HLA-B*57:01 transgenic mice. Immunology Letters, 2022, 249, 5-11.	1.1	3
2256	What is the evidence that a pharmacy team working in an acute or emergency medicine department improves outcomes for patients: A systematic review. Pharmacology Research and Perspectives, 2022, 10, .	1.1	O

#	Article	IF	CITATIONS
2257	Elderly Patients' Perspectives on the Acceptability of Deprescribing Medicines: A Qualitative Study Protocol. International Journal of Qualitative Methods, The, 2022, 21, 160940692211169.	1.3	O
2258	Exploring the value of a multidisciplinary-led medication review for elderly individuals at a long-term care facility performed by four different health-care professions in an equal and closely integrated collaboration. Journal of Family Medicine and Primary Care, 2022, 11, 4519.	0.3	4
2259	Reporting and recording of adverse drug reactions of highly active antiretroviral therapy by HIV infected patients and healthcare professionals respectively in the Ethekwini Metropolitan, of Kwa-Zulu Natal, South Africa: a cross sectional and retrospective comparative study. Pan African Medical Journal, 0, 42, .	0.3	0
2260	Association between continuity of primary care and both prescribing and adherence of common cardiovascular medications: a cohort study among patients in England. BMJ Open, 2022, 12, e063282.	0.8	1
2261	A Narrative Review of Adverse Event Detection, Monitoring, and Prevention in Indian Hospitals. Cureus, 2022, , .	0.2	0
2262	Knowledge, attitude and practice of pharmacovigilance among Nepalese health professionals. Journal of Pharmacovigilance and Drug Research, 2022, 3, 40-50.	0.1	0
2263	Genetic Variation among Pharmacogenes in the Sardinian Population. International Journal of Molecular Sciences, 2022, 23, 10058.	1.8	1
2264	Precision medicine from a citizen perspective: a survey of public attitudes towards pharmacogenomics in Flanders. BMC Medical Genomics, 2022, 15, .	0.7	O
2265	Need for involving the pharmaceutical industry in the national pharmacovigilance program of Nepal. Journal of Pharmacovigilance and Drug Research, 2022, 3, 6-9.	0.1	0
2266	Electronic prescribing systems in hospitals to improve medication safety: a multimethods research programme. Programme Grants for Applied Research, 2022, 10, 1-164.	0.4	1
2267	Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance. Clinical and Experimental Allergy, 2022, 52, 1379-1390.	1.4	2
2268	A Systematic Review of Healthcare Professionals' Knowledge, Attitudes, and Practices Regarding Adverse Drug Reaction Reporting in Ethiopia. Turkish Journal of Pharmaceutical Sciences, 2022, .	0.6	0
2269	Adverse drug reactions and associated patient characteristics in older community-dwelling adults: a 6-year prospective cohort study. British Journal of General Practice, 2023, 73, e211-e219.	0.7	5
2270	Development of a multivariate prediction model to identify individual case safety reports which require clinical review. Pharmacoepidemiology and Drug Safety, 0, , .	0.9	2
2271	Pharmacists' involvement with and pharmacy clients' awareness of adverse drug reaction reporting in Nigeria – a mixed-methods approach. Journal of Pharmaceutical Health Services Research, 0, , .	0.3	0
2272	Trends in Adverse Drug Reactions Among Children: Evidence from Jiangsu Province of China, 2010–2019. Paediatric Drugs, 0, , .	1.3	1
2273	Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation. Biochemical Pharmacology, 2022, 206, 115336.	2.0	3
2274	Investigation of cytochrome P450 inhibitory properties of deoxyshikonin, a bioactive compound from <i>Lithospermum erythrorhizon</i> Sieb. et <i>Z</i> ucc. Phytotherapy Research, 0, , .	2.8	1

#	Article	IF	Citations
2275	Endpoints for safety in health technology assessments–The experiences of the Danish Medicines Council. Health Policy and Technology, 2022, 11, 100692.	1.3	0
2276	Medication errors in cancer therapy: Reports from German hospital pharmacists between 2008 and 2019. Journal of Oncology Pharmacy Practice, 0, , 107815522211351.	0.5	0
2277	Polygenic risk scores: An overview from bench to be dside for personalised medicine. Frontiers in Genetics, 0,13,.	1.1	17
2278	Implementation of a medicine management plan (MMP) to reduce medication-related harm (MRH) in older people post-hospital discharge: a randomised controlled trial. BMC Geriatrics, 2022, 22, .	1.1	O
2279	Medication changes and potentially inappropriate prescribing in older patients with significant polypharmacy. International Journal of Clinical Pharmacy, 2023, 45, 191-200.	1.0	3
2280	Precision Medicine Using Pharmacogenomic Panel-Testing. Clinics in Laboratory Medicine, 2022, 42, 587-602.	0.7	1
2281	Clinical consequences of drug-induced mitochondrial dysfunction., 2023,, 77-100.		0
2282	Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment. Bioactive Materials, 2023, 24, 37-53.	8.6	9
2283	Coâ€designing an intervention to improve the process of deprescribing for older people living with frailty in the United Kingdom. Health Expectations, 2023, 26, 399-408.	1.1	4
2284	Opioidâ€related adverse drug reactions in patients visiting the emergency division of a tertiary hospital. Pharmacology Research and Perspectives, 2022, 10, .	1.1	2
2285	A Study about the pattern of adverse effects of various oncology drugs in a Tertiary Care Hospital of North East India. Research Journal of Pharmacology and Pharmacodynamics, 2022, , 208-212.	0.1	1
2286	Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications. Cureus, 2022, , .	0.2	0
2287	Inhalation therapies in COPD $\hat{a}\in$ " adverse drug reactions impact on emergency department presentations. European Journal of Clinical Pharmacology, 0, , .	0.8	0
2288	MedArch—Medical Archive and Analytical Solution. Lecture Notes in Electrical Engineering, 2023, , 835-846.	0.3	0
2289	Duplicate prescriptions in the emergency department: a retrospective cohort study. European Journal of Clinical Pharmacology, 2023, 79, 207-217.	0.8	4
2290	Polypharmacy in Older People with Heart Failure: Roles of the Geriatrician and Pharmacist. Cardiac Failure Review, 0, 8, .	1.2	1
2291	iADRGSE: A Graph-Embedding and Self-Attention Encoding for Identifying Adverse Drug Reaction in the Earlier Phase of Drug Development. International Journal of Molecular Sciences, 2022, 23, 16216.	1.8	2
2292	Drug-Related Problems in Pulmonary Hypertension with Valvular Heart Disease. Therapeutics and Clinical Risk Management, 0, Volume 18, 1069-1079.	0.9	O

#	ARTICLE	IF	CITATIONS
2293	Clinical Relevance of Drug–Drug Interactions With Antibiotics as Listed in a National Medication Formulary: Results From Two Large Populationâ€Based Caseâ€Control Studies in Patients Aged 65–100 Years Using Linked English Primary Care and Hospital Data. Clinical Pharmacology and Therapeutics, 2023, 113, 423-434.	2.3	0
2294	Explore Adverse Drug Reactions (ADRs) reporting by clinical and community pharmacists in Duhok, Kurdistan region-Iraq: hampered and perspective. Pharmacia, 2022, 69, 1057-1062.	0.4	O
2295	Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients. Frontiers in Pharmacology, $0,13,.$	1.6	4
2297	Dissolvable polymeric microneedles loaded with aspirin for antiplatelet aggregation. Asian Journal of Pharmaceutical Sciences, 2023, 18, 100776.	4.3	5
2298	Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics, 2023, 24, 350-362.	7.7	46
2299	Adverse drug reactions (ADRs) case studies: Moderate ADRs. , 2023, , 33-80.		0
2300	Control-Relevant Adaptive Personalized Modeling From Limited Clinical Data for Precise Warfarin Management. IEEE Open Journal of Engineering in Medicine and Biology, 2022, 3, 242-251.	1.7	1
2301	Incidence and Economic Burden of Adverse Drug Reactions in Hospitalization: A Prospective Study in Korea. Journal of Korean Medical Science, 2023, 38, .	1.1	8
2302	The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study. Journal of Pharmacy and Pharmaceutical Sciences, 0, 26, .	0.9	2
2303	Comparison of the Liverpool Causality Assessment Tool <i>vs</i> . the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study. British Journal of Clinical Pharmacology, 2023, 89, 2407-2412.	1.1	1
2305	Efficient parameter tuning of neural foundation models for drug perspective prediction from unstructured socio-medical data. Engineering Applications of Artificial Intelligence, 2023, 123, 106214.	4.3	1
2306	Molecular modeling, vibrational dynamics and NBO analysis of a synthetic bioâ€relevant warfarin analog. Journal of Molecular Structure, 2023, 1284, 135347.	1.8	2
2307	Prevalence of Drug–Drug Interactions in Older Community-Dwelling Individuals: A Systematic Review and Meta-analysis. Drugs and Aging, 2023, 40, 117-134.	1.3	3
2308	The Association Between Medication Use in Older Women with Early-Stage Operable Primary Breast Cancer and Decision Regarding Primary Treatment. Oncologist, 2023, 28, e128-e135.	1.9	0
2309	In Vitro Antioxidant and Anti-inflammatory Effects of <i>Erythroxylum cuneatum</i> Leaf Extract on Oxidized Low-density Lipoprotein-stimulated Human Aortic Endothelial Cells. Pharmacognosy Magazine, 0, , 097312962211374.	0.3	0
2310	Disentangling concepts of inappropriate polypharmacy in old age: a scoping review. BMC Public Health, 2023, 23, .	1.2	2
2311	Evaluation of a multifaceted medication review in older patients in the outpatient setting: a before-and-after study. International Journal of Clinical Pharmacy, 0, , .	1.0	0
2312	Which Adverse Events and Which Drugs Are Implicated in Drug-Related Hospital Admissions? A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 1320.	1.0	3

#	Article	IF	CITATIONS
2313	Polypharmacy Pattern in Iran: A Comprehensive Analysis of a Large Prescription Database. Iranian Journal of Pharmaceutical Research, 2023, 21, .	0.3	0
2314	Medication incidents and medication errors in Danish healthcare: A descriptive study based on medication incident reports from the Danish Patient Safety Database, 2014–2018. Basic and Clinical Pharmacology and Toxicology, 2023, 132, 416-424.	1.2	2
2315	Detection of Hepatic Drug Metabolite-Specific T-Cell Responses Using a Human Hepatocyte, Immune Cell Coculture System. Chemical Research in Toxicology, 2023, 36, 390-401.	1.7	4
2316	Trends of polypharmacy among older people in Asia, Australia and the United Kingdom: a multinational population-based study. Age and Ageing, 2023, 52, .	0.7	4
2317	Incidence and patterns of adverse drug reactions among adult patients hospitalized in the University of Gondar comprehensive specialized hospital: A prospective observational follow-up study. PLoS ONE, 2023, 18, e0282096.	1.1	3
2318	Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. Human Genomics, 2023, 17, .	1.4	11
2319	A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease. Clinical Rheumatology, 0, , .	1.0	0
2320	Reporting Antimicrobial-Related Adverse Drug Events in Jordan: An Analysis from the VigiBase Database. Antibiotics, 2023, 12, 624.	1.5	1
2321	Progress of Stem Cell Research in Knee Osteoarthritis. , 0, 36, 1421-1426.		2
2322	Comparison of hospitalization costs for the same adverse reaction associated with different medications. American Journal of Health-System Pharmacy, 0, , .	0.5	0
2323	Inconsistencies of absolute drug–drug contraindication reports: Analysis of Summaries of Product Characteristics of commonly prescribed drugs. British Journal of Clinical Pharmacology, 0, , .	1.1	0
2324	Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open, 2023, 13, e069915.	0.8	9
2325	Aspirin microcrystals deposited on high-density microneedle tips for the preparation of soluble polymer microneedles. Drug Delivery and Translational Research, 2023, 13, 2639-2652.	3.0	2
2326	Drug information sources in professional work—a questionnaire study on physicians' usage and preferences (the drug information study). European Journal of Clinical Pharmacology, 0, , .	0.8	1
2327	A review of the effectiveness of interventions to reduce medication errors among older adults in Singapore. Proceedings of Singapore Healthcare, 2023, 32, 201010582311722.	0.2	0
2332	Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions., 2023,, 71-86.		0
2336	Medikamentenkomplikationen – Dosisfindung und Interaktionen. , 2023, , 179-186.		0
2345	Evidence of the Impact of Interventions to Decrease Polypharmacy. , 2023, , 1-20.		0

#	Article	IF	CITATIONS
2350	Adverse Drug Reactions in Older People: A Twenty-First Century View. Practical Issues in Geriatrics, 2023, , 69-80.	0.3	0
2351	Arzneimittel- und MedizinproduktschÃ <b>d</b> en – Begutachtung. Springer Reference Medizin, 2023, , 1-15.	0.0	0
2355	Leveraging ADME/PK information to enable knowledge-driven decisions in drug discovery and development., 2023,, 9-24.		0
2357	Hierarchical Classification of Adverse Events Based on Consumer's Comments. Lecture Notes in Computer Science, 2023, , 188-195.	1.0	0
2367	Biological and functional multimorbidity—from mechanisms to management. Nature Medicine, 2023, 29, 1649-1657.	15.2	9
2376	Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
2389	Prediction of frequencies of drug side effects using social recommendation algorithm based on multi-feature fusion. , 2023, , .		0
2390	Evidence of the Impact of Interventions to Decrease Polypharmacy. , 2023, , 454-473.		0
2392	Pharmacogenomics in cardiovascular disease. , 2024, , 623-642.		0
2401	Enzymology of Mitochondrial Amino Acid Conjugation Reactions. , 2023, , .		0
2409	Appeal for Increasing the Impact of Pharmacovigilance. Drug Safety, 0, , .	1.4	0
2412	Future Perspectives of Pharmacogenomics. , 2023, , 463-471.		0
2413	Public Health Issues in Pharmacogenomics. , 2023, , 325-346.		0
2417	Economic Evaluation of Pharmacogenomic Testing. , 2023, , 373-386.		O
2420	Tod im Zusammenhang mit ĀÞtlichen Maßnahmen. , 2023, , 491-508.		0
2423	Challenges in Drug Development for Neurological Disorders. , 2023, , 27-45.		O